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The demonstration of antithrombotic efficacy in man is challenging. Most techniques 
evaluate specific plasma or cellular components under static conditions in vitro. In 
contrast, in vivo thrombus initiation and growth occur in whole blood, under 
conditions of continuous flow and in the presence of vascular injury. An in vivo 
model for use in clinical studies presents significant safety issues and does not 
currently exist. The Badimon chamber is an ex vivo model of thrombosis that is 
suitable for use in clinical studies and has previously been used to assess novel 
antithrombotic regimens. Although well-established, previous characterisation studies 
were performed in a porcine system and using methodology that has since been 
superceded. In addition, it has a number of disadvantages that limit its broader 
applicability and has not previously been used to assess fibrinolysis. 
 
Having established The Badimon Chamber within my own institution, I developed the 
methodology and performed careful validation and characterisation studies with a 
particular emphasis on reproducibility. These developments allowed more efficient 
data analysis and the accurate addition of compounds to the extracorporeal circuit, 
both of which broaden the applicability of the technique. In subsequent studies, using 
a series of double-blind randomised controlled crossover studies in healthy volunteer 
cohorts, I utilised the updated methodology to address questions in separate but 
overlapping areas of cardiovascular medicine. 
 
The dynamic regulation of intravascular thrombus formation by the endogenous 
fibrinolytic system is central to the pathogenesis of acute atherosclerotic events, 
particularly within the coronary circulation. Previous work within our institution has 
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provided novel insights into the role of endogenous fibrinolysis. Despite a growing 
body of evidence, a key limitation of studies to date is that the effects of acute 
endogenous t-PA release on in situ thrombus formation have not been demonstrated. 
Is endogenous endothelial t-PA released under agonist stimulation functionally active 
and able to enhance fibrinolysis of in situ thrombus? Firstly, I demonstrated that the 
addition of exogenous t-PA into the extracorporeal circuit of The Badimon Chamber 
results in a dose dependent increase in plasma D-dimer associated with a dose 
dependent reduction in thrombus formation, consistent with enhanced fibrinolysis.  
Having validated the model, I proceeded to investigate whether freshly released 
endogenous t-PA would have similar effects to exogenous t-PA. By combining intra-
arterial infusion of bradykinin into the human forearm in order to stimulate acute 
release of endogenous t-PA with an assessment of thrombus formation in the 
Badimon Chamber, I demonstrated that endogenous t-PA released acutely from the 
human vascular endothelium enhances fibrinolysis and limits in situ thrombus 
formation. These data validate the forearm model as a relevant model with which to 
assess acute fibrinolytic capacity, confirm the functional significance of t-PA released 
during agonist stimulation and suggest that further studies to explore its therapeutic 
manipulation are warranted.  
 
I went on to evaluate a promising small molecule PAI-1 inhibitor, PAI-749, using 
assessments of ex vivo thrombosis complimented by extensive in vitro studies. 
Interestingly, in contrast to the promising results seen with this compound in 
preclinical models, we were unable to demonstrate efficacy in any of the clinical 
models used, highlighting the potential pitfalls of relying solely on in vitro and pre-
clinical models during early compound development. 
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In the final phase of this work, I used the chamber to explore the prothrombotic effects 
of exposure to air pollution. A plethora of observational data exist to suggest that acute 
exposure to particulate air pollution can trigger vascular events including myocardial 
infarction although the underlying mechanisms are only partly understood. Using a 
unique human exposure facility, we demonstrated that inhalation of diesel exhaust 
causes platelet activation and enhances thrombus formation. These data provide a 
plausible mechanism linking exposure to particulate air pollution with acute 
cardiovascular events including myocardial infarction. Furthermore, in a separate 
study we were able to demonstrate that reducing the particulate component of the 
exposure using a commercially available particle trap prevents the detrimental effects 
on ex vivo thrombosis and endothelial function. These data support calls for the 
application of particle traps to diesel-powered vehicles in order to limit a range of 
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The work described within this thesis was broadly performed in three phases.  
 
The first phase involved establishing the Badimon Chamber, a technique for assessing 
ex vivo thrombosis formation, within my own institution followed by validation of the 
methodology with a particular emphasis on reproducibility. This phase also involved 
development and adaption of the methodology to broaden its versatility. 
 
Following successful validation and development, the applicability of the technique 
was explored by using it in combination with other methodologies to address specific 
questions within two separate but overlapping areas of cardiovascular medicine. 
 
The Introduction chapter of the thesis is divided into sections corresponding to these 
phases. The final sections focus on the aims and specific hypotheses that are explored 











1.2 INTRAVASCULAR THROMBOSIS  
 
Cardiovascular disease is the commonest cause of premature death in the United 
Kingdom accounting for 30% of deaths among men and 22% among women.  Despite 
the identification of a number of risk factors, the underlying pathophysiological 
mechanisms remain only partly characterised. However, it is clear that intravascular 
thrombus formation is central to the pathogenesis of acute atherosclerotic events, 
particularly within the coronary circulation. Acute coronary syndromes (ACS) are 
caused by rupture or erosion of an atherosclerotic plaque leading to exposure of plaque 
contents and constituents of the vessel wall to flowing blood [Badimon, et al., 2002]. 
Subsequent thrombus formation may ultimately result in total or partial vessel 
occlusion with resulting clinical sequelae including sudden death and myocardial 
infarction (MI) [Badimon, et al., 2002]. 
 
Thrombus formation is a complex multistep process consisting of two major 
pathways: the activation and aggregation of platelets; and the activation of soluble 
components of the coagulation cascade with the resultant formation of an insoluble 
fibrin clot [Badimon, et al., 2002]. Due to the rheological conditions within the arterial 
circulation, the critical initiating factor in arterial thrombosis is the aggregation and 
adhesion of platelets to collagen and von Willebrand factor (vWF). Subsequent 
thrombin generation serves to further enhance platelet activation and drive the 






Figure 1.1 Scheamatic diagram showing the mechanisms responsible for thrombus formation 
at the site of a ruptured atherosclerotic plaque [Lucking, et al., 2007]. 
 
 
1.2.1 MEASURING AND ASSESSING THROMBUS FORMATION IN MAN 
Given the central role that thrombosis plays in a number of important 
pathophysiological processes, including ACS, it has been the subject of extensive 
study. Whilst interrogation of specific components and pathways are valuable, the 
ability to make an assessment of overall thrombotic potential that results from the net 
interaction of all relevant factors remains important, both clinically and particularly 
during the investigation of novel antithrombotic compounds. Whilst several preclinical 
models exist, species-specific differences ensure that clinical studies remain an 
essential part of antithrombotic drug development. This has been highlighted in the 
case of several potential antithrombotic compounds that showed promise in vitro and 
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during preclinical studies but failed to be efficacious in man [Cox, et al., 1992; Hara, 
et al., 1995]. 
 
The demonstration of antithrombotic efficacy in man is challenging. Most techniques 
involve the evaluation of specific plasma and cellular components in isolation, require 
the addition of an anticoagulant to limit in vitro activation, and are often performed 
under static conditions. In contrast, in vivo thrombus initiation and growth occurs in 
whole blood, under conditions of continuous flow, and often in the presence of 
vascular injury. Thus assessment of the efficacy of antiplatelet and anticoagulant 
agents may not be reflected by static or unidimensional systems employed by in vitro 
assays [Kroll, et al., 1996]. An in vivo model for use in clinical studies presents 
significant safety issues and does not currently exist. 
 
Only a limited number of ex vivo techniques have been developed that allow 
assessment of thrombus formation under controlled conditions [Baumgartner, 1973; 
Martines, et al., 2004; Sakariassen, et al., 1983]. The Baumgartner chamber was the 
first popular such technique and consisted of a central rod surrounding by a cylinder 
[Baumgartner, 1973]. A reverted arterial segment could be mounted on the central rod 
with the gap between the surface and the cylinder allowing blood to pass over the 
surface. In addition to being extremely labour intensive, limitations were related to the 
size and shape of material that could be accommodated within the chamber and 
difficulties in accurately predicting shear rates at the thrombogenic surface. 
Subsequently, other ex vivo systems were developed that allowed studies using 
prosthetic surfaces but which were limited by their inability to accommodate 
biological substrates or study a broad range of flow conditions [Martines, et al., 2004; 
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Sakariassen, et al., 1983]. All involve an extracorporeal circuit in which blood is 
perfused over a thrombogenic substrate. The flow rate of blood through the circuit is 
controlled by a pump and in combination with the lumen of the channel or chamber 
determines the rheological conditions including the shear stress under which the 
thrombus forms. A variety of thrombogenic substrates have been used including 
purified components, extracellular matrix components [Vilahur, et al., 2004], cultured 
human cells and modified human [Toschi, et al., 1997] and animal blood vessels. 
Thrombus quantification can be assessed by the use of radiolabelled blood products, 
immunofluorescence or histomorphometrically. 
 
The Badimon Chamber 
The Badimon chamber is an ex vivo model of thrombosis that is suitable for use in 
clinical studies. It provides a powerful and elegant method of assessing ex vivo 
thrombus formation in an extracorporeal flow chamber [Badimon, et al., 1999; 
Badimon, et al., 1987]. The technique utilises a continuous flow of venous effluent 
blood from the human forearm that is passed into a series of extracorporeal chambers 




Figure 1.2 Individual unassembled Badimon Chamber. 
 
Each perfusion chamber consists of a Plexiglass block through which a cylindrical 
hole of 1 or 2 mm diameter has been machined in order to mimic the tube-like shape 
of the vascular system (Figure 1.2). The upper face of the block, parallel to the axis of 
the cylindrical hole, is milled to create a channel. Biologic or prosthetic substrates can 
be placed on the channel, with a Plexiglass pressure plate placed on the non-exposed 
side of the test surface. A ridge on the face of the pressure plate contacts the surface 
around the periphery of the channel gap and pressure is exerted on the back of the 
pressure plate by a screw. This compresses the test surface and ensures a sealed 
system such that blood can be passed through without leakage. For non-compressible 
surfaces, a gasketing material can also be used. The use of two chambers with 
different internal diameters was originally decided on by Badimon in order to allow 
the generation of a broad range of blood velocities and wall shear rates on the 
substrate with relatively modest changes in the rate of blood flow. 
 
Different biological substrates and biomaterials can be placed within the chamber and 
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studies using specially prepared porcine vessels, atherosclerotic human vessels 
[Badimon, et al., 1999; Toschi, et al., 1997], collagen-coated plastic slides [Vilahur, 
et al., 2004] and prosthetic material [Badimon, et al., 1987; Badimon, et al., 1990] 
have been completed. The most commonly used substrate consists of specially 
prepared strips of porcine aorta from which a thin layer of intima has been carefully 
removed. Flowing blood is thus exposed to the fibromuscular layer of the porcine 
aorta that comprises of a variety of subendothelial components including collagen 
(types I and III), proteoglycans, glycosaminoglycans, elastin, and smooth muscle 
cells. These components are known to be exposed in the ruptured atherosclerotic wall, 
although probably in different relative proportions with respect to the normal vessel 
wall. This substrate is highly thrombogenic and induces thrombus formation at any 
shear rate and perfusion time. In fact, even high shear rates are unable to dislodge 
significant quantities of platelet thrombi, and deposits continue to increase with 
exposure time [Badimon, et al., 1986]. 
 
Using a blood flow rate of 10 mL/min, the rheological conditions in the first chamber 
simulate those of patent coronary arteries (channel width 2 mm - low shear rate, 
approximately 212 s-1), while those in the second and third chambers simulate those 
of mildly stenosed coronary arteries (channel width 1 mm - high shear rate, 
approximately 1690 s-1). Whilst blood flow within this system is not pulsatile, 
rheological conditions otherwise broadly simulate those at the site of intra-coronary 
atheromatous plaque rupture. Combined with the use of porcine tunica media as a 
pathophysiologically relevant thrombogenic substrate, the technique serves as a model 
of deep coronary arterial injury. As such, it is particularly useful for evaluating the 
efficacy of interventions likely to modulate thrombus formation within the coronary 
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circulation at a site of vessel injury, including the assessment of novel antithrombotic 
agents.  
 
Previous studies have utilised the technique to evaluate novel antithrombotic agents or 
regimens, principally in patients undergoing percutaneous coronary intervention [Lev, 
et al., 2006; Wahlander, et al., 2006; Zafar, et al., 2007]. It has a number of important 
advantages over other techniques, particularly the ability to assess thrombus 
formation on a pathophysiologically relevant substrate and under conditions of 
continuous flow [Badimon, et al., 1986; Badimon, et al., 1987]. 
 
Limitations of the Badimon Chamber Technique 
Although the Badimon chamber technique is well-established, previous 
characterisation studies have been performed in a porcine system and using 
methodology that has since been superseded [Badimon, et al., 1986; Badimon, et al., 
1987]. In addition, there are features of the current technique that limit its broader 
applicability. 
 
Early animal studies quantified thrombus burden by measuring the quantity of 
radiolabelled platelets incorporated into the ex vivo thrombus [Badimon, et al., 1987]. 
Given the safety and logistical difficulties of using radiolabelled blood components in 
human studies, histological methods for assessing thrombus area were developed. 
Whilst more time-consuming, histological analysis has several important advantages 
over 111Indium-labelled platelets. By using appropriate conventional staining 
techniques in combination with immunohistochemistry, total thrombus area and 
specific components can be quantified [Dangas, et al., 1998; Giesen, et al., 1999]. For 
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the majority of studies, Masson’s trichrome stain is sufficient to quantify both fibrin-
rich and platelet-rich thrombus. Histological assessment also allows for the 
identification of confounding factors such as those caused by gross surface 
irregularities and flaps that can occur on the denuded aortic strips. Here thrombus 
formation is driven by tissue disruption rather than the thrombotic state of the subject 
or the proposed drug intervention.  The limitation of histological assessment is that, 
given the large amount of image data produced, it is extremely time consuming and 
labour intensive. In previous studies, individual images have been acquired using a 
microscope-mounted camera before being transferred and analysed using separate 
image analysis software. 
 
Addition of Compounds to the Extracorporeal Circuit 
As discussed, many previous studies using the chamber have been Phase I clinical 
studies investigating novel antithrombotic agents or regimens and have relied on 
intravenous or oral administration of the test compound to the subject. Clearly for 
compounds that require in vivo modification, including oral compounds requiring first 
pass metabolism, exposure of the subject to the test compound is mandated. However, 
for novel compounds with a prompt mechanism of action and not reliant on in vivo 
modification, there are advantages to being able to assess efficacy without directly 
exposing the subject to the agent. A significant potential advantage of the Badimon 
Chamber that has not previously been exploited is the ability to add compounds 
directly to the extracorporeal circuit of the chamber thus obviating the need to expose 
human subjects to the agent. This would allow efficacy to be evaluated in a robust and 
pathophysiologically relevant clinical model using native human blood prior to safety 
testing. This may allow more timely identification of compounds that show promise 
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in preclinical models but fail to demonstrate efficacy in man. The ongoing 
development of such compounds could then be discontinued earlier saving time and 
money. 
 
However, there are potential limitations to this approach. Firstly, the time available 
for the compound to mix with flowing blood prior to contacting the chamber is short 
(~2-3 s). Whilst this may be sufficient for small soluble molecules, it may preclude 
the testing of larger compounds, particularly where solubility is limited. Although the 
interaction time could be lengthened by introducing a mixing chamber or reservoir, 
this would necessitate modulation of blood flow with potential effects on platelet and 
coagulation factor activation. Secondly, in order to avoid marked dilution of blood as 
the agent is added, it is necessary add small relatively small volumes of a 
concentrated solution containing the test agent. For example, to achieve a 1:100 
dilution it is necessary to produce a solution 100 times more concentrated than the 
final desired chamber concentration. Clearly depending on the quantity of compound 
available and practical issues relating to the production of a concentrated solution, this 
may not be possible. 
 
1.2.2    SUMMARY 
Intravascular thrombosis is central to the pathogenesis of acute atherosclerotic events. 
The assessment of interventions that may affect thrombosis, including the evaluation 
of antithrombotic drugs, is reliant on suitable models. Whilst several preclinical 
models of thrombosis exist, species-specific differences ensure that clinical studies 
remain an essential part of antithrombotic drug development. The demonstration of 
antithrombotic efficacy in man is challenging and an in vivo model does not currently 
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exist. The Badimon Chamber provides a means of assessing ex vivo thrombus 
formation in humans, potentially without direct drug exposure, although limitations in 






















The initiation, modification and resolution of thrombus associated with eroded or 
unstable coronary plaques is critical in determining the clinical outcome from a 
complex atherosclerotic plaque. Areas of endothelial denudation and thrombus 
deposition are a common finding on the surface of atheromatous plaques [Davies, 
2000]. They usually remain sub-clinical as endogenous fibrinolysis prevents thrombus 
propagation [Davies, 2000], although plaque expansion may result as residual 
thrombus becomes incorporated into the lesion [Mann, et al., 1999]. Indeed, the vast 
majority of atherosclerotic lesions causing significant luminal stenosis have evidence 
of previously healed plaque disruption. However, in the presence of an adverse pro-
inflammatory state or an imbalance in the fibrinolytic system, microthrombi on the 
surface of atherosclerotic plaques may propagate acutely, leading to arterial occlusion 
and tissue infarction [Rosenberg, et al., 1999]. Thus, the initiation, modification and 
resolution of thrombus associated with eroded and unstable plaques appear to be 
critically dependent on the efficacy of endogenous fibrinolysis that is itself dependent 
upon the surrounding endothelium.  
 
In previous studies, novel techniques have provided intriguing insights into the role of 
endogenous fibrinolysis, endothelial function and intravascular thrombosis in the 
peripheral and coronary circulations. A greater understanding of these mechanisms 
and development of a model that allows the assessment of agents with the potential to 
modulate the endogenous fibrinolytic system is likely to be of scientific interest and 
has the potential to develop and shape future therapeutic interventions. 
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1.3.1 THE ENDOGENOUS FIBRINOLYTIC SYSTEM 
The endogenous fibrinolytic system protects against intravascular thrombosis and 
appears to be particularly important in the coronary circulation [Rosenberg, et al., 
1999]. Its importance is exemplified by the high rate of spontaneous reperfusion in the 
infarct-related artery after acute MI, which occurs in around one third of patients 
within the first 12 hours.  
 
The critical final step of the pathway is the generation of active plasmin from 
plasminogen, mediated by tissue plasminogen activator (t-PA). Plasmin facilitates clot 
dissolution through the degradation of fibrin, generating soluble fibrin degradation 
products including D-dimer (Figure 1.3). 
 
Although the precise mechanism is unclear, t-PA is released from the endothelium 
through the translocation of a dynamic intracellular storage pool [van den Eijnden-
Schrauwen, et al., 1995]. In the absence of fibrin, t-PA is a very weak activator of 
plasminogen. However, once bound to fibrin, its catalytic activity increases 1000-fold 
due to conformational changes with the resultant formation of a ternary complex 




Figure 1.3 The endothelial fibrinolytic response to luminal thrombus. Agonists generated from the 
coagulation cascade act on endothelial cell surface G protein-coupled receptors (GPCRs) (1) to 
stimulate release of tissue plasminogen activator (t-PA) from storage granules, a step that requires an 
increase in intracellular calcium (Ca2+) concentration (2). Free t-PA acts on thrombus-bound 
plasminogen (3) to produce plasmin (4) that, in turn, degrades cross-linked fibrin into fibrin 
degradation products (FDPs) (5), thus dissolving the thrombus. The fibrinolytic process is inhibited by 













The rate of plasminogen conversion to plasmin is determined by the release of t-PA 
from the adjacent endothelium. If endogenous fibrinolysis is to be effective, then the 
rapid mobilisation of t-PA from the endothelium is essential. The efficacy of the 
system is determined by the relative balance between the acute local release of t-PA 
and its subsequent inhibition by a number of serine protease inhibitors, most notably 
plasminogen activator inhibitor type 1 (PAI-1). PAI-1 normally circulates in 
substantial molar excess to t-PA and causes its rapid inhibition. In addition, thrombus 
dissolution is far more effective if t-PA is incorporated during, rather than after, 
thrombus formation [Brommer, 1984; Fox, et al., 1985]. Many workers have assessed 
the basal plasma concentrations of t-PA and PAI-1.  Whilst potentially informative, 
these measurements do not reflect the acute fibrinolytic capacity of the vasculature and 
it is the dynamic release of t-PA from the endothelium that is directly relevant to the 
pathogenesis of atherothrombosis.  
 
The Dynamic Assessment of Endogenous Fibrinolytic Capacity 
In vivo models of assessing acute endogenous t-PA release in the forearm circulation 
[Newby, et al., 1997] and coronary circulation [Newby, et al., 2001] of man have been 
developed. In the forearm circulation, using venous occlusion plethysmography 
combined with bilateral venous blood sampling, local t-PA release has been 
demonstrated in response to a variety of pharmacological stimuli including thrombin 
receptor agonism [Gudmundsdottir, et al., 2006], substance P [Newby, et al., 2002; 
Newby, et al., 1997], tumour necrosis factor α [Chia, et al., 2003] and bradykinin 




The Clinical Relevance of Stimulated t-PA Release 
Cigarette smoking is strongly associated with atherosclerosis and is also a major risk 
factor for acute coronary thrombosis [Burke, et al., 1997]. Despite higher basal plasma 
t-PA antigen concentrations, cigarette smokers have an impaired capacity to release t-
PA acutely from the endothelium [Newby, et al., 2001; Newby, et al., 1999]. The 
increased risk of spontaneous thrombosis seen in smokers may relate to the 
propagation of thrombus that would otherwise undergo fibrinolysis and remain sub-
clinical. Although cigarette smokers have a higher overall mortality from MI than non-
smokers [Haheim, et al., 1993], their in-hospital mortality is lower [Barbash, et al., 
1993; Mueller, et al., 1992; Zahger, et al., 1995]. This apparent paradox can be 
explained by the observation that the infarct related artery is more than twice as likely 
to become patent in current smokers compared to non-smokers following thrombolytic 
therapy for acute MI [de Chillou, et al., 1996; Gomez, et al., 1993; Zahger, et al., 
1995] perhaps because patients with impaired endogenous fibrinolytic capacity are 
likely to benefit most from thrombolytic therapy compared to those with a preserved 




As well as being an inflammatory mediator, bradykinin is released during the contact 
phase of coagulation [Schiffman, et al., 1980]. Patients with unstable angina have 
increased plasma levels of bradykinin [Hoffmeister, et al., 1995]. When infused into 
the forearm, bradykinin causes a large dose-dependent release of t-PA that is 
substantial enough to cause systemic elevations in plasma t-PA concentrations 
[Labinjoh, et al., 2000]. Thus, the local liberation of bradykinin in acute coronary 
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syndromes may represent an important negative feedback loop in which bradykinin-
induced t-PA release inhibits intravascular thrombus formation. Bradykinin has a very 
short plasma half-life due to rapid degradation by a number of peptidases, the most 
important of which is angiotensin-converting enzyme (ACE). Elegant studies in 
healthy volunteers and patients with chronic heart failure have demonstrated that 
bradykinin induced t-PA release is markedly increased in the presence of ACE 
inhibition [Labinjoh, et al., 2001; Witherow, et al., 2002]. Thus, the potentiation of t-
PA release by enhancement of endogenous bradykinin activity may account for some 
of the cardiovascular benefits observed with ACE inhibition. 
 
Endothelial t-PA Release as a Measure of Endothelial Function 
The endothelium has a number of important complementary functions, including 
regulation of vasomotor tone, coagulation, fibrinolysis and inflammation. Most 
clinical studies have focused on endothelium-dependent vasomotion. Whilst a useful 
surrogate marker for the role of the endothelium in atherothrombosis [Perticone, et 
al., 2001], the observation of impaired t-PA release with preservation of vasomotor 
function in response to endothelium-dependent vasodilators in cigarette smokers 
[Chowienczyk, et al., 1993] and patients with hypertension [Hrafnkelsdottir, et al., 
2004; Hrafnkelsdottir, et al., 1998] highlights both the complexity of vascular biology 
and suggests that fibrinolytic capacity may be a more sensitive marker of endothelial 
dysfunction in some circumstances. Indeed, the fibrinolytic capacity of the 
endothelium predicts future adverse cardiovascular events in patients with coronary 




1.3.2 ENHANCING FIBRINOLYSIS 
Endogenous fibrinolysis plays a critical role in preventing thrombus propagation on 
the surface of unstable atherosclerotic. In addition, fibrinolytic therapy with 
recombinant t-PA remains an important treatment in MI and pulmonary embolus. 
Novel compounds able to accelerate fibrinolysis may therefore enhance the therapeutic 
efficacy of thrombolytic agents as well as having the potential to prevent adverse 
cardiovascular events through augmentation of endogenous fibrinolysis. 
 
Work to date on the fibrinolytic system has principally been conducted using plasma-
based systems in vitro and has allowed the identification and characterisation of the 
key components. Whilst other plasminogen activators exist, including urokinase-type 
plasminogen activator, t-PA is the major protagonist of fibrinolysis in plasma. In 
contrast, several inhibitors of fibrinolysis have been identified including PAI-1, PAI-
2, a2-antiplasmin (a2-AP) and thrombin activatable fibrinolysis inhibitor (TAFI) 
[Lijnen, et al., 1995]. Although their function is complementary, they appear to have 
distinct roles and locations. Others have explored the potential to enhance fibrinolysis 
by targeting some of the inhibitors of fibrinolysis. The majority of work to date has 
looked at inhibition of PAI-1 and TAFI. 
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PAI-1 and PAI-1 Inhibition 
PAI-1 is a member of the superfamily of serine proteinase inhibitors and is the 
primary inhibitor of t-PA in vivo [Lijnen, et al., 1995; Pannekoek, et al., 1986]. It is a 
379 amino acid glycoprotein produced by several tissues, mainly endothelial cells and 
vascular smooth muscle cells, but with a contribution from platelets and the liver 
[Simpson, et al., 1991]. 
 
In its active form, PAI-1 limits t-PA activity through the rapid formation of an 
inactive PAI-1/t-PA complex [Kruithof, et al., 1984; Thorsen, et al., 1988]. The active 
form of PAI-1 is unstable (half-life 1–2 h at 37 °C) and converts spontaneously into a 
non-inhibitory latent form [Hekman, et al., 1985] in a process unique among serpins 
in that it occurs spontaneously at a relatively rapid rate [Levin, et al., 1987; Lindahl, 
et al., 1989]. A third conformation, the non-inhibitory substrate form, interacts with t-
PA resulting in the cleavage and irreversible inactivation of PAI-1 and the 
regeneration of the proteinase activity [Declerck, et al., 1992; Munch, et al., 1993; 
Urano, et al., 1992]. 
 
In vivo, most plasma PAI-1 is in a complex with vitronectin (VN) [Sigurdardottir, et 
al., 1990], which stabilises PAI-1 in the active conformation [Lindahl, et al., 1989; 
Sigurdardottir, et al., 1990; Zhou, et al., 2003]. However, PAI-1 that is stored in the α- 
vesicles in platelets is not in complex with VN [Robbie, et al., 1996] and is active 
[Brogren, et al., 2011]. Following platelet activation, this stored PAI-1 is released 
protecting the primary clot from fibrinolysis [Brogren, et al., 2011; Robbie, et al., 
1996] by inhibiting t-PA secreted from nearby endothelium. Even though an inhibitor 
for PAI-1 that neutralises the activity of both PAI-1 in complex with VN and free 
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PAI-1 may yield the most effective inhibition, it is still possible that selective 
inhibition of free PAI-1 could provide therapeutic benefit. 
 
PAI-1 plays a pivotal role in a myriad of physiological processes [Dellas, et al., 
2005]. Increased levels of PAI-1 activity have been reported in a broad range of 
thrombotic disease states including venous thromboembolism, coronary artery disease 
and acute myocardial infarction [Lijnen, 2005]. In addition, elevated levels of PAI-1 
are being increasingly being regarded as central to the pathogenesis of metabolic 
syndrome. Both glucose and insulin increase PAI-1 synthesis in vascular endothelial 
and smooth muscle cells [Mertens, et al., 2006] and improved glycaemic control in 
type 2 diabetes results in a decrease in PAI-1 levels. Some of the benefit derived from 
statins may relate to their ability to alter the balance of the fibrinolytic pathway, 
decreasing PAI-1 expression at the same time as enhancing t-PA expression 
[Bourcier, et al., 2000; Wolfrum, et al., 2003]. PAI-1 has also been linked 
extravascular disease processes including fibrin deposition and alterations of cell 
adhesion and migration mediating cancer progression and metastasis [Bajou, et al., 
1998]. Inhibition of nitric oxide synthase induces PAI-1 expression that appears to 
contribute to perivascular fibrosis [Kaikita, et al., 2001].  
 
Given its role in a number of diverse disease states, several strategies to inhibit PAI-1 
have been explored. PAI-1 inhibitors include inhibiting peptides, antisense 
oligonucleotides blocking PAI-1 synthesis [Gils, et al., 2004] and inhibitory 
monoclonal antibodies [Gils, et al., 2004; van Giezen, et al., 1997]. Finally, a number 
of small molecule synthetic antagonists have been developed. These inhibit PAI-1 
activity by reducing accessibility to the reactive site loop or by inducing 
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conformational change to a latent- or substrate-like conformation [Elokdah, et al., 
2004; Fjellstrom, et al., 2012; Friederich, et al., 1997; Gardell, et al., 2007; Gils, et 
al., 2002; Gorlatova, et al., 2007].  
 
However, despite considerable interest and several promising preclinical studies, no 
clinical studies have yet been performed. 
 
TAFI and TAFI Inhibition 
TAFI is a zymogen that is activated by plasmin, thrombin or the thrombin–
thrombomodulin complex to form an active carboxypeptidase, TAFIa [Bajzar, et al., 
1995]. During the partial degradation of fibrin clots by plasmin, new C-terminal 
lysine residues are generated that further stimulate plasmin formation. TAFIa removes 
these C-terminal lysines from fibrin, resulting in a decreased rate of plasmin 
generation and thus downregulation of fibrinolysis [Wang, et al., 1998]. This mode of 
action is in clear contrast to the working mechanism of PAI-1, which inhibits t-PA by 
direct interaction. 
 
In humans, a positive correlation has been demonstrated between TAFI levels and the 
risk for coronary artery disease, venous thrombosis and angina pectoris [Silveira, et 
al., 2000; van Tilburg, et al., 2000]. 
 
Activated TAFI is inhibited (relatively non-specifically) by chelating agents, 
compounds that interfere with the disulfide bridges, small synthetic compounds and 
naturally occurring metallocarboxypeptidase inhibitors (e.g. potato tuber 
carboxypeptidase inhibitor) [Cruden, et al., 2005; Leurs, et al., 2005; Wang, et al., 
 38 
2007].  In addition inhibition of TAFI has been achieved using inhibitory monoclonal 
antibodies [Gils, et al., 2005]. 
 
As with PAI-1 inhibition, work with novel inhibitors of TAFI has been performed in 
preclinical models only. 
 
1.3.3    SUMMARY 
The outcome of atherosclerotic plaque erosion or rupture is critically dependent on the 
endogenous fibrinolytic system, particularly in the coronary circulation. In addition, 
fibrinolytic therapy remains an important treatment for acute pulmonary embolus and 
myocardial infarction. The fibrinolytic system has been well-characterised and 
potential targets for therapeutic intervention to prevent and treat cardiovascular 
diseases identified. In vitro and preclinical studies have explored novel agents with 
the potential to enhance fibrinolysis although no substantive human studies have yet 
been performed. This is due, in part, to the absence of suitable clinical models in 











1.4 INVESTIGATING THE THROMBOTIC EFFECTS 
OF AIR POLLUTION EXPOSURE 
 
A plethora of observational studies conducted over many years have consistently 
demonstrated an association between exposure to particulate air pollution and 
increased cardiovascular morbidity and mortality. Despite the strength of the 
epidemiological evidence, the pathophysiological mechanisms responsible remain 
incompletely characterised. Growing evidence exists to suggest that oxidative stress 
and inflammation are central to both the toxicology of particulate air pollution and the 
pathogenesis of atherothrombosis. It is possible that nanoparticulate or soluble 
components may translocate into the circulation, resulting in direct effects on 
atherosclerotic plaque stability, the vascular endothelium, platelet function and 
thrombosis. Given the widespread exposure to air pollution, a greater understanding 
of the mechanisms responsible for its deleterious cardiovascular effects should help to 
develop and target specific interventions to reduce the impact of environmental air 
pollution on cardiovascular disease.  
 
1.4.1 AIR POLLUTION AND CARDIOVASCULAR RISK  
The association between air pollution and cardiorespiratory morbidity and mortality 
has been widely established [Anderson, et al., 1996; Dockery, et al., 1993] and there 
is growing evidence that cardiovascular events are responsible for the majority of 
excess deaths [Pope, 2000]. The World Health Organisation (WHO) currently 
estimates three million people die each year of air pollution, representing 5% of the 
55 million deaths occurring annually in the world [WHO Statistics] with estimates 
from the UK government broadly in keeping with this (around 8,000 excess deaths in 
the UK annually). In the most comprehensive study to date, Miller and colleagues 
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estimate that long-term exposure to air pollution increases the risk of death from 
cardiovascular disease by as much as 76% [Miller, et al., 2007].  
 
More recently, several studies have highlighted the risk of acute exposure to air 
pollution. Short-term increases in air pollution exacerbate existing cardiorespiratory 
disease leading to an increase in hospital admissions, MI and death [Peters, et al., 
2001]. In Edinburgh, a city with relatively low levels of pollution, an increase in 
particulate matter (PM) of 10 µg/m3 was associated with an increase in emergency 
cardiovascular admissions of 4.8% [Prescott, et al., 1998]. Exposure to air pollution 
causes myocardial ischaemia during light exercise in patients with coronary heart 
disease [Mills, et al., 2007] and the triggering of acute MI [Peters, et al., 2001]. 
Accordingly, the risk of mortality from cardiovascular disease is greater for those 
living in areas of greater pollution [Dockery, et al., 1993; Pope, et al., 2002]. 
 
A recent updated Scientific Statement by the American Heart Association [Brook, et 
al., 2010] acknowledges a causal relationship between exposure to PM less than 2.5 
micrometers in diameter (PM2.5) and cardiovascular morbidity and mortality as well 
as identifying PM2.5 as a modifiable factor that contributes to cardiovascular morbidity 
and mortality. 
 
1.4.2 THE ROLE OF PARTICULATE AIR POLLUTION 
Whilst air pollution consists of a complex heterogeneous mixture of gaseous and 
particulate matter, adverse cardiovascular events are most strongly associated with 
exposure to fine particulate matter (PM2.5) [Dockery, et al., 1993; Miller, et al., 2007]. 
An important component of PM2.5 is nanoparticulate matter generated principally 
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during the combustion of diesel fuel [Charron, et al., 2005]. These particles, with an 
aerodynamic diameter ≤100 nm, readily deposit within human alveoli and possess a 
considerable surface area that likely contributes to their biological toxicity 
[Donaldson, et al., 2002]. A sizeable observational study by Pope et al demonstrated 
the risk of adverse effects associated with PM2.5 was greater than for PM10 [Pope et 
al., 2002] and toxicological studies have also highlighted the increased toxicity of the 
smaller size fractions [Donaldson, et al., 2000; Donaldson, et al., 2001]. It has been 
hypothesised that ultrafine particles show more free radical oxidant capacity than non-
ultrafine particles suggestive of a greater direct oxidative stress at the particle surface 
[Li, et al., 1999]. Thus the toxicity of particulate matter appears to relate to the 
number of particles encountered, their size or surface area, and their chemical 
composition [MacNee, et al., 2000]. 
 
 
1.4.3 HUMAN EXPOSURE SYSTEMS  
Observational studies cannot prove a causative biological effect of air pollution 
exposure and assessing individual exposure to particles using data from local area 
monitoring systems is hampered by inaccuracy as personal exposure may be several 
times higher than corresponding area measurements [Watt, et al., 1995]. Because of 
the hypothesis that combustion-derived particles are important, studies utilising diesel 
exhaust remain crucial in determining the health effects of exposure to the 
combustion-derived component of air pollution [Nightingale, et al., 2000; Rudell, et 
al., 1994]. The particulate emission from diesel engines is over 100 times higher than 
that from an equivalent petrol engine with a catalytic converter [Sydbom, et al., 
2001]. Over 80% of diesel exhaust particles have a size of <0.1 µm, and these 
represent a substantial component of the PM2.5 fraction in ambient air. Due to their 
 42 
larger surface area, these submicron particles may carry a large fraction of toxic 
compounds on their surface [Levsen, 2002]. They are deposited deep within the lung 
and are only slowly cleared leading to a prolonged time period over which they might 
exert harmful effects.  
 
1.4.4 POTENTIAL MECHANSIMS  
A number of theories have been proposed to explain the association between 
increased PM and cardiovascular disease, including endothelial dysfunction [Mills, et 
al., 2007; Mills, et al., 2005; Tornqvist, et al., 2007], myocardial ischemia [Mills, et 
al., 2007], altered autonomic function [Gold, et al., 2000], systemic inflammation 
[Tornqvist, et al., 2007] and platelet activation [Nemmar, et al., 2003]. A summary of 
the potential pathways linking inhaled particles to atherothrombosis and adverse 
cardiovascular outcomes is presented in Figure 1.4. According to this model, inhaled 
particles cause pulmonary and systemic inflammation that indirectly impacts on the 
cardiovascular system. In addition, there is evidence to suggest that smaller particles 
can translocate into the bloodstream to exert direct effects on endothelial cells and 
platelets, or may penetrate the vessel wall, promoting atherosclerosis or predisposing 





Figure 1.4 Hypothetical pathways linking inhaled particles to the pathogenesis of 
atherothrombosis and acute cardiovascular events [figure kindly supplied by Dr NL Mills]. 
 
Endothelial Vasomotor Function and Endogenous Fibrinolysis 
In health the vascular endothelium delicately balances regulatory pathways 
controlling blood flow, coagulation, fibrinolysis and inflammation. It is widely 
recognised that a variety of risk factors including cigarette smoking can influence 
vascular tone through endothelium-dependent actions, and there is extensive evidence 
of abnormal endothelium-dependent vasomotion in patients with atherosclerosis 
[Celermajer, et al., 1996; Ludmer, et al., 1986; Newby, et al., 1999]. As discussed in 
the previous section, whilst endothelium-dependent vasomotion is important, it may 
not be representative of other aspects of endothelial function, such as the regulation of 
fibrinolysis. Work within our institution has demonstrated impaired endothelial t-PA 
release in patients with cardiovascular risk factors, including smokers [Newby, et al., 
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1999]. As combustion products and particulate matter are common to both air 
pollution and cigarette smoke, we hypothesised that air pollution is likely to have 
similar detrimental effects on several complementary aspects of vascular function.   
 
Direct Effects of Translocated Particles on the Endothelium  
The nanoparticle component of inhaled PM may influence the cardiovascular system 
through indirect effects mediated by pulmonary inflammation or through the direct 
action of particles that have become blood-borne. Translocation of inhaled 
nanoparticles across the alveolar-blood barrier has been demonstrated in animal 
studies using a range of nanoparticles delivered by inhalation and instillation 
[Kreyling, et al., 2002; Nemmar, et al., 2002; Nemmar, et al., 2003; Oberdorster, et 
al., 2002]. Whether inhaled nanoparticulate can readily access the circulation in 
humans is controversial and continues to be the subject of intense research debate. 
 
Once circulating, nanoparticles may interact with the vascular endothelium, or have 
direct effects on atherosclerotic plaques causing local oxidative stress and pro-
inflammatory effects similar to those found in the lungs. Increased inflammation 
could destabilise the coronary arterial plaque, resulting in rupture, thrombosis and an 
acute coronary syndrome. Certainly, injured blood vessels can take up blood borne 
nanoparticles [Guzman, et al., 1996], a fact exploited by the nanotechnology industry 
for both diagnostic and therapeutic purposes in cardiovascular medicine. The intra-
arterial infusion of carbon black nanoparticles has a detrimental effect on the mouse 
microcirculation with upregulation of vWF expression and enhanced fibrin deposition 
on the endothelial surface [Khandoga, et al., 2004]. These prothrombotic effects are in 
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keeping with toxicological evidence from inhalation studies, which suggest particle 
exposure may promote thrombogenesis [Nemmar, et al., 2003; Nemmar, et al., 2003]. 
 
Direct Effects of Particles on Platelets 
Platelets are central to the process of intravascular thrombus formation. Few studies 
have addressed the direct effects of particles on platelets. In an elegant series of 
studies by Nemmar [Nemmar, et al., 2003; Nemmar, et al., 2003], in vivo thrombosis 
was induced by endothelial injury using the Rose-Bengal model. In hamsters treated 
with intra-tracheal diesel particles, both arterial and venous thrombosis was increased 
in a dose dependent manner. Platelets taken from the instilled animals underwent 
greater aggregation in vitro, although it is unclear whether enhanced in vivo thrombus 
formation was due to inflammation or the direct effects of the particles on platelet 
function. However, platelets isolated from normal hamsters and treated with diesel 
exhaust particles showed increased aggregation, suggesting that direct effects were at 
least plausible.   
 
In a comprehensive study [Radomski, et al., 2005], a range of manufactured 
nanoparticles including carbon nanotubes, fullerenes, urban PM and carbon 
nanoparticles were incubated with platelets in vitro. Platelet aggregation was assessed 
and clear differences in the potency of these particles were demonstrated. Fullerenes 
were without effect, urban dust and multi-walled nanotubes caused modest 
aggregation, whilst mixed carbon nanoparticles and single walled nanotubes were 
highly potent activators of platelets upregulating platelet glycoprotein IIb/IIIa receptor 
expression and enhancing aggregate formation. In a ferric chloride induced rat carotid 
artery thrombosis model, a similar potency was observed with particles enhancing the 
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rate of thrombus formation. Unfortunately, there was little characterisation of these 
particles that might have allowed features such as surface area or chemistry to be 
linked to the variation in effect on platelet aggregation or thrombus formation.  
 
Effect of Diesel Exhaust on Coagulation 
A number of ambient exposure studies have evaluated the association between plasma 
concentrations of coagulation factors and particulate air pollution with mixed results. 
Whilst some have demonstrated increased levels of fibrinogen [Ghio, et al., 2000; 
Mutlu, et al., 2007; Pekkanen, et al., 2000] and vWF [Ruckerl, et al., 2006], other 
studies measuring the same factors have failed to show any association with 
particulate exposure [Elder, et al., 2004; Gong, et al., 2003; Ruckerl, et al., 2006]. 
This apparent disparity may well be explained by variations in study design and 
perhaps more importantly, the type of exposure investigated. Two previous studies 
have investigated the effect of controlled diesel exhaust exposure on coagulation 
factors including fibrinogen, vWF, D-dimer, pro-thrombin fragment 1 and 2, t-PA and 
PAI-1 in man with neither demonstrating a significant effect [Blomberg, et al., 2005; 
Carlsten, et al., 2007]. 
 
1.4.5    SUMMARY 
Exposure to particulate air pollution is strongly associated with cardiovascular 
morbidity and mortality with multiple plausible mechanistic pathways identified 
whereby particles may exert adverse effects on the cardiovascular system. Acute 
exposure to combustion-derived pollutants appears to act as a trigger for myocardial 
infarction. Given that the majority of such events are due to thrombus formation on 
the surface of an atheromatous plaque and instillation of diesel exhaust particles 
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increases thrombus formation in pre-clinical models, it appears reasonable to explore 
whether these pathways are relevant in man and underpin the association between air 



































1.5    AIMS 
 
 
The aims of this body of work fell into three principal parts. 
 
1. The first step was to determine whether the Badimon Chamber technique could be 
established within our centre as a robust method of assessing ex vivo thrombus in 
man. During this process I explored the possibility of whether the process for 
quantifying thrombus formation could be made more efficient by utilising semi-
automated image acquisition and analysis equipment. In addition, I looked at ways to 
accurately add of compounds to the extracorporeal circuit of the chamber in order to 
broaden the applicability of the technique. 
 
Once these initial methodological and validation steps were successfully completed, I 
used the chamber to address questions with clinical relevance. 
 
2. Recent work within our centre has provided significant insights into the role of 
endogenous fibrinolysis, endothelial function and intravascular thrombosis. However, 
the primary end-point in all studies to date has been the quantification of t-PA release. 
In order to strengthen the clinical relevance of this technique, there was a need to 
develop a model of in situ thrombus formation that would permit the assessment of the 
relationship between endogenous fibrinolysis and the dynamics of thrombus formation 
and dissolution. I proposed to resolve this problem by using the Badimon Chamber in 
combination with the forearm model. Together, they provided an elegant means of 
stimulating acute t-PA release from the forearm endothelium in order to assess its 
ability to enhance fibrinolysis and modulate ex vivo thrombus formation. In addition, 
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the technique allows the assessment of modulators of thrombosis and fibrinolysis, 
permitting the investigation of a broad range of disease processes and mechanisms.  
3. Finally, given that preclinical data exist to suggest that thrombosis may be responsible 
for some of the deleterious effects of acute exposure to air pollution, I explored 
whether controlled exposure to diesel exhaust could cause platelet activation and/or 
enhance ex vivo thrombus formation and whether these effects could be attenuated by 



















1.6    HYPOTHESES 
 
The following hypotheses will be addressed: 
 
1. The Badimon Chamber provides a reproducible assessment of ex vivo thrombus 
formation (Chapter 3).  
2. Exogenous and endogenous t-PA inhibits in situ thrombus formation in the Badimon 
Chamber by enhancing fibrinolysis (Chapter 4). 
3. Inhibition of PAI-1 potentiates dissolution of in situ thrombus formation in the 
Badimon Chamber (Chapter 5).  
4. Exposure to diesel exhaust causes in vivo platelet activation and enhances ex vivo 
thrombus formation (Chapter 6). 
5. The use of a particle trap attenuates the adverse cardiovascular effects of diesel 







































2.1    GENERAL 
 
An overview of the techniques and statistical analysis employed in this thesis is 
presented below. Details specific to each study can be found in the methods section of 
subsequent chapters. 
 
2.1.1    SUBJECT RECRUITMENT 
Healthy male non-smoking volunteers (aged between 18 and 44 years) were recruited 
by local advertisement or from volunteer databases held at the Universities of 
Edinburgh and Umeå. An information sheet was sent to suitable volunteers who 
fulfilled the inclusion/exclusion criteria outlined below. The general practitioner of 
each participating subject was informed in writing. 
 
Subjects taking regular medication and those with clinical evidence of atherosclerotic 
vascular disease, arrhythmia, diabetes mellitus, hypertension (systolic blood pressure 
>150 mmHg), renal or hepatic failure, asthma, or an inter-current illness likely to be 
associated with inflammation were excluded. Subjects taking part in the diesel 
exposure studies had normal lung function, no significant occupational exposure to air 
pollution and reported no symptoms of respiratory tract infection for at least six 
weeks prior to or during the study. 
 
2.1.2    ETHICAL CONSIDERATIONS 
All studies were undertaken in accordance with the regulations of the appropriate 
local research ethics committee: Lothian Research Ethics Committee or Umeå 
Regional Ethical Review Board; and with the Declaration of Helsinki. Written 
informed consent was obtained from each subject prior to entry into the study.  
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2.1.3 SUBJECT PREPARATION 
Subjects were requested to abstain from alcohol for 24 hours and food, caffeine-
containing drinks and tobacco for at least six hours before each study. Studies were 

















2.2    DRUGS 
2.2.1    PAI-749 
PAI–749, 1-benzyl-3-pentyl-2-[6-(1H-tetrazol-5-ylmethoxy)naphthalen-2-yl]-1H-
indolemin (MW 502 Da), was synthesised and characterised for chemical identity and 
purity at Wyeth Research (Collegeville, USA). Aliquots of stock solution (0.5 
mg/mL; 1 mM) were prepared in 50% PEG-200/50% sterile water and stored at         -
80°C prior to use. A single batch of PAI–749 was used for all studies.  
 
2.2.2    TISSUE PLASMINOGEN ACTIVATOR 
Aliquots of recombinant t-PA (Boehringer Ingelheim, Germany) for infusion into the 
extracorporeal circuit of the Badimon Chamber were prepared in 0.9% saline and 
stored at -80°C prior to use. 
 
2.2.3    VASODILATORS 
Acetylcholine, bradykinin (both supplied by MSD, UK) and sodium nitroprusside 
(David Bull Laboratories, UK) solutions for intra-arterial infusion were prepared in 
0.9% saline on the day of use. 
 
2.2.4    ENALAPRIL 
Enalapril 10 mg (MSD, UK) and matched placebo were prepared and packaged by 






2.3    EX VIVO THROMBOSIS STUDIES 
 
Ex vivo thrombus formation was measured using the Badimon Chamber. A 17-gauge 
venous cannula was inserted into a large subcutaneous vein in the antecubital fossa. A 
peristaltic pump (Masterflex model 7013, Cole-Palmer Instruments, USA), positioned 
distal to the chambers, was used to draw blood from the venous cannula via a length 
of polyethylene tubing, through a series of three cylindrical perfusion chambers 
maintained at 37˚C in a water bath (Figure 2.1). Each study lasted for five minutes 
during which blood flow was maintained at a constant rate of 10 mL/min. Carefully 
prepared strips of porcine aorta (Pel-Freez Biologicals, USA), from which the intima 
and a thin layer of media had been removed, acted as the thrombogenic substrate 
[Fernandez-Ortiz, et al., 1994]. The rheological conditions in the first chamber 
simulate those of patent coronary arteries (low shear rate, approximately 212 s-1), 
while those in the second and third chambers simulate those of mildly stenosed 
coronary arteries (high shear rate, approximately 1690 s-1). Following perfusion of 
blood, the chambers were flushed with 0.9% saline for one minute under the same 
rheological conditions to remove residual blood and non-attached cells. All studies 
were performed using the same perfusion chambers. Immediately after each study, the 
porcine strips with thrombus attached were removed and fixed in 4% 










2.3.1    ADDITION OF COMPOUNDS TO THE EXTRACORPOREAL 
CIRCUIT 
For studies requiring the addition of compounds to the extracorporeal circuit, study 
drugs were added using a calibrated syringe driver (Alaris Arsena GH, Cardinal 
Health, USA) and allowed to mix prior to entering the perfusion chambers (Figure 
2.1). Appropriate samples were taken from the effluent of the chamber in order to 
confirm accurate addition of compounds. 
 
2.3.2 HISTOLOGICAL ANALYSIS 
As thrombus forms along the entire length of the exposed porcine aortic strip, the 
cross-sectional area gives a reliable reflection of total thrombus [Dangas, et al., 1998]. 
Following fixation, the proximal and distal 1 mm of the exposed substrate were 
removed and discarded. The remainder was cut into four pieces. These pieces were 
subsequently paraffin-wax embedded and 5 µm sections were prepared from each in 
order that quantification was performed on sections taken from all parts of the 
exposed tissue strip. 
 
Sections were stained with Masson’s trichrome stain to detect total thrombus or with 
an anti-fibrin II β chain mouse monoclonal antibody (clone T2G1; Accurate Chemical 
& Scientific Corporation, USA) to detect fibrin. For immunohistochemical staining, 
endogenous peroxidase activity was blocked by treatment with 3% hydrogen peroxide 
and serum free protein block (Dako, Denmark). Sections were then incubated with the 
primary antibody at a final concentration of 10 µg/mL for 1 hour at room temperature. 
Detection was performed using EnVision™ (Dako, Denmark) and treatment with 3,3'-
Diaminobenzidine substrate chromogen (Dako, Denmark). Finally, sections were 
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counterstained with haematoxylin. No staining was present on specimens not 
incubated with the primary antibody or on areas of the specimens not exposed to 
blood flow. 
 
A purpose-designed semi-automated scanning microscope (BX61, 142 
Olympus, UK) and image analysis system (Ariol 3.1, Applied Imaging, USA) were 
used to quantify thrombus area and composition. Digital images of each section were 
acquired at ×20 magnification. High-resolution classifiers, based on colour and shape 
parameters, were established to detect total thrombus and fibrin staining. Results from 
at least six sections were averaged to determine thrombus area for each chamber as 













2.4 FLOW CYTOMETRIC ASSESSMENTS OF 
PLATELET ACTIVATION 
 
Samples were obtained directly from the venous cannula, from the tubing 
immediately before the perfusion chambers and from the effluent immediately after 
the perfusion chambers, as appropriate, and processed according to previously 
described protocols [Harding, et al., 2006]. Blood was anticoagulated with D-
phenylalanyl-L-prolyl-L-arginine chloromethylketone (PPACK, 75 µm; Cambridge 
Biosciences, UK). Five minutes after sample collection, samples were stained with the 
following conjugated monoclonal antibodies, as appropriate: PE-conjugated CD14 
(Dako, Denmark), PE-conjugated CD154, PE-conjugated CD62P (Becton-Dickinson, 
UK); PE-conjugated CD11b, PE-conjugated CD40, FITC-conjugated CD42a, FITC-
conjugated CD14 (Serotec, USA); and appropriate control isotypes. All antibodies 
were diluted 1:20. Once stained, samples were incubated for 20 minutes at room 
temperature to identify P-selectin and CD40L on the platelet surface and CD40 on the 
monocyte surface. Platelet-monocyte samples were fixed with FACS-Lyse (Becton-
Dickinson, UK); platelet samples were fixed with 1% paraformaldehyde. Samples 
were analysed within 24 hours using a FACScan flow cytometer (Becton-Dickinson, 
UK). Platelet–monocyte and platelet–neutrophil aggregates were defined as 
monocytes or neutrophils positive for CD42a, as described previously [Harding, et al., 






2.5 DIESEL EXHAUST EXPOSURES 
 
The diesel exhaust exposures were standardised to ensure a particle matter (PM) 
concentration circa 350 µg/m3. These concentrations are found on a regular basis in 
heavy traffic, occupational settings, and in the world’s most-polluted cities. 
 
2.5.1 DIESEL EXHAUST EXPOSURES IN EDINBURGH, UK 
Exposures in Edinburgh, UK were performed using a mobile ambient particle 
concentrator exposure laboratory (MAPCEL) in collaboration with a group from the 
Dutch National Institute of the Environment (RIVM). 
 
During exposures, subjects performed moderate exercise (minute ventilation 25 
L/min/m2) on a bicycle ergometer for 15 minutes alternated with 15-minute rest 
periods. Temperature and humidity in the chamber were controlled at 22ºC and 50% 
respectively. Diesel exhaust was generated by an idling engine (type F3M2011, 2.2 L, 
500 rpm; Deutz, Germany) using gas oil (Petroplus Refining, UK). Over 90% of the 
exhaust fumes were shunted away, with the remainder being diluted with air and fed 
into the exposure chamber at a steady-state concentration. Air in the chamber was 
continuously monitored with exposures standardised using continuous measurement 
of nitrogen oxide (NOx) concentrations to deliver a particulate concentration of 350 
µg/m3. There was little variation in particle mass (348±68 µg/m3), particle number 
(1.2±0.1 x 106/cm3), NOx (0.58±0.03ppm), NO2 (0.23±0.02ppm), NO 
(0.36±0.02ppm), CO (3.54±0.76ppm) and total hydrocarbon (2.8±0.1 µg/m3) 




2.5.2 DIESEL EXHAUST EXPOSURES IN UMEA, SWEDEN  
Exposures in Umeå, Sweden were performed using a well-characterised exposure 
facility in Umeå, Sweden. This facility has been used to study the effects of dilute 
diesel exhaust on lung inflammation and function in a range of healthy volunteers and 
patients with pulmonary disease since its inception in 1994.  
 
The diesel exhaust was generated from an idling Volvo diesel engine (Volvo TD45, 
4.5L, 4 cylinders, 680rpm) from Swedish Low Sulphur Gasoil E10 (Preem, Sweden). 
Over 90% of the exhaust was shunted away, and the remainder diluted with filtered 
air heated to 20oC (humidity ~50%) before being fed into a whole body exposure 







Figure 2.2 (a) Idling diesel engine and (b) whole body exposure chamber for human exposure 
studies to dilute diesel exhaust. 
 
During exposures, subjects performed moderate exercise as described above. 
Exposures were standardised using continuous measurement of NOx to deliver a 
particulate concentration of 350 µg/m3. There was little variation in particle mass 
(330±12 µg/m3), particle number (1.26±0.01 x 106/cm3), NOx (2.78±0.03ppm), NO2 
(0.62±0.01ppm), NO (2.15±0.03ppm), CO (3.08±0.12ppm) and total hydrocarbon 
(1.58±0.16 µg/m3) concentrations between exposures. 
 
Air inside the chamber was continuously monitored for pollutants with exposures 
standardised using real time measurements of NOx. Nitrogen dioxide and nitrogen 
oxide were measured online using a chemiluminescence technique (ECO Physics 
CLD 700 AL Med, Switzerland). A UNOR 610 infrared spectrophotometer (Maihak 
AG, Germany) was used for online monitoring of carbon monoxide. Total 
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hydrocarbon in the exposure aerosol was measured using a flame ionisation detection 
method (Hydrocarbon Analyser, Model 3-300, JUM Engineering Co., USA). 
Continuous registration of the number of particles <1 µm diameter/cm3 was obtained 
with a condensation particle counter (TSI, USA). The size distribution of particulate 
in the exposure chamber was determined using a scanning mobility particle sizer 
(TSI, USA). 
 
The size distribution of PM in the exposure chamber demonstrated a lognormal 
distribution, typically ranged from 20 to 120 nm, with a count median diameter of 54 
nm (geometric standard deviation = 1.7 nm; Figure 2.3). The polycyclic aromatic 
hydrocarbons (PAHs) consisted of semi-volatile gaseous compounds with only a 
minor fraction (3.5%) present as particulate associated material, 0.04% of total PM 
and 0.06% of the PM organic fraction. The dominating PAHs were phenanthrene, 
fluorene, 2-methylfluorene, dibenzothiophene and different methyl-substituted 






Figure 2.3 a) Particle number (○) and count median diameter (●) of particulate during 
controlled exposure to dilute diesel exhaust for 60 minutes (mean±SEM, n=5). b) The size of 
inhaled diesel particulates (n=5) showed a lognormal distribution and typically ranged from 





2.5.3    PARTICLE TRAP 
The particle trap (DPF-CRT® [Continuously Regenerating Trap], Johnson Matthey, 
Royston, UK) used is an unmodified CRT filter, available commercially throughout 
the world as a factory-fit option or as a retrofit unit to buses and heavy goods vehicles 
(Figure 2.4). It is similar in design to filters produced by a number of manufacturers. 
It consists of a ceramic structure containing a honeycomb-like complex of channels 
through which the exhaust is passed. A platinum catalyst at the front of the filter 
oxidises part of the NO gas in the exhaust into NO2, which flows through the particle 
filter and subsequently reacts with trapped carbonaceous particles to generate CO2 and 
N2. This increases NO2 levels in the exhaust after the particle trap, without causing 
significant changes in total NOx concentrations, whilst achieving an efficient 

























Figure 2.4 The exhaust particle trap used in these studies was a continuously regenerating 
trap similar to that depicted above  
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2.6 ASSESSMENT OF VASCULAR AND 
FIBRINOLYTIC FUNCTION 
 
Measuring the response to vasoactive substances released by, or those that interact 
with, the vascular endothelium in the forearm is a useful measure of endothelial 
function. Local intra-arterial drug infusion into the brachial artery permits the direct 
assessment of vascular responses in the forearm without invoking concomitant effects 
on other organs. In this way the vessels are studied in their physiological environment 
under the influence of neuronal, circulating, and local mediators [Benjamin, et al., 
1995].  Although measurement of coronary vascular response is of greatest clinical 
relevance, invasive coronary studies can only really be performed in patients 
undergoing angiography. The close correlation between coronary and peripheral 
endothelium-dependent responses [Anderson, et al., 1995] suggests that endothelial 
dysfunction may be a systemic state or that circulating factors have parallel effects in 
both coronary and peripheral arteries [Vita, et al., 2004].  
 
2.6.1  VENOUS OCCLUSION PLETHYSMOGRAPHY 
This method of assessing resistance vessel function in the forearm is based on the 
principle of strain gauge venous impedance plethysmography. This technique 
examines the change in forearm blood flow (FBF) during intra-arterial (brachial 
artery) administration of agonists at locally active doses (Figure 2.5) [Benjamin, et al., 








Figure 2.5 a) Intra-brachial artery infusions along with venous occlusion (upper arm) and 
supra-systolic pressure (wrist) cuffs in a healthy volunteer. b) A venous cannula for blood 





The technique of venous occlusion plethysmography relies on intermittently 
preventing venous drainage from the arm using upper arm cuffs inflated to above 
venous pressure whilst arterial inflow is unaltered: blood can enter the forearm but 
cannot escape. This results in a linear increase in forearm volume over time, which is 
proportional to arterial blood inflow (Figure 2.6). Under resting conditions, 
approximately 70% of total forearm blood flow is through skeletal muscle. As the 
hand contains a high proportion of arteriovenous shunts with a different 
pharmacology and physiology it is excluded from the circulation by the application of 
inflation cuffs at supra-systolic pressure during the measurement. The technique of 
bilateral forearm blood flow measurement is highly reproducible within individuals 
[Walker, et al., 2001] and is ideally suited to assessment of interventional strategies 
























Figure 2.6 Typical blood flow recording from non-infused and infused arms with infusion of 
intra-brachial bradykinin during venous plethysmography study. 
Brachial Artery Cannulation 
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The brachial artery of the non-dominant arm was cannulated with a 27-gauge steel 
needle (Cooper's Needle Works Ltd, UK) under 1% lidocaine (Xylocaine; Astra 
Pharmaceuticals Ltd, UK) local anaesthesia. The cannula was attached to a 16-gauge 
epidural catheter (Portex Ltd, UK) and patency maintained by infusion of saline 
(0.9%; Baxter Healthcare Ltd, UK) via an IVAC P6000 syringe pump (IVAC Ltd., 
UK). The total rate of intra-arterial infusions was maintained constant throughout all 
studies at 1 mL/min.  
 
Blood Flow Measurement 
Blood flow was measured in the infused and non-infused forearms by venous 
occlusion plethysmography using mercury-in-silastic strain gauges that were applied 
to the widest part of the forearm [Benjamin, et al., 1995]. Both arms were placed 
above the level of the right atrium and upper arm cuffs were inflated intermittently to 
40 mmHg (venous occlusion) pressure for 10 seconds in every 15 seconds to achieve 
venous occlusion and obtain plethysmographic recordings. During measurement 
periods, the hands were excluded from the circulation by rapid inflation of the wrist 
cuffs to a pressure of 220 mmHg (supra-systolic) using E20 Rapid Cuff Inflators 
(D.E. Hokanson Inc., Washington, USA). Analogue voltage output from an EC-4 
strain gauge plethysmograph (D.E. Hokanson Inc., USA) was processed by a 
PowerLab® analogue-to-digital converter and Chart™ v5.0.1 software (AD 
Instruments Ltd., UK) and recorded onto a Dell Latitude® laptop (Dell Computers 
Ltd., UK). Calibration was achieved using the internal standard of the 
plethysmograph. Heart rate and blood pressure were monitored in the non-infused arm 
throughout each study with a non-invasive, semi-automated oscillometric 
sphygmomanometer (Boso Medicus, Germany). 
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Plethysmographic Data Analysis 
A single operator undertook analysis of all plethysmographic data collected during the 
forearm studies in a blinded manner. Forearm blood flow responses are reported as 
absolute blood flow responses (mL/100 mL tissue/min) in the infused and non-infused 
arm. Plethysmographic data were extracted from the Chart™ data files and forearm 
blood flows were calculated for individual venous occlusion cuff inflations by use of 
a template spreadsheet (Excel v12.3, Microsoft Corp., USA). Recordings from the 
first 60 seconds after wrist cuff inflation were not used because of the variability in 
blood flow during this period [Benjamin, et al., 1995]. Usually, the last five flow 
recordings in each 3-minute measurement period were calculated and averaged for 
















2.7    VENOUS SAMPLING AND LABORATORY 
ASSAYS 
 
2.7.1    SAMPLE PREPARATION AND PROCESSING 
Differential white cell count, haematocrit, clinical biochemical assays, prothrombin 
and activated partial thromboplastin times were undertaken on fresh venous samples 
in Edinburgh (Departments of Haematology and Clinical Biochemistry, Lothian NHS 
University Hospitals Trust, UK) and Umeå (Departments of Haematology and 
Clinical Biochemistry, Umeå Hospital University, Sweden).  
 
Citrate and acidified buffered citrate samples (StabilyteTM, Biopool International, 
USA; for fibrinolytic components) were kept on ice before being centrifuged at 
2,000g for 30 minutes at 4°C. Ethylenediaminetetraacetic acid samples (BD 
Vacutainer, USA; for PAI–749 assays) were kept at room temperature before being 
centrifuged at 1,000g for 10 minutes at 20°C. Serum samples were centrifuged at 
2,000g for 20 minutes after being allowed to clot on ice. Following centrifugation, 
platelet free plasma or serum was decanted and stored at -80ºC before assay. 
 
2.7.2    FIBRINOLYTIC AND INFLAMMATORY ASSAYS 
Plasma t-PA antigen and activity (t-PA Combi Actibind Elisa Kit, Technoclone, 
Austria), PAI-1 antigen and activity (Zymutest PAI-1 antigen and Zymutest PAI-1 
Activity, Hyphen Biomed, France), D-dimer (Asserachrom, Roche, Switzerland) 
and thrombin-antithrombin (TAT) complex (Enzgnost, Dade Behring Inc., UK) were 
determined by commercially available enzyme linked immunosorbant assays 
(ELISA). Intra-assay coefficients of variation were 7.0% and 5.5% for t-PA and PAI-
1 antigen, 4.0% and 2.4% for t-PA and PAI-1 activity, 4.2% for D-dimer and 6.1% for 
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TAT complex, respectively. Inter-assay coefficients of variability were 4.0%, 7.3%, 
4.0%, 7.6%, 6.0% and 4.5%, respectively. The sensitivities of the assays were 0.5 
ng/mL, 0.10 IU/mL, 2.5 ng/mL, 5 IU /mL, 2.0 ng/mL and 2.2 ng/mL respectively. 
Measurement of t-PA/PAI-1 complex was undertaken as described previously 
[Bennett, et al., 1990]. 
  
Plasma IL-6, tumour necrosis factor-alpha (TNF-α), soluble P-selectin, and soluble 
intracellular adhesion molecule-1 (ICAM-1) were measured with commercially 
available ELISAs (Quantikine, R&D Systems). Intra-assay, and inter-assay 
coefficients of variability were 5.0% and 6.9%, and 4.3% and 6.6% for plasma TNF-α 
and IL-6 respectively. Serum CRP concentrations were determined using with a 
validated highly sensitive assay (Department of Clinical Biochemistry; Fife NHS 
Trust, UK) using the method of particle-enhanced immunonephelometry (Behring BN 
II nephelometer, Dade Behring Inc., UK). Intra-assay and inter-assay coefficients of 
variability for hs-CRP were 3.3% and 4.9% respectively. 
 









2.8 DATA ANALYSIS AND STATISTICS 
 
Continuous variables are reported as mean ± standard error of the mean (SEM). 
Statistical analysis was performed with GraphPad Prism (GraphPad Software, USA) 
using paired Student’s t-tests, analysis of variance (ANOVA) with repeated measures 
and calculation of the Pearson correlation coefficient as appropriate. Statistical 
significance was taken at the 5% level. Reproducibility was assessed by the method of 
Bland & Altman [Bland, et al., 1986] and coefficients of reproducibility calculated for 





























CHARACTERISATION AND REPRODUCIBILITY 












Published by Lucking AJ, Chelliah R, Trotman AD, Connolly TM, Feuerstein GZ, 
Fox KA, Boon NA, Badimon JJ, Newby DE. Characterisation and reproducibility of a 
human ex vivo model of thrombosis 




3.1    SUMMARY 
The Badimon chamber is a clinical ex vivo model of thrombosis that mimics flow 
conditions within the coronary circulation of man. The aims of this study were to 
characterise thrombus formation in the chamber and evaluate its reproducibility. In 24 
healthy volunteers, total thrombus area was assessed at low and high shear rates with 
porcine aortic tunica media as the thrombogenic substrate. Reproducibility of 
thrombus formation was assessed by paired measurements made both within and 
between days. Platelet activation was assessed by flow cytometry, and fibrin content 
and distribution were assessed by immunohistochemistry. Thrombus area was highly 
reproducible in the low ([mean thrombus area, mean difference ± SEM] 8,018 µm2, 
58±204 µm2 and 8,177 µm2, -154±168 µm2 within and between days respectively) 
and high shear chambers (11,802 µm2, -52±175 µm2 and 11,877 µm2, 220±181 µm2 
within and between days respectively). Total thrombus area was greater in the high 
compared to the low shear chamber (11,970±285 µm2 versus 7,892±298 µm2; 
P<0.0001). Thrombus within the low shear chamber contained a greater proportion of 
fibrin (25.0±6.0% versus 8.3±1.6% in high shear chamber, P<0.001). Platelet 
activation was only detected once blood had passed through the chamber (P=0.049 for 
platelet-monocyte aggregate formation and P=0.078 for P-selectin expression). There 
was no association between basal platelet activation and thrombus area (P=0.85 and 
P=0.66 in the low and high shear chamber respectively).  
 
The Badimon chamber provides a highly reproducible technique for the assessment of 
ex vivo thrombus formation in man. 
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3.2    INTRODUCTION 
Cardiovascular disease is the leading cause of death worldwide with thrombosis 
playing a central role in its pathogenesis, particularly during acute events such as 
myocardial infarction. Whilst preclinical models can provide useful insights into 
novel antithrombotic interventions, species-specific differences ensure that phase I 
clinical studies remain an essential part of antithrombotic drug development [Leadley, 
et al., 2000].  
 
The demonstration of antithrombotic efficacy in man is challenging, Most techniques 
involve the evaluation of specific plasma and cellular components in isolation, require 
the addition of an anticoagulant to limit in vitro activation, and are often performed 
under static conditions. In contrast, in vivo thrombus initiation and growth occur in 
whole blood, under conditions of continuous flow, and often in the presence of 
vascular injury. Thus assessment of the efficacy of antiplatelet and anticoagulant 
agents may not be reflected by static or unidimensional systems employed by in vitro 
assays [Kroll, et al., 1996]. An in vivo model for use in clinical studies presents 
significant safety issues and does not currently exist. The Badimon chamber is an ex 
vivo model of thrombosis that is suitable for use in clinical studies and has previously 
been used to assess novel antithrombotic regimens [Lev, et al., 2006; Wahlander, et 
al., 2006; Zafar, et al., 2007; Zafar, et al., 2007]. It has a number of important 
advantages over other techniques including the ability to assess thrombus formation 
on a pathophysiologically relevant substrate and under conditions of continuous flow 
[Badimon, et al., 1986; Badimon, et al., 1987].  
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Although the Badimon chamber technique is well-established, previous 
characterisation studies were performed in a porcine system and using methodology 
that has since been superseded [Badimon, et al., 1986; Badimon, et al., 1987]. In 
addition, there are no published studies specifically addressing the reproducibility of 
thrombus formation in the chamber. Therefore, the principal aims of this study were 
to characterise the thrombus formed in the chamber, and to assess within and between 
day reproducibility. Specifically, we used a semi-automated combined image 
acquisition and analysis system to measure total thrombus area and the contribution of 
fibrin. In addition, the potential for platelet activation to occur within the 
extracorporeal circuit may limit the sensitivity of the technique to detect subtle 
changes in thrombotic potential, particularly in situations where platelet activation is 
likely to be a major determinant of thrombus formation. Using flow cytometry, we 
therefore assessed the effect of blood transit through the extracorporeal circuit and the 
perfusion chambers on platelet activation. Finally we investigated whether basal 










3.3    METHODS 
3.3.1    SUBJECTS 
Twenty-four healthy non-smokers aged between 18 and 30 years old were enrolled 
into the study that was performed with the approval of the local research ethics 
committee, in accordance with the Declaration of Helsinki, and the written informed 
consent of all volunteers. Exclusion criteria were bleeding diasthesis, the use of 
regular medication or any clinically significant illness. 
  
3.3.2    EX VIVO THROMBOSIS STUDIES 
Thrombus formation was measured using the Badimon Chamber as described in 
section 2.3.  
 
Histological Analysis 
Sections were stained with Masson’s trichrome stain to detect total thrombus or with 
an anti-fibrin II β chain mouse monoclonal antibody (clone T2G1; Accurate Chemical 
& Scientific Corporation, USA) to detect fibrin. For immunohistochemical staining, 
endogenous peroxidase activity was blocked by treatment with 3% hydrogen peroxide 
and serum free protein block (Dako, Glostrup, Denmark). Sections were then 
incubated with the primary antibody at a final concentration of 10 µg/mL for 1 hour at 
room temperature. Detection was performed using EnVision™ (Dako, Denmark) and 
treatment with 3,3'-Diaminobenzidine substrate chromogen (Dako, Denmark). 
Finally, sections were counterstained with haematoxylin. No staining was present on 
specimens not incubated with the primary antibody or on areas of the specimens not 
exposed to blood flow. 
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A purpose-designed semi-automated scanning microscope (BX61, 142 
Olympus, UK) and image analysis system (Ariol 3.1, Applied Imaging, USA) was 
used to quantify thrombus area and composition. Digital images of each section were 
acquired at ×20 magnification. High-resolution classifiers, based on colour and shape 
parameters, were established to detect total thrombus, platelet and fibrin staining. 
Results from at least six sections were averaged to determine thrombus area for each 
chamber as described previously [Lev, et al., 2006; Wahlander, et al., 2006; Zafar, et 
al., 2007]. 
 
3.3.3    FLOW CYTOMETRY 
Samples were obtained directly from the venous cannula, from the tubing 
immediately before the perfusion chambers and from the effluent immediately after 
the perfusion chambers and processed according to previously described protocols 
[Harding, et al., 2006]. In brief, blood was anticoagulated with D-phenylalanyl-L-
prolyl-L-arginine chloromethylketone (PPACK, 75 µm; Cambridge Biosciences, 
UK). Five minutes after sample collection, samples were stained with the following 
conjugated monoclonal antibodies: PE-conjugated CD14 (Dako, Denmark), PE-
conjugated CD62P (Becton-Dickinson, UK); PE-conjugated CD11b, FITC-
conjugated CD42a, FITC-conjugated CD14 (Serotec, USA); and appropriate control 
isotypes. All antibodies were diluted 1:20. Once stained, samples were incubated for 
20 minutes at room temperature. Platelet-monocyte samples were fixed with FACS-
Lyse (Becton-Dickinson, UK); platelet samples were fixed with 1% 
paraformaldehyde. Samples were analysed within 24 hours using a FACScan flow 
cytometer (Becton-Dickinson, UK). Platelet–monocyte aggregates were defined as 
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monocytes staining positive for CD42a, as described previously [Harding, et al., 
2007]. Analysis was performed using FlowJo (Treestar, USA). 
  
3.3.4    STUDY DESIGN 
To assess within and between day reproducibility, sixteen subjects attended on two 
separate occasions, two weeks apart. On the first visit, two studies were performed 45 
minutes apart followed by a final study on the second visit. Samples for flow 
cytometry were taken during the first visit in eight of the subjects. A separate cohort 
of eight subjects attended for a single study to allow the specific assessment of fibrin 
area and distribution within the thrombi.  All 24 subjects attended fasted at 9 am on 
the day of the study. All abstained from alcohol for 24 hours and from food and 
caffeine-containing drinks for at least six hours before each study. Studies were 
carried out with subjects lying supine in a quiet, temperature-controlled room 
maintained at 22°C to 25°C. 
 
3.3.5    STATISTICAL ANALYSIS 
Continuous variables are reported as mean ± standard error of the mean (SEM). 
Statistical analysis was performed with GraphPad Prism (GraphPad Software, USA) 
using paired Student’s t-tests, analysis of variance (ANOVA) with repeated measures 
and calculation of the Pearson correlation coefficient as appropriate. Statistical 
significance was taken at P<0.05. Reproducibility was assessed by the method of 
Bland & Altman [Bland, et al., 1986] and coefficients of reproducibility calculated for 




3.4    RESULTS 
All study visits were completed in each subject and were well tolerated.  
 
3.4.1    REPRODUCIBILITY 
Thrombus area was highly reproducible in the low and high shear chambers, both 
within and between days (Figures 3.1 and 3.2; Table 3.1). The 95% confidence 
intervals, indicated by the coefficients of reproducibility, are similar within and 
between days indicating that thrombus formation assessed in the Badimon Chamber is 
consistent over time within this healthy population. 
 
 







                
Figure 3.2 Bland-Altman plots of thrombus formation within and between days (n=16). 
 
 














Low Shear Chamber 8018 58 1443 8177 -154 1231 
High Shear Chamber 11802 -52 1331 11877 220 1490 
 
 
Table 3.1 Within and between day reproducibility of ex vivo thrombus formation 
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3.4.2    QUANTIFICATION AND DISTRIBUTION OF FIBRIN 
Total thrombus area was greater in the high compared to the low shear chamber 
(12,730±550 µm2 versus 7,401±512 µm2, P<0.0001; Figure 3.3a). Although absolute 
fibrin area appeared only marginally greater in the low shear chamber (2,347±129 
µm2 versus 1,877±233 µm2, P=0.068; Figure 3.3a), fibrin formed a substantially 
greater proportion of the thrombus within the low shear chamber compared to the 
high shear chamber (25.0±6.0% versus 8.3±1.6%, P<0.001). The fibrin was 
predominantly distributed along the base of the thrombus, with platelets aggregates 
forming above this layer of fibrin (Figure 3.3b). 
 
3.4.3    PLATELET ACTIVATION 
Consistent with a healthy volunteer cohort, baseline levels of platelet-monocyte 
aggregates (22±2.8%) and platelet P-selectin expression (0.42±0.12%) were low 
[Harding, et al., 2007]. Whilst levels of platelet-monocyte aggregates and platelet P-
selectin expression appeared to increase as blood passed across the perfusion 
chambers (P=0.049 and P=0.078 respectively; Figure 3.4), tubing in the 
extracorporeal circuit did not cause platelet activation. There was no correlation 
between baseline levels of platelet-monocyte aggregates and thrombus formation in 










Figure 3.3 a) Total thrombus area and fibrin area within the low and high shear chambers. 
Data shown are mean ± SEM (n=8). b) Representative photomicrograph of porcine media 
exposed to flowing blood in the high shear chamber, demonstrating the method used to 
quantify thrombus formation. This section has been stained for fibrin and counterstained with 
haematoxylin. Staining reveals two morphologically distinct components within the thrombus; 
irregularly shaped platelet aggregates (light pink) and a more uniform, fibrin layer that forms 
along the surface of the porcine media (brown). The rectangular box indicates an area 
marked out for analysis. The software is calibrated using colour to differentiate between 
areas of fibrin (highlighted in green) and areas of platelet-rich thrombus (highlighted in red). 
Total thrombus area was calculated by adding fibrin area to platelet-rich area. Original 
magnification × 20. 
 
 
Figure 3.4 The effect of passage through the extracorporeal circuit and across the perfusion 
chambers on platelet activation. Data shown are mean ± SEM (n=8). 
 87 
3.5    DISCUSSION 
The Badimon chamber produces a platelet-rich thrombus that forms upon a basal 
layer of fibrin. The contribution of fibrin is greater under conditions of lower shear 
stress, whilst platelets contribute more under conditions of high shear stress. We have 
here found that measurement of the total area of this type of thrombus is highly 
reproducible both within and between days. We suggest that this technique provides a 
flexible clinical ex vivo model of thrombosis suitable for use in crossover 
interventional studies.  
 
3.5.1    REPRODUCIBILITY 
The reproducibility of the Badimon chamber in human subjects has not been 
previously assessed and is an important aspect of validating the technique. In addition, 
several important changes to the methodology have recently been made, necessitating 
re-evaluation of the technique. Here, we found that thrombus formation within the 
low and high shear chambers was highly reproducible both within and between days 
with similar coefficients of reproducibility. This suggests that the Badimon Chamber 
provides a robust and reproducible means of assessing whole blood thrombogenicity 
that is valid for use in multi-visit crossover studies.  
 
Whilst blood flow within this system is not pulsatile, rheological conditions otherwise 
broadly simulate those at the site of intra-coronary atheromatous plaque rupture. In 
combination with the use of porcine tunica media as a pathophysiologically relevant 
thrombogenic substrate, the technique serves as a model of deep coronary arterial 
injury. As such, we believe that it is particularly useful for evaluating the efficacy of 
novel antithrombotic interventions.  
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Previous preclinical studies evaluating the Badimon chamber included several 
important differences to its current application in clinical studies. First, many studies 
were performed in pigs using heparinised blood from the carotid artery passing 
through the extracorporeal circuit containing the perfusion chambers, before returning 
to the animal via the jugular vein. These studies also evaluated porcine aortas in 
which selective endothelial injury had been caused without disruption to the 
underlying basement membrane. Moreover, initial studies used platelet deposition 
(measured using 111Indium-labelled platelets) as a surrogate for thrombus formation. 
Thus, many distinct differences exist that necessitate critical evaluation in its 
application to the clinical setting. 
 
Given the safety and logistical difficulties of using radiolabelled blood components, a 
histological method for assessing thrombus area was developed for clinical studies. 
Whilst more time-consuming, histological analysis has several important advantages 
over 111Indium-labelled platelets. By using appropriate conventional staining 
techniques in combination with immunohistochemistry, total thrombus area and 
specific components can be quantified [Dangas, et al., 1998; Giesen, et al., 1999]. For 
the majority of studies, Masson’s trichrome stain is sufficient to quantify both fibrin-
rich and platelet-rich thrombus. Histological assessment also allows for the 
identification of confounding factors such as those caused by gross surface 
irregularities and flaps that can occur on the denuded aortic strips. Here thrombus 
formation will be driven by tissue disruption rather than the thrombotic state of the 
subject or the proposed drug intervention.  
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In this study we utilised a validated purpose-designed imaging system capable of 
combined semi-automated image acquisition and analysis coupled with a slide loading 
system [Gokhale, et al., 2007]. This contrasts with other work where image data were 
acquired using manual camera/microscope stages before being transferred and 
analysed using separate image analysis software. Given the large amount of image 
data produced during these studies, the use of an integrated system improves the 
efficiency and accuracy of the analysis process, and minimises the potential for errors 
to be made during image acquisition. 
 
Although the majority of previous studies have used a parallel group design, we here 
specifically addressed the suitability of the technique for use in multi-visit crossover 
studies by assessing both between day as well as within day reproducibility. However, 
given that only healthy volunteers were used, we acknowledge that between day 
reproducibility, in particular, may not be as robust in a patient cohort where period 
and time-order effects caused by fluctuations in disease-activity and treatment-
response may play a role; factors that were mitigated in this study. 
 
3.5.2    CHARACTERISATION  
Consistent with studies of arterial thrombus formation performed using real-time in 
vivo imaging in the mouse [Falati, et al., 2002], fibrin was distributed in a uniform 
manner along the surface of the porcine aortic strip. The remainder of the thrombus is 
predominantly composed of platelets that project into the chamber lumen as irregular 
shaped aggregates. This distribution of fibrin and platelets is consistent with previous 
clinical reports of the Badimon chamber [Dangas, et al., 1998]. This would suggest 
that a carpet of fibrin is formed on the surface of a disrupted vessel that then acts as a 
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platform for platelet aggregates to form. The proportionate contribution of fibrin to 
total thrombus area was greatest for the low shear chamber consistent with the greater 
role of platelets under conditions of high shear stress. This may have implications for 
the investigation of interventions likely to have a predominant effect on fibrin content. 
 
3.5.3    PLATELET ACTIVATION 
The extracorporeal circuit of the system comprises polypropylene tubing specifically 
selected in order to minimise activation of platelets and components of the 
coagulation system. It was reassuring that platelet activation did not occur within the 
extracorporeal circuit prior to contact with the perfusion chambers themselves. 
However, platelet activation did occur following passage through the perfusion 
chambers themselves, consistent with exposure to elevated shear conditions and the 
thrombogenic surface therein. The surface of the arterial media is comprised of a 
variety of subendothelial components including collagen types III and IV, fibronectin 
and smooth muscle cells [Dangas, et al., 1998], all of which are know to activate 
platelets, principally through interaction with the platelet glycoprotein Ib receptor. 
Indeed, given exposure to these conditions, it might be expected that platelet 
activation would be greater. However, a large proportion of activated platelets may 
have become incorporated into the thrombus itself and were thus not detectable in the 
chamber effluent or alternatively the relatively short transit time across the chambers 
permitted only limited platelet activation or formation of platelet-monocyte 
aggregates. 
 
Baseline levels of platelet activation did not correlate with thrombus area in either the 
low or high shear chambers. This suggests that in healthy volunteers, the principal 
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determinant of thrombus formation is the nature of the thrombogenic substrate rather 
than the state of platelet activation.  However, we acknowledge that given the limited 
sample size combined with low baseline levels of platelet activation in a healthy 
volunteer cohort, this study was not adequately powered to detect any potential 
correlation; the chance of a type II error is thus high. Further studies are required in 
subjects and patients with a wider range of platelet activation. 
 
3.5.4    CONCLUSION 
We have demonstrated that ex vivo thrombus formation in the Badimon Chamber is 
highly reproducible when assessed within and between days in healthy volunteers. We 
believe that this technique provides a flexible model with which to assess novel and 
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4.1    SUMMARY 
Fibrinolysis inhibits thrombus propagation on the surface of unstable atherosclerotic 
plaques. Using a clinical model of deep arterial injury, we assessed the ability of 
exogenous and endogenous tissue plasminogen activator (t-PA) to limit acute in situ 
thrombus formation. Ex vivo thrombus formation was assessed in the Badimon 
Chamber at low and high shear rates in two double-blind randomised cross-over 
studies of 20 healthy volunteers during extracorporeal administration of recombinant 
t-PA (0, 40, 200 and 1000 ng/mL) or during endogenous t-PA release stimulated by 
intra-arterial bradykinin infusion in the presence or absence of oral enalapril. 
Recombinant t-PA caused a dose-dependent reduction in thrombus area under low 
and high shear conditions (p<0.001 for all). Intra-arterial bradykinin increased plasma 
t-PA concentrations in the chamber effluent (p<0.01 for all versus saline) that was 
quadrupled in the presence of enalapril (p<0.0001 versus placebo). These increases 
were accompanied by an increase in plasma D-dimer concentration (p<0.005 for all 
versus saline) and, in the presence of enalapril, a reduction in thrombus area in the 
low shear (16%±5%, p=0.03) and a trend towards a reduction in the high shear 
chamber (13%±7%, p=0.07).  
 
Using a well-characterised clinical model of coronary arterial injury, we demonstrate 
that endogenous t-PA released from the vascular endothelium enhances fibrinolysis 
and limits in situ thrombus propagation. These data support a crucial role for the 
endogenous fibrinolytic system in vivo and suggest that continued exploration and 




4.2    INTRODUCTION 
The endogenous fibrinolytic system protects against intravascular fibrin formation 
and thrombosis, and appears to be particularly important within the coronary 
circulation [Rosenberg, et al., 1999]. In the presence of a developing thrombus, tissue 
plasminogen activator (t-PA) is rapidly released from a dynamic storage pool within 
the vascular endothelium through its stimulation by various factors that include 
bradykinin, thrombin and factor Xa [van den Eijnden-Schrauwen, et al., 1995]. The 
released t-PA causes a 1000-fold increase in the enzymatic conversion of 
plasminogen to plasmin [Fox, et al., 1985; Tranquille, et al., 1989]. This ensures that 
rapid plasmin generation, fibrin degradation and clot dissolution are tightly regulated 
and localised to sites of vascular injury. Thus, the rapidity and extent of acute t-PA 
release from the endothelium is a critical factor in determining the efficacy of local 
endogenous fibrinolysis and the prevention of intravascular thrombus propagation 
[Jern, et al., 1994; Newby, et al., 1997]. Whilst many workers have assessed basal 
plasma concentrations of t-PA and its principal inhibitor, plasminogen activator 
inhibitor type 1 (PAI-1), these do not reflect the capacity of the endothelium to release 
t-PA acutely nor the dynamic ability to dissolve intravascular thrombus. 
 
Robust methods to determine acute t-PA release within the human forearm and 
coronary circulations have been developed [Newby, et al., 2001; Newby, et al., 1997]. 
In the forearm circulation, local t-PA release has been demonstrated in response to a 
variety of physiological and pharmacological stimuli including thrombin receptor 
agonism [Gudmundsdottir, et al., 2006], substance P [Newby, et al., 2002; Newby, et 
al., 1997], tumour necrosis factor α [Chia, et al., 2003] and bradykinin [Labinjoh, et 
al., 2000]. Indeed, the fibrinolytic capacity of the endothelium predicts future adverse 
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cardiovascular events in patients with coronary disease and may provide additional 
insights into endothelial function [Robinson, et al., 2007]. However, the primary end-
point in all studies to date has been the quantification of t-PA release and it is 
unknown whether this acute endogenous release of t-PA can truly influence or modify 
dynamic thrombus formation.  
 
The demonstration of antithrombotic efficacy in man is challenging. Most techniques 
evaluate specific plasma or cellular components in isolation and are performed under 
static conditions in vitro. In contrast, in vivo thrombus initiation and growth occur in 
whole blood, under conditions of continuous flow and in the presence of vascular 
injury. Thus the assessment of the efficacy of antithrombotic interventions may not be 
reflected by static or unidimensional systems employed by in vitro assays [Kroll, et 
al., 1996]. An in vivo model for use in clinical studies presents significant safety 
issues and does not currently exist. The Badimon chamber is an ex vivo model of 
thrombosis with the ability to assess thrombus formation on a pathophysiologically 
relevant substrate under conditions of continuous flow [Badimon, et al., 1986; 
Badimon, et al., 1987]. It has previously been used to assess novel antithrombotic 
interventions [Lev, et al., 2006; Wahlander, et al., 2006; Zafar, et al., 2007; Zafar, et 
al., 2007] but has not been used to assess fibrinolysis.   
 
By combining two well-characterised and established techniques, the aim of the 
present study was to assess the ability of exogenous and endogenous t-PA to limit 




4.3    METHODS 
4.3.1    SUBJECTS 
Twenty healthy non-smokers aged between 18 and 26 years were enrolled into the 
study that was performed with the approval of the local research ethics committee, in 
accordance with the Declaration of Helsinki, and the written informed consent of all 
volunteers. Exclusion criteria were bleeding diathesis, the use of regular medication 
or any clinically significant illness. Except for study medication, none of the subjects 
received vasoactive medication during the study and all abstained from alcohol for 24 
hours and from food and caffeine-containing drinks for at least six hours before each 
study. Studies were carried out with subjects lying supine in a quiet, temperature-
controlled room maintained between 22°C and 25°C. 
 
4.3.2    EX VIVO THROMBOSIS STUDIES 
Thrombus formation was measured using the Badimon Chamber as described in 
section 2.3.  
 
Histological Analysis 
As thrombus forms along the entire length of the exposed porcine aortic strip, the 
cross-sectional area gives a reliable reflection of total thrombus [Dangas, et al., 1998]. 
Following fixation, the proximal and distal 1-mm sections of the exposed substrate 
were discarded and the remainder cut into four pieces. These pieces were paraffin-
wax embedded and 5 µm sections were prepared from each in order that 




Sections were stained with Masson’s trichrome stain to detect total thrombus or with 
an anti-fibrin II β chain mouse monoclonal antibody (clone T2G1; Accurate Chemical 
& Scientific Corporation, USA) to detect fibrin. For immunohistochemical staining, 
endogenous peroxidase activity was blocked by treatment with 3% hydrogen peroxide 
and serum free protein block (Dako, Glostrup, Denmark). Sections were then 
incubated with the primary antibody at a final concentration of 10 µg/mL for 1 hour at 
room temperature. Detection was performed using EnVision™ (Dako, Denmark) and 
treatment with 3,3'-diaminobenzidine substrate chromogen (Dako, Denmark). Finally, 
sections were counterstained with haematoxylin. No staining was present on 
specimens not incubated with the primary antibody or on areas of the specimens not 
exposed to blood flow. 
 
A purpose-designed semi-automated scanning microscope and image analysis system 
(Ariol 3.1, Applied Imaging, USA) was used to quantify thrombus area and 
composition. Digital images of each section were acquired at ×20 magnification. 
High-resolution classifiers, based on colour and shape parameters, were established to 
detect total thrombus and fibrin staining. Results from at least six sections were 
averaged to determine thrombus area for each chamber as described previously [Lev, 
et al., 2006; Wahlander, et al., 2006; Zafar, et al., 2007]. 
 
4.3.3    FOREARM BLOOD FLOW 
To confirm intrarterial infusion of the vasoactive agents, blood flow was measured in 
both forearms by venous occlusion plethysmography using mercury-in-silicone 
elastomer strain gauges as previously described [Webb, 1995]. Heart rate and blood 
pressure were monitored in the non-infused arm throughout each study with a non-
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invasive, semi-automated oscillometric sphygmomanometer (Boso Medicus, 
Germany). 
 
4.3.4    BLOOD SAMPLING AND FIBRINOLYTIC ASSAYS 
Blood samples were taken immediately distal to the perfusion chambers (and from the 
non-infused arm where appropriate) during each study and collected into citrate for 
PAI-1 assay and acidified buffered citrate (StabilyteTM, Biopool International, USA) 
for t–PA and D-dimer assays. Samples were kept on ice before being centrifuged at 
2000 g for 30 min at 4 °C. Platelet-free plasma was decanted and stored at -80 °C 
prior to assay. Plasma t-PA antigen and activity (t-PA Combi Actibind Elisa Kit, 
Technoclone, Austria), PAI-1 antigen (Zymutest, Hyphen Biomed, France) and D-
dimer (Asserachrom D-dimer, Roche, Switzerland) concentrations were determined 
using enzyme-linked immunosorbent assays. 
 
4.3.4    STUDY DESIGN     
Exogenous t-PA Administration 
To assess the effect of recombinant t-PA (rt-PA) administered into the extracorporeal 
circuit, eight subjects attended on two separate occasions, two weeks apart in a 
double-blind randomised crossover design. On each visit, two ex vivo thrombosis 
studies were performed 45 min apart during extracorporeal administration of rt-PA 
(Boehringer Ingelheim, Germany; infused to achieve anticipated final concentrations 
of 40, 200 and 1000 ng/mL) or saline control. Study drugs were added to the 
extracorporeal circuit using a calibrated syringe driver (Alaris Arsena GH, Cardinal 
Health, USA) and allowed to mix prior to entering the perfusion chambers as 
previously described [Lucking, et al., 2010]. Samples for fibrinolytic components 
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were taken from the chamber effluent and thrombus formation assessed by measuring 
fibrin and total thrombus area. 
 
Endogenous t-PA Release 
We assessed the ability of endogenous t-PA released from the vascular endothelium to 
limit acute thrombus formation in a separate cohort of 12 subjects who attended on two 
separate occasions, two weeks apart, having received matched placebo or the 
angiotensin-converting enzyme (ACE) inhibitor, enalapril, 10 mg once daily for seven 
days prior to attendance in a double-blind randomised crossover design. On each study 
day, the final dose of placebo or enalapril was taken at 08.00 hr. Four hours later, the 
subjects rested recumbent, and strain gauges and cuffs were applied to the forearms. 
The brachial artery of the non-dominant arm was cannulated with a 27-standard wire 
gauge steel needle (Cooper’s Needle Works Ltd., Birmingham, UK) under local 
anaesthesia (1% lidocaine). The total rate of intra-arterial infusions was maintained 
constant at 1 mL/min. Forearm blood flow was measured every 3 min during infusion 
of vasodilators and every 5 min during infusion of saline. Intrabrachial infusions of 
bradykinin (MSD, UK; endothelium-dependent vasodilator releasing t-PA) at 1,000 
pmol/min [Labinjoh, et al., 2001; Witherow, et al., 2002] and sodium nitroprusside 
(David Bull Laboratories, UK; endothelium independent vasodilator not releasing t-
PA) at 8 µg/min [Labinjoh, et al., 2000; Newby, et al., 1997] were given for 12 min in 
a randomised order. Saline was infused for 30 min between vasodilator infusions. 
Samples for fibrinolytic components were taken from the chamber effluent and the 
non-infused arm. Total thrombus area was assessed at baseline (i.e. during intrabrachial 
infusion of saline) and during infusion of bradykinin and sodium nitroprusside.  
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4.3.5    DATA ANALYSIS AND STATISTICS 
The sample size was selected based on previous studies suggesting that we required a 
sample size of n=8-12 to have an 80% power to detect differences of 6-10% in 
thrombus area at p<0.05 [Fernandez-Ortiz, et al., 1994; Lucking, et al., 2008; Osende, 
et al., 2001; Toschi, et al., 1997]. 
 
Plethysmographic data were extracted from the Chart data files. Forearm blood flows 
were calculated for individual venous occlusion cuff inflations by a template 
spreadsheet (Excel v12.3; Microsoft Corp., USA) as previously described [Labinjoh, 
et al., 2000; Newby, et al., 1999; Newby, et al., 1997]. 
 
Continuous variables are reported as mean ± standard error of the mean (SEM). 
Statistical analysis was performed with GraphPad Prism (GraphPad Software, USA) 
using paired Student’s t-tests and analysis of variance (ANOVA) as appropriate. 
Statistical significance was taken at P<0.05. 
 
4.4    RESULTS 
All study visits were completed for each subject without significant adverse events.  
 
4.4.1    EXTRACORPOREAL RECOMBINANT T-PA 
Plasma t–PA antigen concentrations in the venous effluent of the chamber (6.0±0.6, 
44±6.6, 264±13 and 1567±177 ng/mL) approximated to the anticipated plasma t–PA 
concentrations (5, 40, 200 and 1000 ng/mL respectively; Figure 4.1). There was a 
dose-dependent increase in plasma D-dimer concentrations (p<0.0001; Figure 4.1) 
accompanied by a corresponding dose-dependent reduction in total and fibrin-rich 
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thrombus under both low and high shear conditions (p<0.001 for all; Figure 4.2). 
Thrombus in the low shear chamber had a greater proportion of fibrin compared to the 








Figure 4.1 The effect of recombinant tissue plasminogen activator administered into the 
extracorporeal circuit of the Badimon Chamber on plasma fibrinolytic components measured 






Figure 4.2. (A) The effect of recombinant tissue plasminogen activator (rt-PA) administered into the 
extracorporeal circuit of the Badimon Chamber on total thrombus area (closed circles) and fibrin-rich 
thrombus area (open circles)(n=8). Data shown are mean ± standard error of the mean. (B) 
Representative photomicrographs of porcine aortic media exposed to flowing blood demonstrating the 
effect of rt-PA administered into the extracorporeal circuit of the Badimon Chamber. 
Photomicrographs in the upper panels are from studies with the addition of saline control and those in 
the lower panels from studies with the addition of rt-PA 1000 ng/mL. Sections on the left of each panel 
are stained with Masson’s trichrome stain to demonstrate total thrombus area. Sections on the right 
are stained for fibrin and counterstained with haematoxylin to demonstrate fibrin-rich thrombus area 
(fibrin appears brown). Original magnification × 20. 
 
4.4.2    ENDOGENOUS FIBRINOLYSIS 
Oral and intra-arterial drug administrations were well tolerated without significant 
adverse effects. Consistent with previous studies [Labinjoh, et al., 2000], transient 
patchy flushing and skin oedema of the infused arm occurred with bradykinin 




blood flow during or between study days (data not shown). As previously, sodium 
nitroprusside and bradykinin produced dose-dependent forearm vasodilatation 
(p<0.001 for all; data not shown).  
 
Compared to saline, sodium nitroprusside had no effect on fibrinolytic parameters in 
the presence of placebo or enalapril (data not shown). Intra-arterial bradykinin 
increased plasma t-PA antigen and activity in the chamber effluent during treatment 
with placebo and enalapril (p<0.01 for all versus saline; Figure 4.3).  Bradykinin-
induced t-PA antigen concentrations were increased approximately four-fold and t-PA 
activity increased approximately seven-fold in the presence of enalapril (p<0.0001 for 
both versus placebo; Figure 4.3) such that systemic spillover and elevation of plasma 
t-PA antigen and activity in the non-infused arm were observed (p=0.01 and p<0.001 
respectively versus saline; Figure 4.3). These changes in plasma t-PA antigen and 
activity were accompanied by an increase in plasma D-dimer concentrations in the 
chamber effluent during placebo and enalapril treatment (p=0.003 and p=0.001 
respectively versus saline; Figure 4.3), confirming that t-PA released from the 
forearm endothelium enhanced fibrinolysis within the chamber. PAI-1 antigen 
concentrations were unaffected by the presence of enalapril or during intra-arterial 
administration of bradykinin (Figure 4.3). 
 
The changes in fibrinolytic markers were accompanied by a reduction in total 
thrombus area in the low shear chamber during bradykinin infusion (15±5%, p=0.026 
versus saline) and a trend towards a reduction in the high shear chamber (13±7%, 
p=0.07 versus saline; Figure 4.4). There were no differences in thrombus area in 
either the low or high shear chambers in the presence of placebo (Figure 4.4). 
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Figure 4.3. The effect of intra-arterial bradykinin infusion on plasma fibrinolytic components 
measured in the non-infused arm (clear bars) and the chamber effluent (hashed bars)(n=12). 













































































































































Figure 4.4. The effect of intra-arterial bradykinin infusion on total thrombus area assessed in 
the Badimon Chamber in the presence of placebo (clear bars) and the angiotensin-converting 
enzyme inhibitor, enalapril (filled bars) (n=12). Upper panels show data from the low shear 
chamber, lower panels show data from the high shear chamber. Data shown are mean ± 










4.5    DISCUSSION 
Recent work has provided novel insights into the role of endogenous fibrinolysis. 
Using intra-arterial infusion in the human forearm and coronary circulations, we  
[Chia, et al., 2003; Gudmundsdottir, et al., 2006; Labinjoh, et al., 2000; Labinjoh, et 
al., 2001; Newby, et al., 2001; Newby, et al., 2002; Newby, et al., 1997; Witherow, et 
al., 2002] and others [Brown, et al., 2000; Brown, et al., 1999; Hrafnkelsdottir, et al., 
2004; Hrafnkelsdottir, et al., 1998; Jern, et al., 1994] have demonstrated that a variety 
of agonists can stimulate t-PA release from the human vascular endothelium in vivo. In 
the current study, we have confirmed that acutely released endogenous endothelial t-
PA is functionally active, enhances local fibrinolysis and can limit in situ thrombus 
formation. This establishes the clinical significance of this method of assessing 
endothelial function as well as underscoring the importance of this aspect of vascular 
function. 
 
The endothelium has a number of important complementary functions, including 
regulation of vasomotor tone, coagulation, fibrinolysis and inflammation. Most 
clinical studies have focused on endothelium-dependent vasomotion. Whilst a useful 
surrogate marker for the role of the endothelium in atherothrombosis [Perticone, et 
al., 2001] the observation of impaired t-PA release with preservation of vasomotor 
function in response to endothelium-dependent vasodilators in cigarette smokers 
[Chowienczyk, et al., 1993] and patients with hypertension [Hrafnkelsdottir, et al., 
2004; Hrafnkelsdottir, et al., 1998] highlights both the complexity of vascular biology 
and suggests that fibrinolytic capacity may be a more sensitive marker of endothelial 
dysfunction in some circumstances. 
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Despite a growing body of evidence, a key limitation of studies to date is that the 
effects of acute endogenous t-PA release on in situ thrombus formation have not been 
demonstrated. Is endogenous endothelial t-PA released under agonist stimulation 
functionally active and able to enhance fibrinolysis of in situ thrombus? Clearly, it 
would be unethical to induce intra-arterial thrombus in the human forearm and there is 
currently no model for assessing thrombus formation in vivo in the human circulation. 
In the present study, we attempted to resolve these problems by combining two well-
established techniques: the Badimon Chamber, an ex vivo clinical model of thrombus 
formation, and the forearm technique, using intrabrachial infusion of bradykinin to 
generate enhanced concentrations of endogenous t-PA from the vascular endothelium. 
This methodology provides an elegant means of stimulating local t-PA release from 
the endothelium before channelling the venous effluent of the forearm, containing 
freshly released endogenous t-PA, through the Badimon Chamber allowing an 
assessment of ex vivo thrombus formation to be made.  We initially validated our 
model using the extracorporeal administration of exogenous recombinant t-PA prior 
to assessing the effects of endogenous t-PA. The doses of t-PA used in the initial 
studies were selected based on data from previous forearm studies and measurements 
of t-PA concentration made during studies of systemic thrombolysis for myocardial 
infarction. We estimated that 40 ng/mL was the maximum t-PA antigen concentration 
achievable in healthy volunteers during bradykinin infusion in the presence of ACE 
inhibition [Labinjoh, et al., 2001; Witherow, et al., 2002]. Concentrations of 200 
ng/mL and 1000 ng/mL were selected to represent the lower and upper ends 
respectively of plasma t-PA antigen concentrations achieved during systemic 
therapeutic fibrinolysis [Genser, et al., 1998; Koster, et al., 1991]. Based on this 
rationale, we were able to demonstrate that across a clinically relevant dose range, 
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thrombus formation was reduced in a dose-dependent manner. Consistent with its 
mechanism of action, exogenous t-PA was associated with reductions in fibrin-rich 
clot and an elevation in D-dimer concentrations in the venous effluent. 
 
Having validated our model, we then wanted to explore whether freshly released 
endogenous t-PA would have similar effects to exogenous t-PA. We employed both 
systemic ACE inhibition and intra-arterial bradykinin administration to maximise 
endogenous t-PA release. Using this approach, we were able to increase plasma t-PA 
concentrations to those seen with the lowest dose of exogenous t-PA. Consistent with 
this, we observed comparable reductions in thrombus area and increases in D-dimer 
formation. These data therefore confirm the importance of the endogenous fibrinolytic 
system and the use of the forearm model as a relevant model with which to assess 
acute endogenous fibrinolytic capacity. Furthermore, we believe that this 
methodology provides a robust, versatile and relevant means with which to assess 
novel agents with the potential to modulate the endogenous fibrinolytic system and 
thus may benefit patients with a broad range of disease processes. 
 
We elected to use bradykinin as the agonist to stimulate t-PA release for two principal 
reasons. Firstly, it is pathophysiologically relevant. Although an inflammatory 
mediator, it is also released during the contact phase of coagulation and is a potent 
endothelial cell activator, stimulating release of t-PA from the endothelium [Brown, et 
al., 1999; Labinjoh, et al., 2000] through a B2 receptor mediated mechanism [Brown, 
et al., 2000]. Thus, following activation of the intrinsic coagulation pathway, the 
liberation of bradykinin may represent an important negative feedback loop in which 
bradykinin-induced t-PA release inhibits thrombus formation within the vascular 
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lumen when localised endothelial denudation occurs. Secondly, the use of bradykinin 
affords a safe and efficacious means of maximising t-PA release. Ordinarily, 
bradykinin has a very short plasma half-life of ~15 seconds with >95% of its 
metabolism occurring through ACE. In the presence of ACE inhibition, bradykinin-
induced vasodilatation and t-PA release are selectively and markedly potentiated 
[Benjamin, et al., 1989; Labinjoh, et al., 2001; Witherow, et al., 2002] and this may 
account for some of the anti-ischemic actions of ACE inhibition in vascular disease 
[Yusuf, et al., 2000]). Accordingly, in the presence of placebo, infusion of bradykinin 
resulted in more modest increases in plasma t-PA antigen and activity in the infused 
arm, sufficient to result in an increase in plasma D-dimer concentration confirming 
enhanced fibrinolysis but not sufficient enough to detect a significant change in 
thrombus formation in the Badimon Chamber. However in the presence of ACE 
inhibition, there was a roughly four-fold increase in t-PA antigen and seven-fold 
increase in t-PA activity sufficient to result in systemic spillover and a marked 
elevation of plasma t-PA antigen and activity in the non-infused arm. These marked 
increases in local and systemic plasma t-PA antigen and activity are consistent with 
our previous studies [Labinjoh, et al., 2001; Witherow, et al., 2002] and resulted in an 
increase in plasma D-dimer concentrations and an accompanying reduction in 
thrombus formation. In contrast to a previous study in patients with moderate to 
severe heart failure [Witherow, et al., 2002], basal plasma PAI-1 antigen 
concentrations were not affected by ACE inhibition, suggesting that in this healthy 
volunteer cohort, enhanced endogenous fibrinolysis was due to an increase in t-PA 
activity rather than a reduction in PAI-1 antigen concentration. 
 
Although the magnitude of reduction in thrombus area with endogenous t-PA release 
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was relatively modest and seen only in the presence of ACE inhibition, this occurred 
despite the marked dilutional effect that occurs because of the substantial increase in 
blood flow associated with concomitant bradykinin-induced vasodilatation. At the site 
of unstable plaques within the coronary circulation, it is likely that local 
concentrations will be much higher and, with impending vessel occlusion, dilutional 
effects will be minimised. Furthermore, we studied healthy volunteers with intact 
vasomotor responses and no vascular dysfunction. In our previous studies, ACE 
inhibition had a disproportionately large effect on bradykinin-induced t-PA release in 
patients with established heart disease [Witherow, et al., 2002]. Indeed, in these 
patients, we were able to demonstrate up to 4.5 µg of endogenous t-PA release from 
the forearm and achieve 99 IU/mL of t-PA activity that approached the activity seen 
with systemic therapeutic fibrinolysis (100-1000 IU/mL) [Witherow, et al., 2002]. 
This may, in part, be due to impaired vasodilatation causing the accumulation of 
greater plasma concentrations of released t-PA. Taken together, these considerations 
suggest that local t-PA concentrations generated in the coronary circulation in vivo, 
particularly in patients treated with ACE inhibition, may be higher than those we 
achieved here. It does however remain possible that bradykinin and/or enalapril are 
affecting aspects of platelet function, coagulation or the fibrinolytic system that we 
have not measured here. 
 
4.5.1    STUDY LIMITATIONS 
We acknowledge the modest sample size and exclusive use of healthy volunteers. It 
would be desirable to increase subject numbers and make similar assessments in 
patients with vascular disease but the invasive nature and complexity of combining 
two exacting techniques presents many challenges particularly when attempting to 
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apply this methodology to larger cohorts and patient groups. 
 
Measurement of coronary t-PA release is of greatest relevance to coronary 
pathophysiology but can only be performed in selected subjects undergoing invasive 
coronary angiography. However, consistent findings between the forearm [Labinjoh, 
et al., 2001; Newby, et al., 1999; Witherow, et al., 2002] and coronary circulations 
[Minai, et al., 2001; Newby, et al., 2001] support the notion that the use of the 
forearm model is a reasonable surrogate, particularly in the context of this proof-of-
concept study. 
  
For the reasons discussed earlier, we believe that our rationale for choosing 
bradykinin as the agonist with which to stimulate t-PA release is sound, although we 
acknowledge that the local concentration generated at the surface of an unstable 
atherosclerotic plaque and the exact role played by bradykinin in potentiating the 
endogenous fibrinolytic system in vivo remains incompletely understood.  
 
4.5.2    CONCLUSIONS 
Using a well-characterised clinical model of arterial injury, we have demonstrated that 
endogenous t-PA released acutely from the human vascular endothelium enhances 
fibrinolysis and limits in situ thrombus formation. These data confirm the functional 
significance of t-PA released during agonist stimulation, support a crucial role for the 
endogenous fibrinolytic system and suggest that further studies to explore its 
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5.1    SUMMARY 
The principal inhibitor of fibrinolysis in vivo is plasminogen activator inhibitor type 1 
(PAI–1). PAI–749 is a small molecule inhibitor of PAI–1 with proven antithrombotic 
efficacy in several pre-clinical models. The aim of this study was to assess the effect 
of PAI–749 using an established ex vivo clinical model of thrombosis and a range of 
complementary in vitro human plasma and whole blood-based models of fibrinolysis. 
In a double-blind randomised crossover study, ex vivo thrombus formation was 
assessed using the Badimon Chamber in 12 healthy volunteers during extracorporeal 
administration of t–PA in the presence of PAI–749 or control. Tissue plasminogen 
activator (t–PA) mediated lysis of plasma clots and whole blood model thrombi were 
assessed in vitro. The role of vitronectin was examined by assessing lysis of fibrin 
clots generated from purified plasma proteins. There was a dose-dependent reduction 
in ex vivo thrombus formation by t–PA (P<0.0001). PAI–749 had no effect on in vitro 
or ex vivo thrombus formation or fibrinolysis in the presence or absence of t–PA. 
Inhibition of PAI–1 with a blocking antibody enhanced fibrinolysis in vitro (P<0.05). 
 
Despite efficacy in a purified human system and in pre-clinical models of thrombosis, 
the current study suggests that PAI–749 does not affect thrombus formation or 










5.2    INTRODUCTION 
The release of tissue plasminogen activator (t–PA) from vascular endothelial cells 
initiates the dissolution of intravascular thrombus and is of particular importance 
within the coronary circulation [Rosenberg, et al., 1999]. Indeed, exogenous 
administration of t–PA remains an important treatment for ST segment elevation 
myocardial infarction.  
Plasminogen activator inhibitor type 1 (PAI–1) is a serine protease inhibitor that 
blocks the action of t–PA. Along with α2-antiplasmin, PAI–1 is a key inhibitor of 
fibrinolysis in vivo [Robbie, et al., 1996]. Elevated plasma PAI–1 concentrations are 
associated with a number of prothrombotic conditions including acute coronary 
syndrome [Juhan-Vague, et al., 1996], metabolic syndrome [Alessi, et al., 2006] and 
venous thromboembolism [Crowther, et al., 2001]. 
 
Inhibition of PAI–1 is predicted to promote endogenous and exogenous t–PA 
mediated fibrinolysis. This may enhance the therapeutic efficacy of thrombolytic 
agents as well as having the potential to prevent adverse cardiovascular events 
through augmentation of endogenous fibrinolysis. PAI–749 is a novel synthetic small 
molecule inhibitor of PAI–1 that has advanced to clinical phase I evaluation. It has 
been shown to inhibit PAI–1 rapidly and selectively in vitro [Gardell, et al., 2007]. In 
rodent and canine models, PAI–749 limits de novo thrombus formation and 




The principal aim of this study was to assess the effect of PAI–749 on t–PA mediated 
fibrinolysis using an established ex vivo clinical model of thrombosis. In addition, the 
effect of PAI–749 was assessed using a range of complementary in vitro human 


















5.3    METHODS 
5.3.1    PAI–749 
PAI–749, 1-benzyl-3-pentyl-2-[6-(1H-tetrazol-5-ylmethoxy)naphthalen-2-yl]-1H-
indolemin (MW 502 Da), was synthesised and characterised for chemical identity and  
purity at Wyeth Research (Collegeville, USA). Aliquots of stock solution (0.5 
mg/mL; 1 mM) were prepared in 50% PEG-200/50% sterile water and stored at -80°C 
prior to use. A single batch of PAI–749 was used for all studies.  
 
The ability of PAI–749 to inhibit PAI–1 was confirmed by use of a chromogenic 
assay[Gardell, et al., 2007] and in our hands the IC50 of PAI–749 was 295 nM.  The 
PAI–1 used was recombinant human PAI–1, the specific activity of which was 
approximately 35%.[Sancho, et al., 1994] 
 
5.3.2    IN VITRO STUDIES 
Plasma Clot Lysis  
The effect of PAI–749 on clot lysis was studied in a 30% plasma system using 
thrombin/Ca2+ to induce clot formation and t–PA to induce clot lysis, as described 
previously [Mutch, et al., 2007]. Platelet-rich or platelet-free plasma was mixed with 
t–PA and either antibody to PAI–1 or PAI–749 in a final volume of 200 µL 10 mM 
Tris pH 7.5, 0.01% (v/v) Tween 20 (Tris-Tween buffer). Aliquots from each tube (80 
µL) were added in duplicate to microtitre wells, each containing 20 µL 
thrombin/CaCl2 to give the following final concentrations per well: 30% (v/v) plasma, 
0.4 IU/ml thrombin, 10.6 mM CaCl2, 180 pM t–PA, with or without 200 µg/mL rabbit 
polyclonal antibody to human PAI–1 [Booth, et al., 1987; Booth, et al., 1988] or 
PAI–749 (0, 2.5 or 12.5 µg/mL; 0, 5 or 25 µM).  The plate was incubated at 37°C and 
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read at 405 nm at 5 min intervals [Mutch, et al., 2007]. 
 
Lysis of Whole Blood Model Thrombi Formed Within a Chandler Loop  
FITC-labelled fibrinogen was added to citrated whole blood (0.9 mL) taken from 
healthy donors [Mutch, et al., 2007]. Samples were recalcified with 10.9 mM CaCl2 in 
a volume of 1.15 mL. The blood was then placed in plastic tubing and rotated at 30 
rpm for 90 min as described previously [Mutch, et al., 2007]. Once formed, model 
thrombi were rinsed in 0.9% (v/v) saline, blotted with filter paper and transferred to a 
tube containing t–PA (final concentration 200 ng/mL) in 10 mM Tris buffer, 0.01% 
(v/v) Tween, pH 7.5.  PAI–749 (final concentrations 0.5, 2.5, or 12.5 mg/mL; 1, 5 or 
25 µM) or anti-PAI–1 antibody (200 µg/mL) were incorporated in the thrombi and/or 
added to bathing fluid. Samples were removed at intervals during incubation at 37 °C 
and the released fluorescence was measured in a fluorescence plate reader at 
excitation, 485 nm and emission, 530 nm [Mutch, et al., 2007]. 
 
Lysis of Fibrin Clots Formed Within a Chandler Loop  
Purified proteins were used to generate fibrin clots under flow conditions within a 
Chandler Loop in a variation of the technique described above [Mutch, et al., 2003]. 
Time to complete lysis was monitored visually without wash steps. Clots were 
generated using final concentrations of 0.5 mg/mL of fibrinogen (Calbiochem, UK), 
0.11 IU/mL of thrombin (Calbiochem, UK), 100 ng/mL of t–PA (Technoclone, 
Austria), 66.6 µg/mL of plasminogen (Enzyme Research Laboratories, UK) in 50 mM 
Tris buffer with 100 mM NaCl, 7.5 mM CaCl2, pH 7.4. Thrombin, t–PA and calcium 
were added to the reagent mixtures as a single mix to initiate clot formation. Samples 
were then placed in plastic tubing and rotated at 30 rpm with constant visual 
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monitoring. Clots formed within 5 min (reaching a maximal size between 15-20 min) 
and the time taken for each to disappear completely was noted. Clots were prepared 
using the reagents listed above with the addition of recombinant human PAI–1 
[Sancho, et al., 1994] (final concentration 408 ng/mL) ± PAI–749 (final concentration 
2.5 µg/mL; 5 µM) ± vitronectin (Stratech Scientific, UK; final concentration 300 
µg/mL).  
 
5.3.3    EX VIVO STUDIES 
Subjects 
Twelve healthy non-smokers aged between 21 and 28 years old were recruited. The 
study was conducted with the approval of the local research ethics committee, in 
accordance with the Declaration of Helsinki, and with the written informed consent of 




Subjects attended on three occasions in a double-blind randomised crossover design. 
Ex vivo thrombus was generated in the Badimon chamber. The effect of 
extracorporeal administration of t–PA (Boehringer Ingelheim, Germany; infused to 
achieve estimated final concentrations of 5, 40 and 200 ng/mL) was assessed in the 
presence of PAI–749 (Wyeth Research, USA; targeted final concentration 2.5 
µg/mL), tranexamic acid (Meda Pharmaceuticals, UK; targeted final concentration 0.5 





Thrombus formation was measured using the Badimon Chamber as described in 
section 2.3.  
 
Immediately after each study, the porcine strips with thrombus attached were removed 
and fixed in 4% (w/v) paraformaldehyde for 72 h. Strips were then paraffin-wax 
embedded, sectioned and stained with Masson’s Trichrome. Digital images were 
acquired at ×20 magnification, and thrombus area measured using a semi-automated 
image acquisition system (Ariol, Applied Imaging, USA) by a second blinded 
operator. Results from at least six sections were averaged to determine thrombus area 
for each chamber as described previously [Lucking, et al., 2008].  
 
Blood Sampling 
Blood samples were taken immediately distal to the perfusion chambers during each 
study and collected into acidified buffered citrate (StabilyteTM, Biopool International, 
USA) for t–PA, PAI–1, t–PA/PAI–1 complex, D-dimer, and thrombin-antithrombin 
complex (TAT) assays, and ethylenediaminetetraacetic acid (BD Vacutainer, USA) 
for PAI–749 measurement. Samples for t–PA and PAI–1 assays were kept on ice 
before being centrifuged at 2000 g for 30 min at 4 °C. Samples for PAI–749 assay 
were kept at room temperature before being centrifuged at 1500 g for 30 min at 20 °C. 
Platelet-free plasma was decanted and stored at -80 °C prior to assay. D-dimer 
(Asserachrom D-dimer, Roche, Switzerland) and TAT complex (Dade Behring, 
UK) concentrations were determined using enzyme-linked immunosorbent assays 
(ELISA). Plasma t–PA antigen [Booth, et al., 1987], PAI–1 antigen and activity 
[MacGregor, et al., 1988], and t–PA/PAI–1 [Bennett, et al., 1990] complex were 
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determined as described previously. To determine plasma PAI–749 concentrations in 
the chamber effluent, 100 µL of calibration standard, quality control sample, blank, 
zero standard, or study sample were mixed with 50 µL of internal standard (D11-PAI–
749 [compound isotope to facilitate detection by mass spectroscopy], 500 ng/mL in 
methanol/5 mM ammonium acetate, v/v).  The mixture was precipitated with 0.6 mL 
of acetonitrile and 0.3 mL of the supernatant mixed with 0.1 mL of 5 mM ammonium 
acetate.  The processed samples were then analysed using LC/MS/MS. 
 
5.3.4    STATISTICAL ANALYSIS 
Continuous variables are reported as mean ± standard error of the mean (SEM). 
Statistical analysis was performed with GraphPad Prism (GraphPad Software, USA) 
by two-way analysis of variance (ANOVA) with repeated measures, paired Student t 
tests and calculation of the Pearson correlation coefficient as appropriate. Statistical 



















5.4    RESULTS 
 
5.4.1    IN VITRO STUDIES 
Tissue plasminogen activator mediated lysis of platelet-poor and platelet-rich plasma 
clots was unaffected by PAI–749 (2.5 or 12.5 µg/mL; 5 or 25 µM) while the blocking 
antibody to PAI–1 caused an increase in lysis (P<0.05 for time points between 15 and 
85 min; data not shown). 
 
PAI–749 had no effect on t–PA mediated lysis of model thrombi formed in a 
Chandler loop at any of the concentrations tested. Indeed at 12.5 µg/mL, there was a 
decrease in lysis (P<0.01 for timepoints between 90 and 240 min with PAI–749 added 
to both blood and buffer; Figure 5.1A). The addition of antibody to PAI–1 resulted in 
enhanced lysis (P<0.01) between 120 and 240 min (Figure 5.1B). 
 
PAI–749 had no effect on t–PA mediated lysis of fibrin clots formed from purified 






Figure 5.1 Model thrombi were prepared in a Chandler loop from whole blood collected 
freshly from four volunteers. PAI–749 was added either to the blood prior to thrombus 
formation, to the bathing buffer during lysis or to both the blood and bathing buffer. Anti-
PAI–1 neutralising antibody was added to both blood and bathing buffer. 200 ng/mL of tissue 
plasminogen activator was added to all bathing buffers. Lysis was monitored as fluorescence 
signal released due to the proteolysis of FITC-labelled fibrin. Data shown are mean±SEM.  
A. The difference in lysis was not significant at any time point with PAI–749 added to the 
blood or bathing buffer alone.  Lysis was decreased (P<0.01) between 90 and 240 min with 
12.5 µg/mL PAI–749 in both blood and buffer. 
B. There was no difference in lysis with added PAI–749. The addition of anti-PAI–1 resulted 




5.4.2    EX VIVO STUDIES 
Studies were completed in all 12 subjects and were well tolerated. Mean PAI–749 
concentration was 3.3±0.1 µg/mL; similar to the maximum concentration achieved in 
phase I clinical studies (~2.5 µg/mL). PAI–749 was undetectable in control samples 
(data not shown). 
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Plasma Coagulation and Fibrinolytic Components 
Plasma t–PA concentrations in the venous effluent of the chamber (3.9±1.5, 38±19 
and 248±45 ng/mL respectively) closely matched the targeted t–PA concentrations (5, 
40 and 200 ng/mL) during exogenous t–PA administration. There were no differences 
in plasma t–PA concentrations achieved during the three phases of the study: saline, 
PAI–749 (Table 5.1) or tranexamic acid (data not shown) infusion. Moreover, PAI–
749 did not alter PAI–1 antigen, PAI–1 activity or t–PA/PAI–1 complex formation 
compared to saline control (P=0.76, 0.10 and 0.15, respectively; Table 5.1). 
 
 SALINE PAI–749 
Predicted t–PA (ng/ml) 
Actual t–PA (ng/ml) 
PAI–1 (ng/ml) 
PAI activity (U/ml) 
t–PA-PAI–1 complex (pM) 
D-dimer (ng/ml) 












































Data shown are mean ± SEM 
ND - not determined 
PAI–1 - plasminogen activator inhibitor type 1 
TAT - thombin antithrombin complex 
t–PA - tissue plasminogen activator 
 
Table 5.1 Plasma Fibrinolytic Components in the Badimon Chamber 
 
 
In keeping with in situ thrombus formation, TAT complexes were markedly elevated 
in all samples (274±21 µg/mL; normal range 1.0-4.1 µg/mL). Levels were unaffected 
by tranexamic acid or PAI–749 (P=0.79 and P=0.12 respectively). Consistent with a 
marked fibrinolytic effect, exogenous t–PA increased D-dimer concentrations in the 
venous effluent of the chamber (P<0.0001; Figure 5.2) in a dose-dependent manner 
 124 
(r=0.67, P<0.0001). Plasma D-dimer concentrations were unaffected by tranexamic 





Figure 5.2 D-dimer levels within the effluent of the Badimon chamber.  Tissue plasminogen 
activator added to the extracorporeal circuit of the Badimon Chamber causes a dose-
dependent increase in D-dimer concentration (P<0.0001) in the chamber effluent which is 
unaffected by tranexamic acid or PAI–749. (Data shown are mean ± SEM). 
 
Ex Vivo Thrombus Formation 
Tissue plasminogen activator caused a dose-dependent reduction in thrombus 
formation in the Badimon chamber under low and high shear conditions (P<0.0001 
for both; Figure 5.3). Whilst there appeared to be a trend towards thrombus 
stabilisation in the presence of tranexamic acid at the highest dose of t–PA (P=0.09 
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and P=0.06 versus saline in the low and high shear chambers respectively), PAI–749 





Figure 5.3. Either tranexamic acid or PAI–749 along with tissue plasminogen activator were 
added to the extracorporeal circuit of the Badimon Chamber. Ex vivo thrombus formation 
was measured histomorphometrically. PAI–749 did not potentiate the action of baseline 
endogenous or exogenous tissue plasminogen activator). Data shown are mean ± SEM. 
 
 
Thrombus area correlated well with t–PA concentration in both the low and high 
shear chambers (r=-0.61, P<0.0001 and r=-0.49, P<0.0001 respectively). Thrombus 
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area also correlated with D-dimer concentration in the low shear chamber (r=-0.52, 


















5.5    DISCUSSION 
In the current studies, the novel small molecule PAI–1 inhibitor, PAI–749, did not 
potentiate the action of endogenous or exogenous t–PA on newly formed thrombus in 
clinical in vitro and ex vivo models. These findings are in contrast to the 
antithrombotic and profibrinolytic effects seen with PAI–749 in a variety of pre-
clinical animal thrombosis models. The reason for the lack of efficacy in human blood 
needs to be established if the potential therapeutic strategy of PAI–1 inhibition is to be 
realised. 
 
Work to date on the fibrinolytic system has principally been conducted using in vitro 
plasma-based systems. This has allowed the identification and characterisation of the 
key components of the fibrinolytic system. More recent studies have emphasised the 
importance of considering the overall balance of fibrinolysis in whole blood in which 
the contribution of cellular elements, such as platelets and leucocytes, can be assessed 
[Mutch, et al., 2007].  
 
In the present study, the effect of PAI–749 on t–PA mediated fibrinolysis in platelet-
poor and platelet-rich plasma was first assessed using a turbidity-based system.  The 
concentrations of PAI–749 used, 5 or 25 µM, were greatly in excess of the reported 
IC50 of 157 nM [Gardell, et al., 2007]. We went on to examine the effect of PAI–749 
on the lysis of whole blood model thrombi formed under flow conditions, as well as 
the effect on model thrombi generated from purified plasma proteins. These systems 
are well validated and have previously been shown to be sensitive to the effects of 
PAI–1 [Mutch, et al., 2007]. Indeed, a neutralising antibody directed against PAI–1, 
served as a positive control in each set of experiments and was shown to accelerate 
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lysis. However, consistent with the ex vivo studies, the addition of PAI–749 failed to 
accelerate lysis under any of the conditions used, despite its addition at concentrations 
well in excess of those found to produce an antithrombotic effect in pre-clinical 
animal models. 
 
We employed the Badimon Chamber as an established and validated ex vivo clinical 
model of arterial injury and thrombosis that can be applied to the clinic. It has 
principally been used to evaluate the effects of novel antithrombotic regimens [Lev, et 
al., 2004; Lev, et al., 2006; Sarich, et al., 2003; Zafar, et al., 2007] and has a number 
of advantages over other techniques suitable for use in man. These include assessing 
thrombus in whole flowing blood, under rheological conditions similar to those of a 
coronary artery, and using a biological substrate mimicking deep arterial wall injury. 
Using this model, we administered exogenous t–PA in a reliable, predictable and 
reproducible manner allowing the demonstration of a dose-dependent reduction in 
thrombus area. This is consistent with the dose-dependent increase in plasma t–PA 
and D-dimer concentrations that correlated with the change in thrombus area.  
 
Whilst there are a number of advantages to this model, there are also potential 
limitations. One issue is the time available for interaction of the test compound with 
flowing blood before arrival at the thrombogenic surface in the Badimon chamber. 
Although PAI–749 is a small molecule (MW 502 Da) that rapidly inhibits PAI–1 in 
vitro [Gardell, et al., 2007], the time for interaction between PAI–749 and PAI–1 in 
our system is short (~2 s) and it is possible that despite the high plasma concentration 
of PAI–749 achieved, interaction time is not sufficient to allow effective inhibition of 
PAI–1. However, given that PAI–749 had no effect in any of the in vitro assays 
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performed, all of which involved significant incubation periods, the interaction time 
alone is unlikely to explain the lack of efficacy. A second potential limitation is that 
due to the quantity of antibody that was needed, it was not feasible to include a 
neutralising antibody directed against PAI–1 to serve as a positive control in the ex 
vivo studies. 
 
Although previous in vivo studies of PAI–749 have employed well-established 
techniques [J. Hennan, 2006], there are a number of potentially important differences 
from the present study. The prior animal models used chemical and electrolytic injury 
to induce thrombus formation in the presence of an intact intima. In one of the 
models, PAI–749 was administered orally 90 min prior to vessel injury with 
assessments of blood flow and thrombus weight continuing for at least 40 min [J. 
Hennan, 2006]. In another study [J. Hennan, 2006], the compound was administered 
and thrombus assessed 24 h later. In the current clinical study, PAI–749 was added 
directly to blood with thrombus formation being assessed over only 5 min. Moreover, 
the principal aim in this study was to investigate the ability of PAI–749 to reduce 
thrombus formation in the presence and absence of exogenous t–PA; conditions that 
have not been previously explored. 
 
We achieved the desired plasma PAI–749 concentrations in the Badimon chamber: 
50-fold greater than that required to produce efficacy in pre-clinical studies. Thus it is 
unlikely that inadequate dosing is an explanation for our findings. Why then did we 
not see an effect? Most of the PAI–1 present in plasma complexes with, and is 
stablised by, vitronectin [Declerck, et al., 1988; Wiman, et al., 1988]. In previous in 
vitro studies, vitronectin appeared to prevent PAI–749 from binding to PAI–1 and 
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thereby blocked its inhibitory activity [Gardell, et al., 2007]. However, an 
antithrombotic effect of PAI–749 was observed in the preclinical models and this may 
reflect the capacity of orally administered PAI–749 to interact and inhibit newly 
secreted free PAI–1 prior to it complexing with vitronectin. In the current study, 
where PAI–749 was administered directly into the blood of the extracorporeal circuit 
of the Badimon Chamber, there may not be an opportunity for the compound to 
interact with unbound, free PAI–1.  
 
Hennan et al. studied the effect of another small molecule PAI–1 inhibitor, PAI–039, 
using a rat model of thrombosis [Hennan, et al., 2008]. They noted an increase in 
plasma PAI–1 antigen in both treated and control animals following ferric chloride 
induced arterial injury. In the control animals, there was a corresponding increase in 
PAI–1 activity that was suppressed in the treated animals. Hennan et al. suggest that 
during vascular injury in vivo, a pool of unbound PAI–1 is released that is indeed 
vulnerable to inhibition. Clearly, the in vitro systems we employed here do not 
involve vessel injury. As discussed, although the thrombogenic substrate within the 
Badimon Chamber consists of porcine tunica media, the vessel is surgically prepared 
in advance of the studies before being subsequently frozen prior to use. Thus, such 
injury may not recreate the conditions necessary to generate unbound PAI–1. Finally, 
given that the source of the PAI–1 generated during vessel injury is not clear, and may 
derive from the vessel wall itself, the porcine origin of the vessels may also be 
relevant. 
 
Other studies using PAI–039 have also suggested the importance of vitronectin and 
that this may prevent PAI–749 binding to PAI–1 [Gorlatova, et al., 2007; Leik, et al., 
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2006]. In an attempt to investigate the potential role of vitronectin, we examined the 
effect of PAI–749 on the lysis of fibrin clots generated from purified human plasma 
proteins. This allowed the effect of PAI–749 to be assessed in the presence and 
absence of vitronectin. This approach also failed to demonstrate an effect of PAI–749 
on t–PA mediated lysis, suggesting that the presence of vitronectin alone under these 
conditions is not sufficient to explain the lack of compound efficacy. 
 
Under a single set of experimental conditions in one of the in vitro studies, we 
observed a small but statistically significant decrease in the rate of fibrinolysis in the 
presence of PAI–749 (Figure 1A). Although we cannot rule out the possibility that 
PAI–749 has a negative effect on fibrinolysis through an as yet unrecognised 
mechanism, given that we employed a variety of different models and failed to detect 
such an effect under any other conditions, we believe this is highly unlikely and is 
more likely to represent a type I error. 
  
One further explanation for the observed lack of efficacy may relate to species 
differences such that whilst effective in in vitro systems using purified human 
components, PAI–749 is less effective when assessed in more complex human plasma 
and whole blood based systems. This situation has arisen previously for a number of 
compounds with antithrombotic efficacy in preclinical models that subsequently 
failed to show efficacy in man [Cox, et al., 1992; Hara, et al., 1995]. However, 
consistent with previous work [Biemond, et al., 1995; Levi, et al., 1992], the ability of 
a monoclonal antibody against PAI–1 to accelerate fibrinolysis in vitro suggests that 
whilst PAI–749 lacks efficacy in human blood based systems, the inhibition of PAI–1 
remains a potential therapeutic target worthy of further exploration.  
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5.5.1    CONCLUSIONS 
Taken together, our data, generated in a range of complementary human plasma and 
whole blood-based in vitro and ex vivo systems, suggest that PAI–749 has no 
measurable effect on t–PA mediated fibrinolysis. These findings are in contrast to 
those previously published in animal models where PAI–749 was able to limit 
thrombus formation and enhance fibrinolysis in vivo. This disparity is likely to be due 
to either a failure of PAI–749 to inhibit human PAI–1 to an extent that yields a 
measurable response in the current systems, or a failure of selective inhibition of PAI–
1 to result in an appreciable enhancement of fibrinolysis in man. The inability to 
monitor PAI–749 pharmacodynamically and the lack of an antithrombotic effect in 
these various human model systems suggest that PAI–749 may not be a useful 
therapeutic agent for the prevention and treatment of atherothrombotic disease in man. 
However, it is also possible that these systems do not accurately reflect the ability of 
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6.1    SUMMARY 
Although the mechanism is unclear, exposure to traffic-derived air pollution is a 
trigger for acute myocardial infarction. The aim of  this study was to investigate the 
effect of diesel exhaust inhalation on platelet activation and thrombus formation in 
man. In a double-blind randomised crossover study, 20 healthy volunteers were 
exposed to dilute diesel exhaust (350 µg/m3) and filtered air. Thrombus formation, 
coagulation, platelet activation and inflammatory markers were measured at two and 
six hours following exposure. Thrombus formation was measured using the Badimon 
ex vivo perfusion chamber. Platelet activation was assessed by flow cytometry. 
Compared to filtered air, diesel exhaust inhalation increased thrombus formation 
under low and high shear conditions by 24% (change in thrombus area 2229 µm2, 
95% CI 1143 to 3315 µm2, P=0.0002) and 19% (change in thrombus area 2451 µm2, 
95% CI 1190 to 3712 µm2, P=0.0005) respectively. This increased thrombogenicity 
was seen at two and six hours, and using two different diesel engines and fuels. Diesel 
exhaust also increased platelet-neutrophil and platelet-monocyte aggregates by 52% 
(absolute change 6%, 95% CI 2 to 10%, P=0.01) and 30% (absolute change 3%, 95% 
CI 0.2 to 7%, P=0.03) respectively at two hours following exposure compared to 
filtered air. 
 
Inhalation of diesel exhaust increases ex vivo thrombus formation and causes in vivo 
platelet activation in man. These findings provide a potential mechanism linking 





6.2    INTRODUCTION 
Chronic exposure to air pollution is a major cause of cardiovascular morbidity and 
mortality worldwide [Brunekreef, et al., 2002]. Recently, exposure to traffic-derived 
air pollution has been associated with the triggering of acute MI [Peters, et al., 2001; 
Peters, et al., 2004]. Whilst air pollution consists of a heterogeneous mixture of 
gaseous and particulate matter, adverse cardiovascular events are most strongly 
associated with exposure to fine particulate matter (diameter <2.5 µm, PM2.5) 
[Dockery, et al., 1993; Miller, et al., 2007]. An important component of PM2.5 is 
nanoparticulate matter generated during the combustion of diesel fuel [Charron, et al., 
2005]. These particles, with an aerodynamic diameter ≤100 nm, readily deposit within 
human alveoli and possess a considerable surface area that may contribute to their 
biological toxicity [Donaldson, et al., 2002].  
Despite the strength and consistency of observational data, the pathophysiological 
mechanisms linking air pollution with adverse cardiovascular events remain unclear. 
They have been proposed to include endothelial dysfunction [Mills, et al., 2007; 
Mills, et al., 2005; Tornqvist, et al., 2007], myocardial ischemia [Mills, et al., 2007], 
altered autonomic function [Gold, et al., 2000], systemic inflammation [Tornqvist, et 
al., 2007] and platelet activation [Nemmar, et al., 2003]. Thrombosis plays a central 
role in the pathogenesis of atherosclerosis. As well as contributing to atherogenesis, 
thrombosis at the site of a disrupted coronary arterial plaque may cause acute vessel 
occlusion resulting in an acute coronary syndrome (ACS). In pre-clinical studies 
employing a thrombotic vascular injury model, tracheal instillation of diesel exhaust 
particles caused platelet activation and increased arterial and venous thrombus 
formation [Nemmar, et al., 2003]. Given that exposure to combustion-derived 
pollutants appears to act as a trigger for MI, and that the majority of such events are 
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due to thrombus formation at the site of an atheromatous plaque, we hypothesised that 
exposure to diesel exhaust would increase in vivo platelet activation and enhance 



















6.3    METHODS 
6.3.1    SUBJECTS 
Twenty healthy non-smokers aged between 21 and 44 years old were enrolled into the 
study (Table 6.1). The study was performed with the approval of local research ethics 
committees, in accordance with the Declaration of Helsinki and the written informed 
consent of all volunteers. Volunteers were recruited using advertisements and from 
local healthy volunteer databases. Exclusion criteria were the use of regular 
medication or clinical evidence of atherosclerosis, arrhythmias, diabetes mellitus, 
hypertension, renal or hepatic impairment, asthma, occupational exposure to air 
pollution, intercurrent infective disease or any other clinically significant illness. 
Subjects had normal lung function and reported no symptoms of respiratory tract 
infection within the six-week period preceding the study. 
 
 Value 
Age (years) 26±5 
Height (m) 1.8±0.1 
Weight (kg) 73±3 
Body Mass Index (kg/m2) 22±1 
  
Pulse (bpm) 58±2 
Systolic Blood Pressure (mmHg) 120±3 
Diastolic Blood Pressure (mmHg) 71±2 
  
Forced Expiratory Volume in One Second (FEV1, L) 4.9±0.1 
   % predicted FEV1 108±3 
Forced Vital Capacity (FVC, L) 5.8±0.2 
   % predicted FVC 103±3 
 
Data are presented as mean±standard deviation. 
Pooled data from protocols 1 and 2 (n=20) 
 
 





6.3.2    STUDY DESIGN 
Subjects attended on two occasions at least one week apart and received either filtered 
air or dilute diesel exhaust in a double-blind randomised crossover design. Exposures 
were performed at separate dedicated exposure facilities by technical staff with no 
involvement in the clinical studies. The order of the exposures was randomised based 
on an independently determined exposure protocol. Subjects remained indoors 
following exposures to minimise confounding effects of ambient air pollution. The 
primary endpoint was the ex vivo thrombus formation. Secondary endpoints were in 
vivo platelet activation assessed by flow cytometry and changes in haematological and 
coagulation variables and soluble markers of inflammation.  
 
Clinical studies were performed in dedicated clinical research facilities by clinical 
staff blinded to exposure allocation. Based on previous vascular and inflammatory 
studies [Mills, et al., 2005], initial thrombosis studies were performed six hours after 
exposure in eight subjects (Protocol 1). In light of the findings, further thrombosis and 
flow cytometric studies were performed at two and six hours in a separate cohort of 
12 subjects (Protocol 2). The second protocol was designed to confirm the initial 
findings, assess temporal effects, investigate potential mechanisms and determine if 
the initial findings were reproducible with a different type of diesel exposure. 
 
Protocol 1 
Exposures were performed for two hours in a mobile ambient particle concentrator 
exposure laboratory (MAPCEL) in Edinburgh UK. During exposures, subjects 
performed moderate exercise (minute ventilation 25 L/min/m2) on a bicycle ergometer 
for 15 minutes alternated with 15-minute rest periods. Temperature and humidity in 
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the chamber were controlled at 22ºC and 50% respectively. Diesel exhaust was 
generated by an idling engine (type F3M2011, 2.2 L, 500 rpm; Deutz, Germany) 
using gas oil (Petroplus Refining, UK). Over 90% of the exhaust fumes were shunted 
away, with the remainder being diluted with air and fed into the exposure chamber at 
a steady-state concentration. Air in the chamber was continuously monitored with 
exposures standardised using continuous measurement of nitrogen oxide (NOx) 
concentrations to deliver a particulate concentration of 350 µg/m3. There was little 
variation in particle mass (348±68 µg/m3), particle number (1.2±0.1 x 106/cm3), NOx 
(0.58±0.03ppm), NO2 (0.23±0.02ppm), NO (0.36±0.02ppm), CO (3.54±0.76ppm) and 
total hydrocarbon (2.8±0.1 µg/m3) concentrations between exposures. 
 
Protocol 2 
In Umeå Sweden, subjects were exposed for one hour in a purpose-built diesel 
exposure chamber according to a standard protocol, as described previously [Mills, et 
al., 2005; Rudell, et al., 1994]. Diesel exhaust was generated by an idling Volvo 
engine (TD45, 4.5 L, 680 rpm) using Gasoil E10 (Preem, Sweden) as described 
previously [Mills, et al., 2005; Rudell, et al., 1994]. During exposures, subjects 
performed periods of exercise as described above. Exposures were standardised using 
continuous measurement of NOx to deliver a particulate concentration of 350 µg/m3. 
There was little variation in particle mass (330±12 µg/m3), particle number 
(1.26±0.01 x 106/cm3), NOx (2.78±0.03ppm), NO2 (0.62±0.01ppm), NO 
(2.15±0.03ppm), CO (3.08±0.12ppm) and total hydrocarbon (1.58±0.16 µg/m3) 




6.3.3    EX VIVO THROMBOSIS STUDIES 
Thrombus formation was measured using the Badimon Chamber as described in 
section 2.3.  
 
Immediately after each study, porcine strips with thrombus attached were removed 
and fixed in 4% paraformaldehyde. Strips were wax embedded, sectioned and stained 
with Masson’s Trichrome. Images were acquired at ×20 magnification and thrombus 
area measured using an Ariol image acquisition system (Applied Imaging, USA) and 
Image-Pro Plus software (Media Cybernetics, USA) by a blinded operator. Results 
from at least six sections were averaged to determine thrombus area for each chamber 
as described previously [Badimon, et al., 1987; Osende, et al., 2001; Wahlander, et 
al., 2006].  
 
6.3.4    FLOW CYTOMETRY 
Samples were obtained at two and six hours, immediately prior to each thrombosis 
study, and processed according to previously described protocols [Harding, et al., 
2006]. In brief, blood was taken from an antecubital vein using a 21-gauge cannula 
and anticoagulated with D-phenylalanyl-L-prolyl-L-arginine chloromethylketone 
(PPACK, 75 µm; Cambridge Biosciences, UK). Samples were not analysed unless 
venesection achieved rapid and uninterrupted blood flow. Five minutes after sample 
collection, samples were stained with the following conjugated monoclonal 
antibodies: PE-conjugated CD14 (Dako, Denmark), PE-conjugated CD62P, PE-
conjugated CD154 (Becton-Dickinson, UK); PE-conjugated CD11b, PE-conjugated 
CD40, FITC-conjugated CD42a, FITC-conjugated CD14 (Serotec, USA); and 
appropriate control isotypes. All antibodies were diluted 1:20. Once stained, samples 
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were incubated for 20 minutes at room temperature to identify P-selectin and CD40L 
on the platelet surface and CD40 on the monocyte surface. Monocyte and platelet-
leucocyte samples were fixed with FACS-Lyse (Becton-Dickinson, UK). Platelet 
samples were fixed with 1% paraformaldehyde. Samples were analysed within 24 
hours using a FACScan flow cytometer (Becton-Dickinson, UK). Platelet–monocyte 
and platelet–neutrophil aggregates were defined as monocytes or neutrophils positive 
for CD42a. Data analysis was performed using FlowJo (Treestar, USA). 
 
6.3.5    BLOOD SAMPLING 
Samples were obtained before exposure and at two and six hours. Samples were 
analysed for total white cell count, differential cell count and platelets by an 
autoanalyser. Plasma interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α), soluble 
CD40 ligand (sCD40L), soluble P-selectin, intercellular adhesion molecule-1 (ICAM-
1) and C-reactive protein (CRP) were measured with commercially available ELISAs 
(R&D Systems, UK). Prothrombin time (PT, reagents from Medirox, Sweden) and 
activated partial thromboplastin time (aPTT, reagents from Dade Behring, USA) were 
measured using a CA-7000 analyser (Sysmex, Japan).  
 
6.3.6    STATISTICAL ANALYSIS 
Data presented are pooled from protocols 1 and 2 unless otherwise stated. Continuous 
variables are reported as mean±standard deviation (SD). Statistical analysis was 
performed in Excel (Microsoft Corporation, USA) using a modified t-test (two-
sided) to account for potential period effects [Pocock, 1983]. Statistical significance 
was taken at P<0.05.  
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6.4    RESULTS 
Exposures and clinical studies were well-tolerated with no adverse symptoms 
reported. All volunteers completed both study visits. 
Total leucocyte, monocyte and platelet counts, PT and aPTT were unaltered following 
dilute diesel exhaust and filtered air (Table 6.2). Whilst neutrophil count appeared to 
increase and lymphocyte count appeared to decrease following both exposures, there 
were no differences in the magnitude of these changes following dilute diesel exhaust 
compared with filtered air (Table 6.2).      
 P values 
 Before Exposure 2 Hours 6 Hours Δ  2 Hours Δ  6 Hours 2 Hours 6 Hours 
FILTERED AIR        
Leucocytes (×109 cells/L) 5.44±1.42 5.27±1.16 5.75±1.07 -0.18±1.08 0.26±1.19 …. …. 
Lymphocytes (×109 cells/L) 2.17±0.67 1.92±0.52 1.68±0.43 -0.48±0.46 -0.51±0.53 …. …. 
Neutrophils (×109 cells/L) 2.62±0.69 3.00±0.75 3.51±0.91 0.42±0.68 0.89±0.86 …. …. 
Monocytes (×109 cells/L) 0.47±0.16 0.42±0.14 0.41±0.16 -0.06±0.11 -0.06±0.10 …. …. 
Platelets (×109 cells/L) 223±38 221±35 223±30 -1.80±18 1.79±22 …. …. 
INR‡ 1.00±0.06 1.03±0.07 1.04±0.07 0.02±0.04 0.03±0.05 …. …. 
aPTT‡ (sec) 28.9±0.91 29.1±0.89 28.7±0.90 0.28±0.47 -0.20±0.58 …. …. 
DIESEL EXHAUST        
Leucocytes (×109 cells/L) 5.45±1.22 5.51±1.54 5.53±1.31 0.06±1.34 0.07±1.41 0.54 0.52 
Lymphocytes (×109 cells/L) 2.20±0.73 1.67±0.55 1.61±0.42 -0.53±0.36 -0.59±0.58 0.60 0.30 
Neutrophils (×109 cells/L) 2.60±0.64 3.26±1.42 3.38±1.17 0.68±1.27 0.81±1.17 0.90 0.90 
Monocytes (×109 cells/L) 0.49±0.11 0.45±0.12 0.45±0.13 -0.07±0.09 -0.08±0.08 0.69 0.60 
Platelets (×109 cells/L) 227±38 223±47 218±31 -4.15±21 -3.74±16 0.72 0.32 
INR‡ 1.02±0.06 1.02±0.08 1.03±0.08 0.01±0.03 0.01±0.03 0.55 0.26 
aPTT‡ (sec) 29.3±1.39 29.22±0.87 29.2±0.89 -0.07±0.86 -0.06±0.74 0.22 0.83 
Data are presented as mean±standard deviation. 
Pooled data from protocols 1 and 2, (n=20, except ‡ unavailable for protocol 1). 
P values are for the comparison of diesel exhaust versus filtered air 
aPTT - activated partial thromboplastin time, INR - international normalised ratio of prothrombin time 
Table 6.2 Effects of Dilute Diesel Exhaust on Heamatological and Coagulation Variables 
 143 
6.4.1    MARKERS OF INFLAMMATION AND PLATELET ACTIVATION 
There was a heterogenous cytokine response following both dilute diesel exhaust and 
filtered air exposures (Table 6.3, data from protocol 2). Changes in plasma TNF-α, 
IL-6, CRP and soluble ICAM-1 concentrations were similar following both 
exposures. Following dilute diesel exhaust exposure, plasma sCD40L concentrations 
were increased at two hours (P=0.003 versus filtered air) and the fall at six hours 
following filtered air exposure was attenuated (P=0.011 versus filtered air). Similarly, 
the fall in plasma soluble P-selectin concentration at six hours following filtered air 
exposure was attenuated following diesel exhaust exposure (P=0.003). 
 
P values 
 Before Exposure 2 Hours 6 Hours Δ  2 Hours Δ  6 Hours Δ  2 Hours Δ  6 Hours 
FILTERED AIR        
TNF-α (pg/mL) 0.62±0.73 …. 0.36±0.32 …. -0.26±0.30 …. …. 
IL-6 (pg/mL) 0.60±0.76 …. 0.88±0.80 …. 0.28±1.1 …. …. 
CRP (mg/L) 1.02±0.66 1.09±1.42 1.13±1.64 0.07±0.17 0.12±0.16 …. …. 
Soluble CD40L (pg/mL) 66±29 75±8 41±14 9.00±29 -20±26 …. …. 
Soluble P-selectin (mg/mL) 61±27 37±8 44±18 -25±22 -18±26 …. …. 
Soluble ICAM-1 (mg/mL) 278±65 170±25 271±69 -109±56 -6.40±66 …. …. 
DIESEL EXHAUST        
TNF-α (pg/mL) 0.55±0.41 …. 0.57±0.44 …. 0.06±0.44 …. 0.11 
IL-6 (pg/mL) 0.27±0.19 …. 0.78±0.61 …. 0.52±0.66 …. 0.51 
CRP (mg/L) 0.67±0.65 0.66±0.94 0.65±0.85 -0.01±0.10 -0.02±0.04 0.48 0.30 
Soluble CD40L (pg/mL) 48±16 78±8 42±10 30±15 -0.85±18 0.01 0.01 
Soluble P-selectin (mg/mL) 51±18 37±10 54±14 -14±13 2.89±16 0.11 0.003 
Soluble ICAM-1 (mg/mL) 263±56 181±33 280±58 -82±37 17±59 0.49 0.64 
Data are presented as mean±standard deviation. 
Data from protocol 2 (n=12) 
P values are for the comparison of diesel exhaust versus filtered air 
TNF-α – tumour necrosis factor-α, IL-6 – interleukin-6, CRP – C reactive protein, CD40L – CD40 
ligand, ICAM-1 – intercellular adhesion molecule-1 
Table 6.3 Effects of Dilute Diesel Exposure on Markers of Inflammation and Platelet 
Activation 
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6.4.2    FLOW CYTOMETRY 
Monocyte surface expression of CD40, and platelet surface expression of CD40L and 
P-selectin, were similar following dilute diesel exhaust and filtered air exposure (data 
not shown). Compared to filtered air, diesel exhaust exposure increased platelet-
neutrophil and platelet-monocyte aggregates at two hours by 52% (absolute change 
6%, 95% CI 2 to 10%, P=0.01) and 30% (absolute change 3%, 95% CI 0.2 to 7%, 
P=0.03) respectively (Figure 6.1, data from protocol 2). There was a trend towards 
similar increases at six hours although these were not statistically significant. 
 
Figure 6.1 Platelet-leucocyte aggregates two and six hours following dilute diesel exhaust 
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6.4.3    THROMBUS FORMATION 
Thrombus formation increased following dilute diesel exhaust by 23% in the low-
shear (change in thrombus area 1941 µm2, 95% CI 873 to 3008 µm2, P=0.002) and 
21% in the high-shear chamber (change in thrombus area 2916 µm2, 95% CI 1365 to 




Figure 6.2 Thrombus formation six hours following dilute diesel exhaust () and filtered air 












































In Protocol 2, thrombus formation at two hours increased by 27% in the low- and 21% 
in the high-shear chamber following dilute diesel compared to air (change in 
thrombus area 2772 µm2, 95% CI 879 to 4721 µm2, P=0.04 and change in thrombus 
area 2312 µm2, 95% CI 597 to 4026 µm2, P=0.014 respectively; Figure 6.3). 
Likewise, thrombus formation at six hours was increased by 22% (change in 
thrombus area 2254 µm2, 95% CI 244 to 3924 µm2, P=0.033) in the low-shear 
chamber and appeared to increase (13%; change in thrombus area 1467 µm2, 95% CI 




Figure 6.3 Thrombus formation two and six hours following dilute diesel exhaust () and 












































































6.5    DISCUSSION 
Short-term exposure to traffic-derived air pollution is associated with acute 
cardiovascular events [Peters, et al., 2001; Peters, et al., 2004]. This is the first study 
to demonstrate that inhalation of diesel exhaust, a common urban air pollutant, causes 
platelet activation and enhances thrombus formation in man. This provides a plausible 
mechanism linking exposure to particulate air pollution with acute cardiovascular 
events including MI. 
 
6.5.1    EFFECT OF DIESEL EXHAUST ON THROMBOSIS 
Despite the suggestion from observational studies that exposure to combustion-
derived air pollution is associated with MI, few studies have examined whether 
controlled exposure alters thrombotic potential. Developing a reproducible in vivo 
model of thrombosis for use in human studies is challenging. We therefore used the 
Badimon chamber as a validated ex vivo model of arterial injury and thrombosis 
[Badimon, et al., 1987]. It has previously been used to evaluate the effects of novel 
antithrombotic regimens and has a number of advantages over other techniques 
[Badimon, et al., 1987; Osende, et al., 2001; Wahlander, et al., 2006]. It allows the 
measurement of thrombus formation in native (non-anticoagulated) whole blood 
triggered by exposure to a physiologically relevant substrate, and under flow 
conditions mimicking those in diseased coronary arteries. Thus, this is a particularly 
relevant model as it broadly simulates the intra-arterial conditions following 
spontaneous or iatrogenic plaque disruption within the coronary vasculature.  
 
Taken together with our previous finding that dilute diesel exhaust exposure impairs 
endothelial t-PA release [Mills, et al., 2005], we suggest that enhanced thrombus 
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formation is an important mechanism that may explain the association of MI shortly 
after traffic pollution exposure. 
 
6.5.2    EFFECT OF DIESEL EXHAUST ON PLATELET ACTIVATION 
Platelets are key components of arterial thrombosis. Shortening of closure times in a 
platelet function analyser have been observed following tracheal instillation of diesel 
exhaust particles in hamsters [Nemmar, et al., 2003] and their addition to human 
blood enhances platelet aggregation [Radomski, et al., 2005]. Here we used flow 
cytometry to measure surface expression of platelet and leucocyte activation markers 
as well as platelet-leucocyte aggregates, a technique increasingly recognised as the 
gold standard measure of in vivo platelet activation, including in patients with ACS 
[Freedman, et al., 2002].  
 
We observed an increase in platelet-neutrophil and platelet-monocyte aggregates after 
dilute diesel exhaust exposure suggesting that enhanced thrombus formation was 
mediated through platelet activation. These findings are consistent with an increase in 
circulating platelet-leucocyte aggregates observed in women exposed to biomass 
smoke [Ray, et al., 2006]. In addition, tracheal instillation of carbon nanotubes 
increased platelet-leucocyte aggregates and thrombus formation in a murine model of 
vascular injury [Nemmar, et al., 2007]. Interestingly, blockade of P-selectin abrogated 
platelet-leucocyte aggregation and thrombus formation, suggesting that P-selectin 
serves as a link between pulmonary inflammation, systemic inflammation and 
enhanced thrombogenicity. Although platelet-monocyte binding is principally 
dependent on P-selectin, we did not observe an increase in platelet surface expression 
of P-selectin. However, in patients with MI, platelet-monocyte aggregates have been 
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shown to be a more sensitive marker of platelet activation than P-selectin [Michelson, 
et al., 2001] as P-selectin is rapidly shed from the platelet surface [Michelson, et al., 
1996]. Exposure to dilute diesel exhaust also increased plasma sCD40L levels. This is 
in keeping with studies that demonstrated upregulation of the CD40/CD40L pathway 
in cigarette smokers [Harding, et al., 2004] and following exposure to ultrafine 
particles [Becker, et al., 2003; Ruckerl, et al., 2007]. As platelets contain large 
amounts of CD40L that is released following activation [Phipps, et al., 2001], the 
increase in sCD40L we observed further strengthens the argument that the enhanced 
thrombus formation observed was driven principally by platelet activation.  
  
It is not possible from our study to determine the mechanism of platelet activation. 
Debate remains as to whether inhaled components of diesel exhaust can translocate 
into the systemic circulation [Mills, et al., 2006; Nemmar, et al., 2002] to mediate 
direct effects on blood and vascular components. A substantial body of evidence 
supports a role for oxidative stress and inflammation in mediating the adverse effects 
of air pollution [Donaldson, et al., 2005]. Although we did not observe an increase in 
cellular or soluble inflammatory markers, this does not preclude a role for factors not 
assessed here. The ability of diesel exhaust exposure to cause pulmonary 
inflammation is not in doubt [Salvi, et al., 1999] and we have demonstrated 
previously that diesel particles are capable of generating free radicals [Tornqvist, et 
al., 2007] which may activate platelets by reducing endothelial and platelet derived 





6.5.3    EFFECT OF DIESEL EXHAUST ON COAGULATION 
A number of previous ambient and controlled exposure studies have evaluated the 
association between plasma concentrations of coagulation factors and particulate air 
pollution with mixed results. Whilst some have demonstrated increased levels of 
fibrinogen [Ghio, et al., 2000; Mutlu, et al., 2007; Pekkanen, et al., 2000] and von 
Willebrand factor [Ruckerl, et al., 2006], other studies measuring the same factors 
have failed to show any association with particulate exposure [Elder, et al., 2004; 
Gong, et al., 2003; Ruckerl, et al., 2006]. This apparent disparity may well be 
explained by variations in study design and perhaps more importantly, the type of 
exposure investigated. Two previous studies have investigated the effect of controlled 
diesel exhaust exposure on coagulation factors in man with neither demonstrating a 
significant effect [Blomberg, et al., 2005; Carlsten, et al., 2007]. Although a recent 
observational study reported a small reduction in PT associated with ambient 
exposure to PM10 [Baccarelli, et al., 2007], we found no effect on PT or aPTT 
following exposure to diesel exhaust. Despite higher effective particulate matter 
concentrations, our findings are in keeping with previous controlled diesel exposure 
studies that failed to demonstrate changes in fibrinogen, von Willebrand factor, D-
dimer, pro-thrombin fragment 1 and 2, tissue-plasminogen activator and plasminogen 
activator inhibitor-1 [Blomberg, et al., 2005; Carlsten, et al., 2007].  
 
6.5.4    POPULATION RISK AND DIESEL EXPOSURE 
Diesel exhaust is an important source of combustion-derived air pollution. We have 
now performed a large number of inhalation exposures in healthy subjects and 
patients with cardiovascular disease using well-characterised systems. Particulate 
levels during these exposures are comparable with those in heavy traffic and 
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occupational settings in large cities. Here, we used two types of diesel engine and two 
different commercially available fuels. The particulate component was similar in both 
protocols. Despite differences in the method of diesel exhaust generation and the 
gaseous component, prothrombotic effects were consistent.  
   
Although the overall implications of exposure to traffic-derived pollution are 
significant from a population perspective, individual risk is modest. Observational 
data support the notion that risk is greatest in those with pre-existing cardiovascular 
disease. Indeed, we have recently demonstrated that dilute diesel exhaust inhalation 
has pro-ischemic effects in patients with prior MI [Mills, et al., 2007]. In the present 
study, we have extended these findings using a clinical model of severe arterial injury 
that is reflective of the intravascular conditions in a patient with a ruptured or denuded 
atheromatous plaque. Our findings of enhanced platelet activation and thrombus 
formation further highlight the potential increased propensity of ‘at risk’ populations 
to suffer adverse cardiovascular consequences following exposure to air pollution 
although it is not possible from this study to determine whether diesel exhaust 
exposure enhances thrombogenicity in patients on antiplatelet therapies. 
 
6.5.5    CONCLUSION 
Inhalation of dilute diesel exhaust causes platelet activation and increased thrombus 
formation in man. This study provides a plausible pathophysiological link that may 
explain the association between combustion-derived air pollution and acute 
cardiovascular events. Further work is required to clarify more precisely the 
mechanism of enhanced thrombogenicity and to investigate how this potentially 
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7.1    SUMMARY 
In controlled human exposure studies, diesel engine exhaust inhalation impairs 
vascular function and enhances thrombus formation. The aim of the present study was 
to establish whether an exhaust particle trap could prevent these adverse 
cardiovascular effects in men. Nineteen healthy volunteers (mean age 25±3 years) 
were exposed to filtered air and diesel exhaust in the presence or absence of a particle 
trap for one hour in a randomised double-blind three-way crossover trial. Bilateral 
forearm blood flow and plasma fibrinolytic factors were assessed using venous 
occlusion plethysmography and blood sampling during intra-arterial infusion of 
acetylcholine, bradykinin, sodium nitroprusside and verapamil. Ex vivo thrombus 
formation was determined using the Badimon chamber. Compared to filtered air, 
diesel exhaust inhalation was associated with reduced vasodilatation and increased ex 
vivo thrombus formation under both low and high shear conditions. The particle trap 
markedly reduced diesel exhaust particulate number (150,000-300,000 to 30-300/cm3; 
P<0.001) and mass (320±10 to 7.2±2.0 µg/m3; P<0.001), and was associated with 
increased vasodilatation, reduced thrombus formation and an increase in tissue 
plasminogen activator release. 
 
Exhaust particle traps are a highly efficient method of reducing particle emissions 
from diesel engines. Using a range of surrogate measures, the use of a particle trap 
prevents several adverse cardiovascular effects of exhaust inhalation in men. Given 
these beneficial effects on biomarkers of cardiovascular health, the widespread use of 
particle traps on diesel-powered vehicles may have substantial public health benefits 
and reduce the burden of cardiovascular disease.  
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7.2    INTRODUCTION 
There is a robust and consistent association between air pollution and cardio-
respiratory morbidity and mortality [Brunekreef, et al., 2002; Dockery, et al., 1993; 
Logan, 1953; Samet, et al., 2000]. These harmful effects are most strongly associated 
with exposure to traffic-derived fine particles (particulate matter [PM] with a mean 
diameter <2.5 µm, PM2.5) that predominantly originate from diesel engine exhaust 
emissions [Laden, et al., 2000]. Diesel engines are popular because of their reliability, 
efficiency and relatively low running costs. However, they generate up to 100 times 
more fine particles than petroleum engines of a similar size and contribute 
substantially to the global burden of PM air pollution.  
 
According to the World Health Organisation, air pollution is responsible for at least 
800,000 premature deaths worldwide each year with an average one year loss of life 
[Cohen, et al., 2005]. The long-term risk of cardiovascular death rises by 76% for 
each 10µg/m3 increase in PM2.5 [Miller, et al., 2007; Peters, et al., 2002]. Short-term 
exposure has been linked to the triggering of acute myocardial infarction [Bhaskaran, 
et al., 2009] with patients being three times more likely to be exposed to traffic-
derived air pollution in the hours before their acute myocardial infarction [Peters, et 
al., 2001]. Despite the strength and consistency of observational studies, the 
underlying pathophysiological mechanisms remain unclear. Using well-characterised 
and controlled diesel engine exhaust exposure studies in healthy volunteers, we have 
previously demonstrated impaired vascular vasomotor and fibrinolytic function 
[Mills, et al., 2005], increased arterial stiffness [Lundback, et al., 2009] and enhanced 
ex vivo thrombus formation [Lucking, et al., 2008]. Furthermore, in patients with 
coronary heart disease, we have shown that diesel engine exhaust inhalation 
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exacerbates exercise induced ST-segment depression during light exercise [Mills, et 
al., 2007]. Taken together, these adverse cardiovascular effects provide important 
mechanisms that help to explain the detrimental health effects of air pollution 
exposure. 
 
One approach to limit traffic emissions has been the introduction of diesel engine 
exhaust particle traps or filters. Whilst the efficiency of particle traps to reduce 
particle emission is >90%, particles are not completely eliminated and traps have the 
potential to create new and potentially more toxic particles that may outweigh the 
benefits of reducing the emitted particle mass [Su, et al., 2008]. We therefore sought 
to determine whether the introduction of a particle trap would attenuate or worsen the 
adverse cardiovascular effects of diesel engine exhaust inhalation [Lucking, et al., 












7.3    METHODS  
Twenty-one subjects were screened and one subject was excluded at the initial 
screening. A further subject was excluded after randomisation due to inability to 
complete all exposures leaving 19 healthy non-smoking men who completed the full 
study protocol (see supplement Figure 7a, below [CONSORT diagram]).  The study 
was approved by the local research ethics committee, and conducted in accordance 
with the Declaration of Helsinki, and with the written informed consent of all 
volunteers. 
 
All subjects had normal lung function and no symptoms of upper airway infection for 
the four weeks prior to or during the study. Exclusion criteria were regular 
medication, clinical evidence of atherosclerotic vascular disease, arrhythmias, 
diabetes mellitus, hypertension, renal or hepatic failure, asthma, significant 
occupational exposure to air pollution, or intercurrent illness. All subjects abstained 
from caffeine containing drinks or food for at least four hours and from alcohol for 24 
hours before each assessment.  
 
7.3.1    STUDY DESIGN 
The primary endpoints were endothelial vasomotor and fibrinolytic function and ex 
vivo thrombus formation. Secondary endpoints were soluble markers of inflammation 
and platelet activation. Exploratory endpoints were markers of arterial stiffness and 
airway inflammation. Sample size was determined a priori and based on power 
calculations for the primary end-points derived from our previous studies (see 
supplement material, below) [Lucking, et al., 2008; Mills, et al., 2005]. 
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In a randomised double-blind three-way crossover design, subjects were exposed to 
filtered air, unfiltered dilute diesel engine exhaust, and dilute diesel engine exhaust 
that had passed through a particle trap. The order of the exposures was randomised 
using an independent predetermined exposure sequence. Exposures were performed at 
a separate dedicated exposure facility by technical staff with no involvement in the 
clinical studies. Clinical studies were performed in a dedicated clinical research 
facility by clinical staff blinded to exposure allocation. Exposures were separated by 
at least one week and performed in a purpose-built exposure chamber, according to a 
previously described standard protocol [Mills, et al., 2005]. During each one-hour 
exposure, subjects performed moderate exercise (minute ventilation, 25 L/min/m2 
body) on a bicycle ergometer for 15 min alternated with 15 min of rest. 
 
7.3.2    DIESEL EXHAUST 
A Volvo diesel engine (Volvo TD40 GJE, 4.0 L, four cylinders) running on a Volvo 
standard diesel fuel (SD-VSD-10) was used to generate the diesel exhaust. The 
specification of the Volvo diesel fuel is similar to the European automotive standard 
diesel (EN590), with a sulphur content of 5-7 mg/kg and polycyclic aromatic 
hydrocarbon content of 2-6% by mass. The engine worked under transient speed and 
load conditions in accordance with the standardised European Transient Cycle that 
mimics real-world urban driving conditions [Barath, et al.]. More than 90 % of the 
exhaust was shunted away and the residual exhaust was mixed with filtered air 








Figure 7.1 Scheamatic illustration of the diesel exhaust set-up from the engine to the flow of 




The concentrations of nitrogen oxides (NO, NO2 and NOx) in the chamber were 
continuously monitored together with total gaseous hydrocarbons (THC). During 
diesel exhaust exposures, we aimed to generate a PM mass concentration of 300 
µg/m3. This PM mass concentration was maintained for the inlet conditions of the 
particle trap. Actual exposure was measured gravimetrically with standard glass fibre 
filter sampling together with the use of a TEOM on-line instrument and in accordance 
with a well established protocol, as described previously [Behndig, et al., 2006]. In 




7.3.3    PARTICLE TRAP 
The particle trap (DPF-CRT® [Continuously Regenerating Trap], Johnson Matthey, 
Royston, UK) used is an unmodified CRT filter, available commercially throughout 
the world as a factory-fit option or as a retrofit unit to buses and heavy goods 
vehicles. It is similar in design to filters produced by a number of manufacturers. It 
consists of a honeycomb-like complex of channels through which the exhaust is 
passed. A catalyst at the front of the filter oxidises part of the NO gas in the exhaust 
into NO2, which flows through the particle filter and subsequently reacts with trapped 
carbonaceous particles to generate CO2 and N2. This increases NO2 levels in the 
exhaust after the particle trap, without causing significant changes in total NOx 
concentrations, whilst achieving an efficient reduction in particle emissions. 
 
7.3.4    VASCULAR STUDIES 
Based on data from previous exposure studies [Barath, et al.; Lucking, et al., 2008; 
Mills, et al., 2007; Tornqvist, et al., 2007], vascular assessment was performed six to 
eight hours after each exposure. Assessments were performed with subjects resting 
supine in a quiet temperature controlled (22-24°C) room. Venous cannulae (17 gauge) 
were inserted into large subcutaneous veins in the antecubital fossae of both arms. 
The brachial artery of the non-dominant arm was cannulated with a 27-standard wire 
gauge steel needle. After a baseline 30-min saline infusion, bradykinin at 100, 300 
and 1,000 pmol/min (endothelium-dependent vasodilator that releases tissue 
plasminogen activator [t-PA]; Merck Biosciences, Nottingham, UK); acetylcholine at 
5, 10, and 20 µg/min (endothelium-dependent vasodilator that does not release t-PA; 
Merck Biosciences); and sodium nitroprusside at 2, 4, and 8 µg/min (endothelium-
independent vasodilator that does not release t-PA; David Bull Laboratories,  
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Warwick, UK) were infused for six min at each dose. The three vasodilators were 
given in random order, separated by a 20-min saline infusion. Verapamil was infused 
at 10, 30, and 100 µg/min (endothelium-independent and nitric oxide-independent 
vasodilator that does not release t-PA) at the end of the study protocol. The infusion 
of these vasodilators was undertaken to allow the assessment of distinct aspects of 
vascular function including nitric oxide, endothelium, fibrinolysis and vasomotion.  
 
Forearm blood flow was measured in both infused and non-infused arms using venous 
occlusion plethysmography incorporating mercury-in-silicone elastomer strain gauges 
as described previously [Mills, et al., 2005]. Heart rate and blood pressure were 
monitored in the non-infused arm throughout each study with a non-invasive, semi-
automated oscillometric sphygmomanometer (Boso Medicus, Jungingen, Germany). 
Blood was drawn simultaneously from the venous cannulae in each arm at baseline 
and during infusion of each dose of bradykinin. Samples were collected into acidified 
buffered citrate (Stabilyte®, Biopool International) for t-PA assays and into citrate (BD 
Vacutainer) for plasminogen activator inhibitor type 1 (PAI-1) assays. Samples were 
kept on ice before being centrifuged at 2,000g for 30 minutes at 4°C. Platelet-free 
plasma was decanted and stored at -80°C before assay. Plasma t-PA and PAI-1 
antigen concentrations were determined by ELISA (TintElize t-PA, Biopool EIA, 
Trinity Biotech, Ireland; Coaliza PAI-1, Chromogenix AB, Milan, Italy). Heamatocrit 
was determined by capillary tube centrifugation of samples collected at baseline and 





7.3.5    MARKERS OF INFLAMMATION 
Venous blood samples were obtained before and at two, six and eight hours after 
exposure. Samples were analysed for total and differential cell count using an 
autoanalyser. Plasma interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α), soluble 
CD40 ligand (sCD40L), soluble P-selectin, intercellular adhesion molecule-1 (ICAM-
1) and C-reactive protein (CRP) were measured with commercially available enzyme-
linked immunosorbant assays (R&D Systems, Abingdon, UK).  
 
7.3.6    EX VIVO THROMBOSIS STUDIES 
 
Thrombus formation was measured using the Badimon Chamber as described in 
section 2.3.  
 
Immediately after each study, porcine strips with thrombus attached were removed 
and fixed in 4% paraformaldehyde. Strips were paraffin-wax embedded, sectioned 
and stained with Masson’s Trichrome. Images were acquired at ×20 magnification 
and thrombus area measured using a semi-automated image acquisition system (Ariol, 
Applied Imaging, USA) by a blinded operator. Results from at least six sections were 
averaged to determine thrombus area for each chamber as described previously 
[Badimon, et al., 1987; Osende, et al., 2001]. 
 
7.3.7    ASSESSMENT OF ARTERIAL STIFFNESS 
Please see supplement material, below 
 
7.3.8    ASSESSMENT OF AIRWAY INFLAMMATION 
Please see supplement material, below. 
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7.3.9    DATA ANALYSIS AND STATISTICS 
Plethysmographic data were analysed as described previously [Mills, et al., 2005]. 
Estimated net release of t-PA antigen was defined as the product of the infused 
forearm plasma flow (based on the mean heamatocrit and the infused forearm blood 
flow) and the concentration difference between the infused and non-infused arms as 
described previously [Mills, et al., 2007; Mills, et al., 2005]. Continuous variables are 
reported as mean ± standard error of the mean (SEM). Statistical analyses were 
performed with GraphPad Prism (Graph Pad Software, California, USA). All studies, 
data analysis and data exclusion were performed prior to the data being unblinded.  
To address our primary hypothesis, the analysis plan required two independent 
assessments of the responses in the three randomised arms of the study. First, to 
confirm our previous findings, we assessed whether the inhalation of diesel engine 
exhaust impaired vascular function and promoted thrombogenesis. Second, we 
assessed whether the particle trap improved these surrogate measures of 
cardiovascular health. Comparisons between exposures were undertaken using a two-
sided paired t test and two-way ANOVA with repeated measures, as appropriate. 
Factors assessed in the two-way ANOVA were exposure and vasodilator dose.  
Exposure data were analysed using a two-sided unpaired t test. Statistical significance 







7.4    RESULTS 
The nineteen healthy male volunteers were young, normotensive and had normal lung 
function (Table 7.1). All volunteers completed the three study visits. Exposures were 
well tolerated with no adverse symptoms reported.  
_____________________________________________________________________ 
           
 
Age (years)     25 ± 3 
Height (cm)   181 ± 5 
Weight (kg)     75 ± 8 
BMI (kg/m²)     23.4 ± 2 
 
Pulse (bpm)     54 ± 8 
Systolic Blood Pressure (mmHg) 113 ± 6 
Diastolic Blood Pressure (mmHg)   73 ± 8 
 
 FEV1 (L)    4.6 ± 0.6 
% predicted FEV1  100 ± 12 
FVC (L)     5.6 ± 0.8 
% predicted FVC   103 ± 14 
_____________________________________________________________________ 
Data shown are mean±standard error of the mean (n=19) 
 
BMI = Body mass index 
FEV1 = Forced expiratory volume in one second 
FVC = Forced vital capacity 
 
Table 7.1 Baseline subject characteristics (n=19) 
 
The particle trap reduced the total particle mass concentration in the chamber by 
approximately 98% and the fine (<1 µm) particle number concentration by more than 
99.8%. As anticipated, the particle trap, with an integrated oxidation catalyst, did alter 
the composition of nitrogen oxides, i.e. increased NO2 and decreased NO (Table 7.2). 
However, it had no significant effect on the concentrations of gaseous hydrocarbons.  
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There were no changes in blood pressure, resting heart rate, baseline forearm blood 
flow or markers of arterial stiffness in between the three study visits (data supplement, 
Tables 7b and 7c, below). Haematological variables, markers of inflammation and 
soluble markers of platelet activation did not differ between exposures (data 
supplement, Tables 7d and 7e, below). Markers of airway inflammation did not differ 
between exposures (data supplement, Table 7f, below). 
 
	   Unit Filtered diesel exhaust Diesel exhaust P-value 
NO  ppm	   2.09 ± 0.15 5.72 ± 0.33 <0.001 
NO2	   ppm	   3.44 ± 0.33 0.69 ± 0.02 <0.001 
NOx	   ppm	   5.53 ± 0.44 6.40 ± 0.34 0.049 
Total gaseous hydrocarbons	   ppm	   0.84 ± 0.06 0.91 ± 0.05 0.387 
Total PM mass concentration	   µg/m3	   7.2 ± 2.0 320 ± 10 <0.001 
Fine particle number concentration #/cm3 30 - 300 150,000 - 200,000 <0.001 
 
Data shown are mean±standard error of the mean (n=19) 
Data analysed using 2-tailed unpaired t test 
 
NO - Nitric oxide, NO2 - Nitrogen dioxide, NOx - Nitrogen oxides, PM - Particulate matter 
 
Table 7.2 Exposure conditions in the chamber.  
 
 
7.4.1    VASCULAR STUDIES 
Vasomotor Function 
There was a dose-dependent increase in forearm blood flow with both endothelium-
dependent (bradykinin and acetylcholine) and endothelium-independent (sodium 
nitroprusside and verapamil) vasodilators following each exposure (P<0.0001 for all; 




Figure 7.2  Infused forearm blood flow four to six hours after exposure, during intra-brachial 
infusion of bradykinin, acetylcholine, sodium nitroprusside and verapamil. The left panel displays 
vasomotor response following exposure to air and diesel exhaust, confirming the vascular effects 
from previous investigations. Filtered air exposure shown by open circles, diesel engine exhaust 
exposure by filled circles. The right panel displays the main comparison of vasomotor function 
after exposure to unfiltered diesel exhaust (filled circles) and filtered diesel exhaust (crosses). 
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Compared to filtered air, vasodilatation was impaired following diesel engine exhaust 
exposure in response to bradykinin (P=0.009), acetylcholine (P=0.01) and verapamil 
(P=0.03; Figure 7.2). There was no significant difference in response to sodium 
nitroprusside (P=0.15; Figure 7.2). However, with the introduction of the particle trap, 
vasodilatation increased to all vasodilators: bradykinin (P<0.0001), acetylcholine 
(P<0.0001), verapamil (P=0.001) and sodium nitroprusside (P=0.04; Figure 7.2). 
Indeed, there were no differences in vasomotor responses between filtered air and 
filtered diesel engine exhaust except for acetylcholine, where vasodilatation was 
lower with filtered air (P=0.02). 
 
Fibrinolytic Function 
There were no differences in baseline plasma t-PA and PAI-1 concentrations between 
exposures (data supplement, Table 7g, below). There was a dose-dependent increase 
in t-PA release in response to bradykinin infusion following each exposure (P<0.0001 
for all; Figure 7.3). Although numerically lower, there was no statistical difference in 
t-PA-release following exposure to diesel engine exhaust inhalation compared with 
filtered air (P=0.30; Figure 7.3). However, application of the particle trap was 
associated with an improvement in the net release of t-PA compared to unfiltered 
diesel engine exhaust (P=0.03; Figure 7.3). There was no difference in t-PA-release 








Figure 7.3  Tissue plasminogen activator release from the forearm endothelium four to six 
hours after exposure, during intra-brachial infusion of bradykinin. The left panel displays 
fibrinolytic response following exposure to air and diesel exhaust. Filtered air exposure 
shown by open circles, diesel engine exhaust exposure by filled circles. The right panel 
displays the main comparison of fibrinolytic function after exposure to unfiltered diesel 
exhaust (filled circles) and filtered diesel exhaust (crosses). 
 
7.4.2    EX VIVO THROMBOSIS 
Compared to filtered air, inhalation of diesel exhaust was associated with an increase 
of thrombus formation in the low-shear (21.8%, P<0.001; Figure 7.4) and high-shear 
(14.8%; P=0.02; Figure 7.4) chambers. Compared to unfiltered exhaust, the 
introduction of the particle trap was associated with a reduction in thrombus 
formation in the low-shear chamber (-15.7%, P=0.02; Figure 7.4), whilst the apparent 
reduction in the high-shear chamber did not reach statistical significance (P=0.11; 
Figure 7.4). There were no differences in thrombus formation between filtered air and 











Figure 7.4  Ex vivo thrombus formation assessed using the Badimon Chamber at two hours 
after exposure. Data from the low shear chamber are shown in the upper panels. Data from 
the high shear chamber are shown in the lower panels. Filtered air exposure shown in white, 







7.5    DISCUSSION 
Short-term exposure to traffic-derived air pollution is associated with acute 
cardiovascular events [Bhaskaran, et al., 2009; Peters, et al., 2001; Peters, et al., 
2004]. In the current study, using complementary and relevant measures of 
cardiovascular health, we have reconfirmed the adverse effects of exposure to diesel 
engine exhaust on endothelial function and ex vivo thrombosis. In addition, for the 
first time, we demonstrate that reducing the particulate component of diesel exhaust 
using a commercially available particle trap can prevent these detrimental 
cardiovascular effects. Our study provides support for the application of particle traps 
to diesel-powered vehicles in order to reduce urban particulate concentrations and 
limit a range of adverse cardiovascular effects of exposure to traffic-derived air 
pollution.  
 
In a series of controlled exposure studies in human subjects, we have previously 
shown an impairment of vasomotor responses to endothelium-dependent and 
endothelium-independent vasodilators after diesel exhaust exposure [Tornqvist, et al., 
2007]. These observations are consistent with other reports of brachial artery 
vasoconstriction shortly after exposure to dilute diesel exhaust [Peretz, et al., 2008] 
and concentrated ambient particles [Brook, et al., 2002]. Such vascular impairment is 
not restricted to vasomotor function. We have also demonstrated increased 
thrombogenicity with reduced t-PA release from the endothelium [Mills, et al., 2005], 
enhanced platelet activation [Lucking, et al., 2008] and increased ex vivo thrombus 
formation [Lucking, et al., 2008]. 
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In the present study we employed a range of these complementary measures of 
cardiovascular function in a comprehensive assessment of the potential for particle 
traps to improve human health. We were able to confirm our earlier findings that 
diesel exhaust inhalation causes detrimental vascular and prothrombotic effects. On 
this occasion, we did not observe a statistically significant reduction in t-PA release 
from the endothelium following diesel exhaust exposure and this may represent a type 
II error or reflect the subtle differences between study protocols. However, more 
importantly we were able to demonstrate that the introduction of a particle trap not 
only improved vasomotion, endogenous fibrinolysis and ex vivo thrombosis but 
appeared to normalise them. 
 
Although there are many potentially harmful components in ambient air pollution, 
traffic-derived fine and ultra-fine particles are most closely and consistently linked to 
acute cardiovascular events. This has been the rationale for the development, and 
legislation for, targeted interventions to reduce the particulate matter content of 
vehicle emissions. Whilst there is little doubt that particle traps are effective in 
reducing PM mass and number, concerns have been raised regarding the oxidation 
catalysts required to regenerate and maintain filter efficiency as they may alter the 
toxicity of particulate and gaseous emissions. For example, soot particles generated 
from a low emission diesel engine appear to have greater cytotoxic and pro-
inflammatory effects [Su, et al., 2008]. The potential for particle traps to reduce the 
adverse cardiovascular effects of diesel exhaust emissions therefore needs to be 
assessed in man. Here we observed no adverse cardiovascular effects arising from the 
use of a particle trap. The only difference between filtered air and filtered diesel 
exhaust observed for any variable we assessed was, in fact, an enhancement of 
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vasodilatation in response to acetylcholine following exposure to filtered diesel 
exhaust. Whilst this difference was statistically significant, it was numerically small 
and unlikely to be of major physiological significance. In light of these factors, we 
suspect that this may be a result of a type I error although we cannot rule out an effect 
related to alterations in one or more unmeasured gaseous components. 
 
We employed a commercially available particle trap to reduce particle emissions from 
a heavy-duty diesel engine operating under the transient cycling conditions used as 
the standard for engine testing across the European Union. Particle filtration markedly 
reduced the mass and number of particle emissions. Taken together with our previous 
findings and data from observational studies, we believe it is this reduction that is 
responsible for rectifying the adverse cardiovascular effects of diesel engine exhaust 
inhalation. As expected, oxidation catalysts within the particle trap altered the 
composition of NOx with an increase in NO2 and decrease in NO concentrations. 
However, we have recently assessed the effects of NO2 on healthy volunteers and did 
not identify any adverse effects on vascular or fibrinolytic function [Langrish, et al.]. 
Whilst we did not observe an effect on the other gaseous components of the exposure, 
we acknowledge that the particle trap may have altered the composition of the 
exposures beyond those variables assessed during this study. 
 
Consistent with previous studies [Barath, et al.; Mills, et al., 2005; Tornqvist, et al., 
2007] vasodilatation was impaired following exposure to diesel engine exhaust in 
response to bradykinin and acetylcholine. However, there was also a reduction in 
vasodilatation to verapamil, implying an additional calcium flux-dependent 
impairment of vascular smooth muscle function. A reduction in vasodilatation to 
 172 
verapamil has previously been demonstrated following exposure to diesel exhaust 
generated under transient engine speed and load [Barath, et al.] but not when 
generated under idling conditions [Mills, et al., 2005]. We have previously speculated 
that, in exhaust generated under transient running conditions, the higher diesel-related 
soot content and its associated (adsorbed) organic material may cause these additional 
vascular smooth muscle effects and believe that this observation warrants further 
investigation [Barath, et al.]. Interestingly, impaired vasodilatation in response to 
verapamil was also normalised by the introduction of a particle trap. Although 
variations in responses between studies with different exposure protocols might 
provide insights into the pathophysiological mechanisms responsible for the adverse 
vasomotor effects of diesel exhaust exposure, these studies were designed and 
powered to detect differences within rather than between studies. Thus, whilst 
tempting, we believe that we should be cautious and circumspect in drawing 
conclusions from comparisons made between studies and any such differences should 
be regarded as hypothesis generating and the subject of future investigations. 
 
The exact mechanisms underlying the vascular and prothrombotic effects we observed 
in the current and previous studies remain only partially understood. Regarding the 
increase in ex vivo thrombosis seen following diesel exhaust exposure, data from 
previous in vitro [Radomski, et al., 2005] and animal studies [Nemmar, et al., 2003], 
as well as our own previous controlled exposure studies in humans [Lucking, et al., 
2008], suggest that platelet activation plays a central role. Platelets are key 
components of arterial thrombosis, a process that underpins acute coronary syndromes 
including myocardial infarction. Platelet-leucocyte aggregates, increasingly 
recognised as the gold standard measure of in vivo platelet activation [Freedman, et 
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al., 2002], were increased following tracheal instillation of carbon nanotubes in a 
murine model of vascular injury [Nemmar, et al., 2007] and following diesel exhaust 
exposure in humans [Lucking, et al., 2008]. Debate remains as to whether inhaled 
components of diesel exhaust can translocate into the systemic circulation to mediate 
direct effects on blood and vascular components [Mills, et al., 2006; Nemmar, et al., 
2002] or whether the induction of pulmonary inflammation and the subsequent 
generation of free radicals may activate platelets by reducing endothelium- and 
platelet-derived nitric oxide and antioxidants. Although a single observational study 
reported a small reduction in prothrombin time associated with ambient exposure to 
PM10, [Baccarelli, et al., 2007] the authors are not aware of any controlled exposure 
study demonstrating an effect of pollution exposure on plasma concentrations of 
coagulation factors. 
 
The potential mechanisms underlying the adverse vasomotor effects observed in 
response to diesel exhaust exposure remain only partly understood [Brook, et al.] and 
a full discussion is beyond the scope of this manuscript. However, based on data from 
our earlier studies in which the exposure was generated by an idling diesel engine 
[Mills, et al., 2005; Tornqvist, et al., 2007], we have previously speculated that 
oxidative stress and impaired NO-dependent signalling play a central role in the 
adverse vasomotor effects. Given the broader impairment of vasomotor function we 
observed here and in a previous study using a transient cycling diesel engine [Barath, 
et al.], we acknowledge that we cannot discount upregulation of other circulating or 
cellular vasoconstrictor mediators (such as Rho Kinase [Sun, et al., 2008]) or 
activation of the sympathetic nervous system as an alternative explanation for the 
general blunting of vasodilator responses observed.  
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7.5.1    LIMITATIONS 
Our principal objective was to assess the impact of a commercially available particle 
trap on markers of cardiovascular health by comparing the effects of unfiltered and 
filtered diesel exhaust. In this regard, we clearly demonstrate that vasodilatation, 
endothelial t-PA release and thrombus formation are improved by particle filtration. 
However, we acknowledge that our approach has limitations. The use of multiple and 
complementary surrogates of cardiovascular health is both a strength and a weakness 
of this study. Replication of previous observations suggests that the findings are real 
and provides a clear and consistent message; diesel exhaust impairs vascular function 
[Barath, et al.; Mills, et al., 2005; Tornqvist, et al., 2007] and increases ex vivo 
thrombus formation [Lucking, et al., 2008]. The use of multiple end-points with three 
exposure conditions requires multiple comparisons and increases the possibility of 
type I and II errors. We have not adjusted for multiple comparisons as the initial 
comparison between diesel exhaust and filtered air was made simply to confirm our 
previous findings. Both the direction and magnitude of the changes seen here are 
consistent with our previous findings although the differences in net t-PA release 
failed to achieve statistical significance. Although the study was powered 
prospectively based on measurements of the primary endpoints made during previous 
diesel exposure studies, we acknowledge that the sample size is modest. Whilst we 
are confident that we have not missed effects on endothelial function or ex vivo 
thrombosis, we acknowledge that we may have insufficient power to detect changes 
in some of the secondary endpoints (data supplement, Table 1) and thus cannot 
exclude the possibility of false negative findings confounding their assessment. In 
addition, the study cohort consisted exclusively of young, healthy men. Although one 
might postulate that the benefit of particle traps may actually be greater in those with 
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pre-existing cardiovascular disease, we concede that further studies are required to 
assess the role of particle traps in mitigating cardiovascular effects in women and the 
broader population.  
 
7.5.2    CONCLUSION  
Using several surrogate measures, a range of adverse cardiovascular effects of diesel 
exhaust inhalation in man appears to be prevented by the introduction of a particle 
trap. Given these beneficial effects on biomarkers of cardiovascular health, the 
widespread use of particle traps on diesel-powered vehicles may have substantial 














7.6   SUPPLEMENTAL MATERIAL (published as online supplement) 
7.6.1    SUPPLEMENTAL METHODS 
Power Calculations 
The studies were prospectively powered based on measurements of the primary 
endpoints (endothelial vasomotor function and endogenous fibrinolysis assessed by 
forearm venous occlusion plethysmography; and ex vivo thrombus formation assessed 
using the Badimon Chamber). Based on our previous studies of endothelial vasomotor 
function and endogenous fibrinolysis, to detect a 20% difference in forearm blood 
flow and a 16% difference in t-PA release, we require sample sizes of n=18 at 90% 
power and two-sided P<0.05. Based on previous studies by our own and Professor 
Badimon’s group, to detect differences of 10% in thrombus area, we require sample 
sizes of n=18 at 90% power and two-sided P<0.05. Power calculations for the 
secondary and other endpoints are presented in Table 7a. 
 
Arterial Stiffness 
All measurements were performed by a single operator who was unaware of the 
nature of exposure. Studies were performed in a quiet, temperature controlled room 
with subjects resting in a supine position. Systolic and diastolic blood pressures were 
measured using a semi automated non-invasive oscillometric sphygmomanometer 
(Omron HEM-705CP, Omron, Matsusaka, Japan). Pulse wave analysis was 
performed using applanation tonometry (Millar Instruments, Texas, USA) of the 
radial artery and the SphygmoCor™ system (AtCor Medical, Sydney, Australia) in 
accordance with the manufacturer's recommendations. Briefly, pulse wave analysis 
derives an aortic pulse pressure waveform from the radial artery wave via a 
matheamatical transfer function. The arterial pressure waveform is a composite of the 
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forward pressure wave created by ventricular contraction and a reflected wave 
generated by peripheral vascular resistance. The augmentation pressure is the 
difference between the second and first systolic peaks. The augmentation index 
(augmentation pressure as a percentage of the pulse pressure) is a measure of systemic 
arterial stiffness and wave reflection. The time to wave reflection is reduced with 
increasing arterial stiffness, and provides a surrogate of aortic pulse wave velocity 
[Mills, et al., 2008]. At least two independent waveform analyses were obtained from 
each subject, with measurements only accepted upon meeting SphygmoCor™ quality 
control criteria. Pulse wave velocity was calculated by measuring the time for the 
pulse wave to travel between the carotid and femoral arteries.  
 
Fraction of Exhaled Nitric Oxide 
All measurements were performed by a single blinded operator. Fraction of exhaled 
nitric oxide (FENO) concentrations were evaluated pre exposure, 2 and 6 hours post-
exposure, using a nitric oxide analyser (NIOX®, Aerocrine AB, Stockholm, Sweden). 
Two different exhalation flow rates; 10 and 50 mL×s-1 (± 10%), during a slow 
exhalation against an oral pressure of 2 cm H2O for 8 seconds were examined. The 
measurements were conducted in triplicate and the mean concentration of exhaled NO 
(ppb) was registered according to current ERS/ATS guidelines.  
 
Data Analysis and Statistics 
All studies, data analysis and data exclusion were performed prior to the data being 
unblinded. Continuous variables are reported as mean ± standard error of the mean 
(SEM). Statistical analyses were performed with GraphPad Prism (Graph Pad 
Software, California, USA).  
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Comparisons between exposures were undertaken using one- and two-way analysis of 
variance (ANOVA) with repeated measures, as appropriate. Factors assessed in the 
two-way ANOVA were exposure and time. Statistical significance was taken at 
P<0.05. 
 
7.6.2    SUPPLEMENTAL RESULTS 
There were no differences in resting heart rate, blood pressure or arterial stiffness 
following exposure to diesel exhaust, filtered exhaust or filtered air (Tables b and c). 
Haematological variables, plasma markers of inflammation and platelet activation, 
baseline markers of fibrinolytic function and markers of airway inflammation were 




























Figure 7a  CONSORT diagram 
Assessed for eligibility (n=21) 
Excluded  (n=1) 
♦   Not meeting inclusion criteria (n=1) 
♦   Declined to participate (n=0) 
♦   Other reasons (n=0) 
Lost to follow-up (give reasons) (n=0) 
Discontinued intervention (give reasons) (n=0) 
Allocated to interventions (n=20) 
♦ Received all allocated interventions (n=19) 
♦ Did not receive all allocated intervention 
(personal reasons) (n=1) 
Analysed  (n=19) 
♦ Excluded from analysis (incomplete dataset 






All subjects underwent filtered air, diesel and filtered 
diesel exposure in a crossover design 




7.6.4    SUPPLEMENTAL TABLES 
 
     Effect size detectable at: 
 n mean SD SD2 80% power 90% power 
Systolic blood pressure (mmHg) 19 136 14 190 13 14 
Diastolic blood pressure (mmHg) 19 70 9.9 100 9.0 10 
Pulse (bpm) 19 64 12 132 10 12 
       
TNF-a (pg/mL)  19 0.63 0.31 0.10 0.28 0.32 
IL-6 (pg/mL) 19 0.28 0.21 0.04 0.19 0.22 
CRP (mg/mL) 19 0.56 0.28 0.08 0.25 0.29 
Soluble CD40L (pg/mL) 19 61 18 339 17 19 
Soluble P-selectin (mg/mL) 19 39 11 110 9.5 11 
Soluble ICAM-1 (mg/mL) 19 231 41 1658 37 43 
       
Baseline t-PA (ng/mL) 19 5.0 3.9 15 3.5 4.0 
Baseline PAI-1 (ng/mL) 19 6.3 3.8 14 3.4 4.0 
       
Augmentation Pressure (mmHg) 19 -0.70 3.9 15 3.5 4.1 
Augmentation Index (%) 19 -2.6 12 142 11 12 
Time to Wave reflection (ms) 19 179 28 784 25 29 
       
FENO 50 (ppb) 19 13 5.2 27 4.7 5.4 
FENO 10 (ppb) 19 44 19 375 18 20 
 












6 Hours  8 Hours 
FILTERED AIR     
Systolic Blood Pressure (mmHg) 135 ± 3 139 ± 3 141 ± 3 139 ± 3 
Diastolic Blood Pressure (mmHg) 73 ± 3  66 ± 2 66 ± 2 71 ± 3 
Pulse (bpm) 73 ± 3  64 ± 2 63 ± 2 59 ± 3 
Infused FBF (mL/100mL tissue/min) - - 2.1 ± 0.1 - 
Noninfused FBF (mL/100mL tissue/min) - - 2.0 ± 0.1 - 
 
DIESEL EXHAUST 
    
Systolic Blood Pressure (mmHg) 133 ± 3 131 ± 3 132 ± 3 135 ± 3 
Diastolic Blood Pressure (mmHg) 75 ± 2 66 ± 2 66 ± 2 69 ± 2 
Pulse (bpm) 72 ± 2 63 ± 3 59 ± 2 57 ± 2 
Infused FBF (mL/100mL tissue/min) - - 2.1 ± 0.1 - 
Noninfused FBF (mL/100mL tissue/min) - - 2.1 ± 0.2 - 
 
FILTERED DIESEL EXHAUST 
    
Systolic Blood Pressure (mmHg) 132 ± 3 137 ± 3 138 ± 4 137 ± 3 
Diastolic Blood Pressure (mmHg) 77 ± 2 70 ± 2 69 ± 3 72 ± 2 
Pulse (bpm) 74 ± 2 63 ± 2 59 ± 2 59 ± 2 
Infused FBF (mL/100mL tissue/min) - - 2.1 ± 0.1 - 
Noninfused FBF (mL/100mL tissue/min) - - 2.1 ± 0.2 - 
 
Data shown are mean±standard error of the mean (n=19) 
There were no significant differences between exposures (2 way ANOVA with repeated measures) 
FBF - Forearm blood flow 
 
Table b  Haemodynamic variables  
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Time after exposure +5 mins +20 mins +30 mins +50mins 
FILTERED AIR     
  Augmentation Pressure (mmHg) 0.9 ± 1.4 0.0 ± 1.1 -1.1 ± 0.8 0.1 ± 1.0 
  Augmentation Index (%) 2.0 ± 3.8 -0.8 ± 3.3 -4.7 ± 2.5 -0.2 ± 3.1 
  Time to Wave Reflection (ms) 178 ± 10 175 ± 8 184 ± 7 165 ± 7 
  Systolic Blood Pressure (mmHg) 141 ± 3 137± 2 139 ± 3 137 ± 3 
  Diastolic Blood Pressure (mmHg) 71 ± 2 69 ± 3 66 ± 3 69 ± 3 
  Pulse (bpm) 63 ± 3 63 ± 3 62 ± 2 63 ± 2 
DIESEL EXHAUST     
  Augmentation Pressure (mmHg) -0.6 ± 0.7 -0.6 ± 0.9 -0.8 ± 0.9 -0.6 ± 1.1 
  Augmentation Index (%) -1.8 ± 2.2 -2.3 ± 2.9 -2.7 ± 2.9 -2.9 ± 3.7 
  Time to Wave Reflection (ms) 174 ± 8 188 ± 7 180 ± 7 185 ± 8 
  Systolic Blood Pressure (mmHg) 136 ± 3 138 ± 3 142 ± 4 138 ± 3 
  Diastolic Blood Pressure (mmHg) 69 ± 3 70 ± 2 70 ± 2 67 ± 2 
  Pulse (bpm) 58 ± 2 58 ± 3 59 ± 2 59 ± 2 
FILTERED DIESEL EXHAUST     
  Augmentation Pressure (mmHg) -0.9 ± 0.9 -1.9 ± 1.0 -2.1 ± 1.0 -1.5 ± 1.1 
  Augmentation Index (%) -2.5 ± 2.9 -7.1 ± 3.2 -7.1 ± 3.0 -5.9 ± 3.3 
  Time to Wave Reflection (ms) 177 ± 8 183 ± 7 181 ± 7 186 ± 7 
  Systolic Blood Pressure (mmHg) 144 ± 3 139 ± 3 140 ± 2 140 ± 3 
  Diastolic Blood Pressure (mmHg) 74 ± 2 70 ± 2 74 ± 3 72 ± 2 
  Pulse (bpm) 63 ± 2 60 ± 3 61 ± 2 62 ± 2 
 
 Pulse wave velocity, m/s 
Time after exposure +10 mins +40 mins 
Filtered air 5.6 ± 0.4 5.2 ± 0.1 
Diesel exhaust 5.0 ± 0.1 5.0 ± 0.1 
Filtered diesel exhaust 4.9 ± 0.1 5.0 ± 0.1 
 
Data shown are mean±standard error of the mean (n=19) 
There were no significant differences between exposures (2 way ANOVA with repeated measures) 
Table c  Pulse wave analysis and pulse wave velocity 
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 Before 
Exposure 
2 Hours 6 Hours  8 Hours 
FILTERED AIR     
Haemoglobin (g/L) 143±2 137±2 137±2 135±2 
Leucocytes (×109 cells/L) 4.9±0.3 5.2±0.4 5.1±0.4 5.3±0.4 
Lymphocytes (×109 cells/L) 1.8±0.1 1.7±0.1 1.6±0.1 1.8±0.1 
Neutrophils (×109 cells/L) 2.4±0.2 2.9±0.3 2.9±0.3 2.8±0.3 
Monocytes (×109 cells/L) 0.5±0.0 0.5±0.0 0.4±0.0 0.5±0.0 
Platelets (×109 cells/L) 202±11 203±10 205±11 201±9 
DIESEL EXHAUST     
Haemoglobin (g/L) 141±2 137±2 135±2 134±2 
Leucocytes (×109 cells/L) 5.0±0.3 5.3±0.3 5.2±0.3 5.5±0.3 
Lymphocytes (×109 cells/L) 1.8±0.1 1.8±0.1 1.7±0.1 1.9±0.1 
Neutrophils (×109 cells/L) 2.4±0.2 2.9±0.2 2.9±0.2 2.9±0.2 
Monocytes (×109 cells/L) 0.5±0.0 0.5±0.0 0.4±0.0 0.5±0.0 
Platelets (×109 cells/L) 201±9 204±10 207±9 201±9 
FILTERED DIESEL 
EXHAUST 
    
Haemoglobin (g/L) 141±2 137±2 135±2 133±2 
Leucocytes (×109 cells/L) 4.9±0.2 5.2±0.3 5.1±0.2 5.3±0.2 
Lymphocytes (×109 cells/L) 1.9±0.1 1.8±0.1 1.7±0.1 1.9±0.1 
Neutrophils (×109 cells/L) 2.3±0.1 2.8±0.2 2.9±0.2 2.7±0.2 
Monocytes (×109 cells/L) 0.5±0.0 0.4±0.0 0.4±0.0 0.5±0.0 
Platelets (×109 cells/L) 200±8 190±8 201±8 194±8 
 
Data shown are mean±standard error of the mean (n=19) 
There were no significant differences between exposures (2 way ANOVA with repeated measures) 
 






 Before Exposure 2 Hours 6 Hours 
FILTERED AIR    
TNF-α (pg/mL) 0.59±0.07 0.63±0.08 0.65±0.06 
IL-6 (pg/mL) 0.29±0.05 0.32±0.06 0.23±0.04 
CRP (mg/L) 0.55±0.06 0.55±0.06 0.58±0.07 
Soluble CD40L (pg/mL) 62±2 57±3 63±7 
Soluble P-selectin (mg/mL) 40±3 40±2 37±2 
Soluble ICAM-1 (mg/mL) 228±10 241±8 223±11 
DIESEL EXHAUST    
TNF-α (pg/mL) 0.61±0.06 0.65±0.07 0.65±0.06 
IL-6 (pg/mL) 0.35±0.08 0.40±0.08 0.31±0.08 
CRP (mg/L) 0.60±0.11 0.52±0.08 0.56±0.07 
Soluble CD40L (pg/mL) 67±3 60±2 60±2 
Soluble P-selectin (mg/mL) 42±2 38±3 40±2 
Soluble ICAM-1 (mg/mL) 254±10 220±13 234±10 
FILTERED DIESEL EXHAUST    
TNF-α (pg/mL) 0.61±0.06 0.58±0.07 0.61±0.07 
IL-6 (pg/mL) 0.33±0.06 0.33±0.07 0.36±0.07 
CRP (mg/L) 0.61±0.10 0.60±0.08 0.64±0.10 
Soluble CD40L (pg/mL) 63±4 61±4 62±4 
Soluble P-selectin (mg/mL) 39±2 39±2 39±2 
Soluble ICAM-1 (mg/mL) 242±11 243±14 238±10 
 
Data shown are mean±standard error of the mean (n=19) 
There were no significant differences between exposures (2 way ANOVA with repeated measures) 
 
TNF-α - Tumour necrosis factor-α, IL-6 - Interleukin-6, CRP - C reactive protein, CD40L - CD40 
ligand, ICAM-1 - Intercellular adhesion molecule-1 
 






 Before Exposure 2 Hours 6 Hours 
FILTERED AIR    
  FENO 50 (ppb) 13 ± 1.2 16 ± 2.1 16 ±2.3 
  FENO 10 (ppb)  46 ± 4.9 51 ± 8.6 54 ± 8.1 
DIESEL EXHAUST    
  FENO 50 (ppb) 13 ± 1.2 14 ± 1.3 15 ± 2.1 
  FENO 10 (ppb) 44 ± 4.4 47 ± 4.7 48 ± 7.1 
FILTERED DIESEL EXHAUST    
  FENO 50 (ppb) 12 ± 0.9 13 ± 1.1 13 ± 1.0 
  FENO 10 (ppb) 41 ± 3.3 45 ± 3.3 44 ± 3.6 
 
Data shown are mean±standard error of the mean (n=19) 
There were no significant differences between exposures (2 way ANOVA with repeated measures) 
 
FENO 50 - Fraction of exhaled nitric oxide at exhalation rate 50 mL/s, FENO 10 - Fraction of exhaled 
nitric oxide at exhalation rate 10 mL/s 
 

















 Six Hours 
FILTERED AIR  
  Tissue plasminogen antigen (ng/mL) 2.9 ± 0.5  
  Plasminogen activator inhibitor type 1 (ng/mL) 4.8 ± 0.5 
DIESEL EXHAUST  
  Tissue plasminogen antigen (ng/mL) 2.9 ± 0.5  
  Plasminogen activator inhibitor type 1 (ng/mL) 5.4 ± 0.6 
FILTERED DIESEL EXHAUST  
  Tissue plasminogen antigen (ng/mL) 3.4 ± 0.6   
  Plasminogen activator inhibitor type 1 (ng/mL) 5.1 ± 0.5 
 
Data shown are mean±standard error of the mean (n=19) 
There were no significant differences between exposures (1 way ANOVA with repeated measures) 
 


































8.1    SUMMARY OF FINDINGS 
Cardiovascular disease remains the commonest cause of premature death in the 
developed world and its incidence is rapidly increasing in developing countries. The 
dynamic regulation of intravascular thrombus formation is central to the pathogenesis 
of acute atherosclerotic events, particularly within the coronary circulation 
[Rosenberg, et al., 1999]. Whilst several preclinical models of thrombosis exist, 
species-specific differences ensure that clinical studies remain an essential part of 
translational research and antithrombotic drug development. The demonstration of 
antithrombotic efficacy in man is challenging and an in vivo model for use in clinical 
studies does not currently exist. The Badimon chamber is an ex vivo model of 
thrombosis that is suitable for use in clinical studies and has previously been used 
principally to assess novel antithrombotic agents and regimens in patients undergoing 
percutaneous coronary intervention [Lev, et al., 2006; Wahlander, et al., 2006; Zafar, 
et al., 2007]. Whilst it has the advantage of allowing assessment of thrombus 
formation on a pathophysiologically relevant substrate and under conditions of 
continuous flow, it has limitations that curtail its broader applicability. In addition, 
previous characterisation studies [Badimon, et al., 1987] were performed in a porcine 
system using methodology that has since been superseded and there are no published 
data specifically addressing the reproducibility of thrombus formation in the chamber. 
 
During this body of work I have sought to establish the Badimon Chamber technique 
within my institution and adapt aspects of the methodology in order to broaden its 
applicability and allow important clinical questions to be addressed. As such the work 
can be broadly divided into three phases. 
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The initial validation phase involved establishing the technique in my own institution 
and demonstrating it provided a robust method for assessing thrombus formation. As 
part of this initial phase, I adapted the existing methodology to allow the accurate 
addition of experimental agents and compounds to the extracorporeal circuit and 
modified the analysis phase to make use of contemporary semi-automated image 
acquisition and analysis equipment. The technique is now more efficient and can be 
used to safely assess novel compounds not previously tested in humans. As planned, 
these modifications together have significantly broadened its applicability. 
 
In the subsequent phases, I have demonstrated this enhanced applicability by utilising 
the modifications made to the methodology to address important questions in two 
separate but overlapping areas of cardiovascular medicine. Specific findings are 
discussed below. 
 
8.1.1    VALIDATION, CHARACTERISATION AND REPRODUCIBILITY 
The initial studies, performed in healthy volunteers, provided important validation 
data confirming that the technique had been successfully established within our 
institution. Histological data demonstrated that the thrombus formed within the 
chamber is platelet-rich and forms upon a basal layer of fibrin. The contribution of 
fibrin was greater under conditions of lower shear stress, whilst platelets contributed 
more under conditions of high shear stress.  Importantly, we demonstrated that total 
thrombus area is highly reproducible both within and between days, indicating that 
the technique provides a flexible model with which to assess novel and existing 
interventions using parallel group and crossover study designs.  
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8.1.2    ENDOGENOUS TISSUE PLASMINOGEN ACTIVATOR ENHANCES 
FIBRINOLYSIS  
The second phase involved using the adapted methodology to establish a technique for 
assessing fibrinolysis. Previous work within our institution has provided novel insights 
into the role of endogenous fibrinolysis, endothelial function and intravascular 
thrombosis [Labinjoh, et al., 2001; Newby, et al., 2001; Newby, et al., 1997; 
Robinson, et al., 2007]. However, the primary end-point in all previous studies has 
been the quantification of t-PA release from the endothelium. 
 
In the first part of this study, we demonstrated that the addition of exogenous t-PA 
into the extracorporeal circuit could be achieved in a reliable, predictable and 
reproducible manner allowing the demonstration of a dose dependent reduction in 
thrombus formation. The associated dose dependent increase in D-dimer levels 
observed in the chamber effluent is consistent with enhanced fibrinolysis and 
confirms that the technique can be used as a clinical model of fibrinolysis.  
 
In the second part of the study, by combining intra-arterial infusion of bradykinin into 
the human forearm in order to stimulate acute release of endogenous t-PA with an 
assessment of dynamic thrombus formation using the Badimon Chamber, we 
demonstrated that t-PA released in this manner enhances fibrinolysis and is able to 
limit in situ thrombus formation. 
 
These studies in combination confirm the functional significance of t-PA released 
during agonist stimulation, support a crucial role for the endogenous fibrinolytic 
system and suggest that further studies to explore its therapeutic value are warranted. 
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8.1.3    EVALUATING THE SMALL MOLECULE PAI-1 INHIBITOR, PAI-749 
Having demonstrated that the technique can be adapted to investigate novel agents 
with the potential to enhance fibrinolysis, we went on to evaluate a promising small 
molecule PAI-1 inhibitor, PAI-749, in a double blind randomised controlled study. Ex 
vivo studies were complemented by extensive complementary in vitro assessments 
performed in collaboration with colleagues in Aberdeen and Leeds. Interestingly, in 
contrast to the promising results seen with this and other similar compounds in 
preclinical models [Gardell, et al., 2007; J. Hennan, 2006], we were unable to 
demonstrate efficacy in any of the clinical models used. The reason(s) underlying the 
lack of efficacy was not entirely clear. Compared to previous preclinical studies, 
exposure time in our studies was significantly less and the models we employed were 
selected principally to assess fibrinolytic efficacy rather than to assess antithrombotic 
efficacy that had formed the basis of the preclinical studies. In addition to casting 
doubt on future development of this particular compound, the study highlights the 
potential pitfalls of relying solely on in vitro and pre-clinical models during early 
compound development. Indeed, by adding compounds to the extracorporeal circuit, 
we highlight a particular strength of the Badimon Chamber in that the efficacy of 
novel compounds can be evaluated in a robust and relevant clinical model without the 
subject being exposed. This may allow the more timely identification of compounds 
that show promise in preclinical models but, due to species differences, fail to 
demonstrate efficacy in man. The ongoing development of such compounds could 





8.1.4   DIESEL EXPOSURE INCREASES THROMBUS FORMATION IN MAN 
Robust observational data suggest that acute exposure to particulate air pollution can 
trigger vascular events including acute myocardial infarction [Peters, et al., 2001; 
Peters, et al., 2004]. The biological mechanisms underlying this are only partly 
understood and may be multifactorial. Preclinical data suggest that platelet activation 
and thrombosis may be important [Nemmar, et al., 2003]. In collaboration with 
colleagues from The University of Umeå, Sweden, 20 healthy men were exposed in a 
double blind randomised controlled study to dilute diesel exhaust or air under 
controlled conditions and according to a well-established protocol. This was the first 
study to demonstrate that inhalation of diesel exhaust, a common urban air pollutant, 
causes platelet activation and enhances thrombus formation in man. The data provide a 
plausible mechanism linking exposure to particulate air pollution with acute 
cardiovascular events including myocardial infarction. 
 
8.1.5    PREVENTING THE ADVERSE EFFECTS OF DIESEL EXPOSURE 
In this subsequent study, again conducted in conjunction with colleagues in Sweden 
and The Netherlands, we exposed 19 healthy men to dilute diesel exhaust, air or diesel 
exhaust filtered through a particle trap. Using a powerful study design, we 
demonstrated for the first time that reducing the particulate component of diesel 
exhaust using a commercially available particle trap can prevent the detrimental 
effects on ex vivo thrombosis and endothelial function. The study supports calls for 
the application of particle traps to diesel-powered vehicles in order to reduce urban 
particulate concentrations and limit a range of adverse cardiovascular effects that 
result from exposure to traffic-derived air pollution.  
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8.2    FUTURE DIRECTIONS 
Several questions have arisen from peer review of these studies within and outwith 
my own institution. We hope to address a number of these issues in future studies. 
 
8.2.1    INVESTIGATING THE RELATIVE CONTRIBUTIONS OF 
SPONTANEOUS AND ENDOGENOUS FIBRINOLYSIS  
Plasmin can be generated from plasminogen by t-PA or (single chain [sc]) urokinase 
(u-PA)[Booth NA, 2006]. Fibrinolysis is usually studied in plasma, where the major 
focus is the balance between t-PA and it’s principle inhibitor, PAI-1.  Urokinase 
activity is hardly ever relevant in plasma, since circulating (sc)u-PA is present at very 
low concentrations and is rapidly neutralised [Booth NA, 2006].  Thus t-PA has come 
to be regarded as the key plasminogen activator in the circulation particularly as its 
level rises dramatically following agonist-mediated release from the endothelium. 
 
Recent studies have emphasised the importance of considering the balance of 
proteases and inhibitors in fibrinolysis in whole blood, not just plasma, thus allowing 
assessment of the contribution made by cellular components. A key approach has 
been the use of model thrombi, formed in vitro from whole blood.  Formation under 
flow results in a characteristic thrombus with a cell-rich head and a fibrin-rich tail 
[Chandler, 1958; Robbie, et al., 1997]. The thrombi, either whole or cut into these two 
parts, can be sectioned for in situ zymography [Mutch, et al., 2002], fixed and stained 
[Mutch, et al., 2003; Robbie, et al., 1997] or extracted to assess the proteases and 
inhibitors present [Mutch, et al., 2003; Robbie, et al., 1997].  Fibrinolysis can be 
measured by incorporating FITC-fibrinogen into the forming thrombi and then 
following fluorescence release over time [Mutch, et al., 2003; Robbie, et al., 2000].  
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This is therefore a complex but experimentally tractable system, which has generated 
several insights into fibrinolytic mechanisms [Mutch, et al., 2007]. During the course 
of these studies, it was noted that significant spontaneous lysis occurred in the cell-
rich head of the model thrombi without the addition of any plasminogen activator. 
The term “spontaneous” fibrinolysis was adopted to describe it more accurately and to 
avoid confusion with “endogenous” fibrinolysis.  
 
The effect of spontaneous lysis is sizeable and reproducible. Further work has 
demonstrated that it results from (sc)u-PA activity and is principally related to platelet 
and neutrophil content. These findings, and those of others [Gurewich, 2000; Moroz, 
et al., 1979], question the traditional view that u-PA is involved only outside the 
circulation, with primary roles in cancer, while t-PA is the main intravascular 
fibrinolytic enzyme. 
 
In collaboration with colleagues at the University of Aberdeen, the core focus of an 
ongoing study funded by a BHF project grant is defining the relative efficiency of 
lysis via (sc)u-PA activation and via t-PA release from the endothelium.  Two distinct 
mechanisms are in play, whereby spontaneous lysis leads to local generation of 
activity on the surface of cells within the thrombus, while endogenous lysis shifts the 
balance between t-PA and its main inhibitor, PAI-1, in solution. 
 
We hypothesise that u-PA-dependent and t-PA-dependent fibrinolysis represent 
temporally and environmentally complementary mechanisms for the dissolution of 
thrombi in vivo. We are using complementary in vitro and ex vivo models to help 
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define the precise conditions under which each of the two mechanisms is dominant 
and investigate their respective potential for further therapeutic development. 
 
8.2.2    DEVELOPMENT OF PROFIBRINOLYTIC DRUGS 
Given the importance of the endogenous fibrinolytic system in modulating the 
outcome of thrombotic events that are central to the pathogenesis of cardiovascular 
disease, agents capable of shifting the balance in favour of fibrinolysis remain a target 
for drug development. Such agents may be useful in patients presenting with acute 
events such as myocardial infarction but may also play a role in the primary or 
secondary prevention of vascular disease. PAI-1, in particular, is the focus of ongoing 
interest. Elevated levels are associated with a number of pathological processes that 
play important roles in the development and outcome of cardiovascular disease 
including coagulation, fibrinolysis and inflammation. Levels are particularly high in 
the growing number of patients with metabolic syndrome and it appears that this 
cohort may benefit most from strategies to inhibit PAI-1 activity. 
 
As part of this body of work, we undertook what we believe to be the first robust 
evaluation of a small molecule PAI-1 inhibitor, PAI-749, in human blood. Whilst we 
failed to demonstrate compound efficacy in the in vitro or ex vivo models we 
employed, we did observe accelerated in vitro fibrinolysis in the presence of a 
monoclonal antibody against PAI–1. Along with previous encouraging results from 
preclinical studies, in which a number of inhibiting antibodies and small molecules 
have shown efficacy, this suggests that the inhibition of PAI–1 remains a potential 
therapeutic target worthy of further exploration. Data continue to be published 
[Fjellstrom, et al., 2012] although progress is slow and may relate, in part, to the 
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physical plasticity of this unusual target. To date, we are not aware of any PAI-1 
inhibitor having been tested in patients. We believe that the Badimon Chamber, 
particularly given its ability to assess the effects of compounds added to the 
extracorporeal circuit, provides a flexible and robust model with which to help 
evaluate novel agents able to modulate fibrinolysis for therapeutic benefit. 
 
8.2.3    IS EX VIVO THROMBOSIS ENHANCED IN THOSE WITH 
CARDIOVASCULAR RISK FACTORS OR ESTABLISHED VASCULAR 
DISEASE?  
Ruptured abdominal aortic aneurysms (AAA) are a common cause of death in the UK 
[Ashton, et al., 2002] with cigarette smoking by far the strongest independent risk 
factor for development and progression [Blanchard, et al., 2000; Lederle, et al., 1997; 
Lederle, et al., 2002; Lindholt, et al., 2001]. Although overlap clearly exists between 
risk factors for atherosclerosis and AAA formation, there is growing evidence to 
suggest that the underlying mechanisms may be distinct. 
 
Particular interest has focused on the role of thrombus present within the AAA [Kazi, 
et al., 2003; Touat, et al., 2006]. The presence of laminated intraluminal thrombus is 
virtually ubiquitous. This thrombus mass is biologically active with fibrinolytic 
activity demonstrable at the luminal interface [Touat, et al., 2006] and plasma 
concentrations of components of the fibrinolytic system elevated in peripheral blood 
[Diehm, et al., 2011; Golledge, et al., 2011; Parry, et al., 2009]. D-dimer, in particular 
has been identified as one of the potential prognostic biomarkers in patients with 
AAA [Golledge, et al., 2011; Parry, et al., 2009] and interestingly, plasma markers of 
fibrin turnover fall following AAA repair [Holmberg, et al., 1999; Yamazumi, et al., 
1998]. In addition to its role in the dissolution of fibrin in blood vessels, the 
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fibrinolytic system is also important in the remodelling of the extracellular matrix, 
through activation of proteolytic matrix metalloproteinases. These extracellular 
proteases are involved in AAA expansion and progression towards rupture [Lindholt, 
et al., 2003; Sakalihasan, et al., 2005]. Thus, the predictive values of fibrinolytic 
components found in AAA patients mirror the proteolytic activity of the mural 
thrombus, perhaps explaining the link between the observed thrombus and the 
immediate risk of rupture [Houard, et al., 2007]. 
 
Finally, it has been suggested that intraluminal thrombus in tandem with deranged 
fibrinolytic function in smokers leads to occlusion of the vasa vasorum in aortic wall, 
resulting in vessel wall ischemia that promotes expansion of the aneurysm.  
 
Taken together, these data suggest that imbalances in the endogenous fibrinolytic 
system play a major role in AAA expansion although several key questions remain 
unanswered. 
 
Using forearm venous occlusion plethysmography, we will assess endothelium-
dependent vasomotion and acute endogenous fibrinolytic capacity in patients who are 
current cigarette smokers and have developed AAAs and compare them with age- and 
sex-matched otherwise healthy cigarette smokers. We will also assess 
thrombogenicity in these patients using the Badimon Chamber.  
 
We believe that these studies will shed light on some of the pathological processes 
that drive AAA formation and progression, and particularly address whether there is 
evidence of impaired fibrinolytic function in patients with AAA. 
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 8.2.4    ARE THE ADVERSE CARDIOVASCULAR EFFECTS OF DIESEL 
EXHAUST INHALATION RELATED TO THE MAGNITUDE OF THE 
EXPOSURE? 
In previous studies we have exposed subjects to particulate concentrations circa 300 
µg/m3, levels commonly found in heavy traffic, occupational settings, and in the 
world’s largest cities. A significant proportion of this mass is made up of combustion-
derived nanoparticles principally generated from traffic.  Estimates range from 20% at 
remote monitoring sites [Lanki, et al., 2006] to 70% in a road tunnel [Geller, et al., 
2005]. Exposure to 300 µg/m3 for one hour increases an individual’s average exposure 
over a 24-hour period by only 12 µg/m3. Changes of this magnitude occur on a daily 
basis, and are associated with increases in cardiorespiratory mortality [Dockery, et al., 
1993]. However, we recognise that many people may not be exposed to this level of 
air pollution.  
    
Sixteen non-smoking volunteers with normal lung function and no history of 
respiratory disease will be invited to attend on four separate days at least two weeks 
apart and receive a double-blind randomised cross-over exposure to filtered clean air 
or diesel exhaust at 30, 100 and 300 µg/m3. Vascular function and thrombotic 
potential will be determined 6-8 hours after each exposure using venous occlusion 
plethysmography and the Badimon Chamber. 
 
By exploring the dose-response relationship of these effects we hope to determine 
safe thresholds of diesel exhaust inhalation with which to inform the ongoing debate 
surrounding air quality standards. 
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8.2.5    ARE THE CARDIOVASCULAR EFFECTS OF EXPOSURE TO 
NEWER ‘GREENER’ BIODIESEL EXHAUST SIMILAR TO THOSE 
OBSERVED WITH CONVENTIONAL DIESEL EXHAUST? 
The last decade has seen an exhaustive drive towards finding bioeconomical and 
renewable sources of fuel in order to reduce dependence on fossil fuels. Since 2000 
global biofuel production has tripled. Although several potential climatic advantages 
have been highlighted, there is still much controversy surrounding the ethical and 
wider environmental repercussions of biofuel production and combustion. Despite 
huge investment and calls in 2007 by the US Environmental Protection Agency, 
research into the health effects has been almost completely overlooked; to date there 
is only one animal study performed that addresses the potential cardiovascular effects 
of biodiesel exhaust exposure [Brito, et al., 2010]. The study showed that although 
certain emission parameters were decreased compared with conventional diesel, 
indices of cardiovascular, pulmonary and systemic inflammation were, in fact, 
elevated. Studies focussing on the chemical composition of biodiesel exhaust have 
found that although there seems to be an overall reduction in PAHs, different running 
cycles and fuel blends may increase levels of toxic and carcinogenic PAH subgroups 
[Karavalakis, et al., 2010].   
 
Twenty healthy volunteers are currently being enrolled to receive a double-blind 
randomised cross-over exposure to diesel exhaust generated from standard diesel fuel 
or exhaust generated from rapeseed oil methyl ester (RME) 30 biodiesel. RME 30 is a 
mix of 30% RME and 70% standard diesel and has been chosen as it is the most 
widely commercially available biodiesel in Europe. Several relevant and 
complementary surrogate markers of cardiovascular health, including ex vivo 
thrombus formation in the Badimon Chamber, will be assessed. 
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The ongoing debate surrounding the relative merits of biofuel use is fierce and 
complicated by a number of complex political and ethical considerations. Given the 
absence of previous human exposure studies, we hope that this work will provide 
important safety data that should form a crucial part of the debate. 
 
8.2.6    DO ENGINEERED NANOPARTICLES POSE A PROTHROMBOTIC 
RISK? 
Engineered nanoparticles are currently being developed to facilitate the imaging of 
atherosclerotic plaques and deliver targeted therapies to unstable plaques. However, 
such particles share many properties with combustion-derived nanoparticles, thought 
to be principally responsible for the adverse cardiovascular effects of air pollution. To 
assess the relative risks and benefits of engineered nanoparticles, we need a better 
understanding of the properties that determine their toxicity, potential for systemic 
translocation and biological distribution once blood-borne. We have secured 
substantial funding from the Department of Health (PR-NT-0208-10025) to 
systematically assess the effects of a range of engineered nanoparticles on platelet 
activation, platelet-monocyte aggregation and thrombus formation using flow 
cytometric techniques and by infusion into the extracorporeal circuit of the Badimon 
Chamber. The role of particle size, surface area, surface chemistry and different 
imaging moieties will be assessed in vitro and ex vivo using both in-house synthesised 
and commercially available nanoparticulate contrast agents. In addition, again using 
the Badimon Chamber, we plan to assess ex vivo thrombus formation in patients with 
abdominal aortic aneurysms who have received an infusion of a commercially 
available nanoparticulate contrast agent. 
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These studies will help to resolve a potentially important paradox in medical imaging 
and therapeutics: environmental nanoparticulate are toxic to the cardiovascular system 
even at relatively low concentrations, yet in the quest to enhance cardiovascular 
imaging the cardiovascular community propose direct intravascular infusion of 
nanoparticles of unknown toxicity at high concentrations into patients with unstable 
atheromatous disease. We anticipate that our studies will help define the net clinical 
benefit of using these agents and lead to the development of safer engineered particles 















8.3  CLINICAL PERSPECTIVE 
The initiation, modification and resolution of thrombus associated with unstable 
atheromatous plaques are central to the pathophysiology of vascular events. The 
ability to investigate these processes in a clinical model is crucial for the development 
of novel agents and strategies to treat and prevent a range of cardiovascular disorders. 
 
During this thesis I have demonstrated that the Badimon Chamber is a robust and 
reproducible model with which to assess ex vivo thrombus formation in man. By 
updating the existing methodology, I have broadened the applicability of the 
technique. I have demonstrated it has value in assessing novel agents with the 
potential to modulate exogenous and endogenous fibrinolysis as well as thrombosis. 
In addition, using it to demonstrate that t-PA released from the endothelium following 
bradykinin stimulation is functionally active highlights the importance of the 
endogenous fibrinolytic system and supports further work to investigate its 
therapeutic value. Whilst the small molecule PAI-1 inhibitor, PAI-749, evaluated here 
was not efficacious, the Badimon Chamber is well placed to assess other novel 
compounds and the quest for agents able to enhance fibrinolysis should continue. 
 
Exposure to particulate air pollution is associated with acute cardiovascular events 
including myocardial infarction. Given that such exposure is virtually ubiquitous and 
continues to increase in heavily populated developing countries, particulate air 
pollution is an important risk factor for cardiovascular disease and events on a global 
basis. Using a well characterised, controlled diesel exhaust exposure system we have 
demonstrated, for the first time, that exposure to diesel exhaust activates platelets and 
enhances ex vivo thrombosis in healthy volunteers. In addition, for the first time, we 
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demonstrate that reducing the particulate component using a commercially available 
particle trap can prevent detrimental effects on several complementary surrogate 
markers of cardiovascular health. These studies support policy interventions targeting 
reductions in the traffic-derived component of air pollution including the fitment of 
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